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Summary 
Ideal radiotherapy treatment involves the delivery of a pre-set dose of ionising radiations to a 
well specified target by radiologic imaging techniques. Conforming the dose to the target is 
crucial as ionising radiation causes damage to healthy tissues. Rapid imaging and dose delivery 
modalities, which have also been developed, have brought a great improvement in accuracy of 
targeted cancer treatments. However, current diagnostic and treatment procedures are still 
limited by insufficient accuracy in terms of the radiobiology of radiotherapy. Hence, a major area 
of endeavour is improving their accuracy and therapeutic effects. Recently, research has focused 
primarily on attempting to radio-sensitise targets. This process involves inclusion of high atomic 
number (Z) materials into targets prior to irradiation. To increase efficiency of this process, 
nanoparticles (NPs) consisting of high Z elements are used. Incorporation of these materials with 
medical imaging devices such as X-ray computed tomography (CT) scans leads to improved 
disease characterisation and monitoring of response to therapy. Moreover, nanoparticles can 
enhance dose effects in external beam radiotherapy. 
The rationale behind this work was to develop and characterise NPs and incorporate them 
into the processes employed by current diagnostic CT imaging devices in order to enhance 
sensitivity and increase the chance of identifying disease at a time when the patient can receive a 
positive prognosis. This enhancement is also important in advancing towards eliminating the 
need for invasive biopsies, which is currently the most accurate diagnostic method for cancer 
detection and therapy follow up. In addition, the same NPs can be used as dose enhancement 
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agents to improve radiotherapy effects on cancerous tissues whilst minimising effects on healthy 
tissues. 
Therefore, this thesis had the two major aims: to use bismuth-based NPs as dual-function 
agents for cancer; diagnostic as well as therapeutic. Using a single system to enhance detection 
as well as boost therapeutic efficacy leads to the promising platform called “theranostics”. 
Optimisation of the diagnostic and therapeutic strategies simultaneously enhances cancer control 
and increases patient’s survival rates. Contrast agent studies were conducted using phantoms 
with CT scanners, while radiation dose enhancement was carried out using biological cell 
survival assays and two radiotherapy techniques; superficial radiotherapy (SXRT) (kV) and 
megavoltage (deep) (MV) therapy with a linear accelerator (LINAC).  
The results of the study provided evidence that bismuth (Bi) and its compounds (bismuth 
sulfide (Bi2S3) and bismuth oxyiodide (BiOI) NPs) can be synthesised and surface-modified 
using suitable biocompatible methods. Attention was also given also to nanoparticle-surface 
coating effects in optimising long term stability. Furthermore, the NPs were characterised using 
transmission electron microscopy (TEM), X-ray diffraction (XRD) and X-ray photoelectron 
spectroscopy (XPS), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy 
(FT-IR) and Zeta potential measurements in order to confirm nanoparticle size, compositions and 
surface modifications. It was established that bismuth-based NPs can be produced in small and 
well-defined sizes and are stable in water for a long period of time.  
Initially, experiments investigated the feasibility of employing high-Z Bi2S3-NPs as a 
contrast agent for CT compared to conventional contrast media (CM). An extended study 
determined the optimal clinical tube potentials for visualisation of Bi-based NPs with respect to 
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iodinated CM. Results showed particular promise for maximising contrast enhancement across 
the studied range of 80 to 140 kilovoltage (kV). These results were supported by National 
Institute of Standards and Technology (NIST) mass attenuation data. A second, novel study was 
conducted to determine the benefit of the K-edge value for Bi and iodine (I), using bismuth 
oxyiodide (BiOI) NPs to enhance subject contrast in dual-energy (DE-CT) and spectral (MARS) 
CT imaging. Both CT scanners revealed the superiority of BiOI-NPs over the conventional 
iodinated contrast agents.  
A second series of studies was conducted to develop cell culture-related protocols to 
measure the response of different cell lines exposed to X-ray radiotherapy beams with energies 
in kVp and MV as well as to measure the effect of NPs containing high Z on the radiation 
responses. The first study was carried out to investigate and compare the effect of Bi2S3 and gold 
(Au)-NPs on the radiation response of mouse PC3 prostate and B16 melanoma cells. Equimolar 
concentrations of both Au and Bi2S3-NPs displayed equal dose enhancement with B16 cells, 
while the latter provided higher values with PC3 cells. At equimolar concentrations there are less 
Bi atoms compared to Au in their respective NPs. Both NPs at comparable concentrations (0.5-1 
mM) elicited similar cytotoxicity in PC3 cells. This study demonstrates that the less expensive 
Bi2S3-NPs are a viable alternative to Au-NPs as a dose-enhancing agent in clinical applications. 
The second study investigated the cytotoxicity of Bi- and Bi2S3-NPs towards two human cell 
lines, A549 (lung adenocarcinoma epithelial) and DU145 (prostate carcinoma). Results revealed 
that Bi-NPs at comparable concentrations to Bi2S3- NPs (0.5-1 mM) caused higher cytotoxicity 
in both cell lines. The presence of both NPs led to decreasing the surviving fraction of cells when 
NPs were combined together with X-ray irradiation, compared to the control (irradiation alone). 
Cells irradiated with kVp energies showed the greatest radiosensitisation value compared to MV 
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energies. Results also demonstrated that Bi-NPs generated a greater dose enhancement effect 
than Bi2S3-NPs in irradiated cells. The maximum Dose Enhancement Factor (DEF) obtained at 
the lower energy kV range for cells treated with Bi-NPs (0.25 mM) was 2.29 in A549 cells and 
1.56 in DU145 cells, compared to the DEF values of 1.41 in A549 cells and 1.63 in DU145 cells 
when cells were treated with higher concentrations (1mM) of Bi2S3-NPs. Lower radiation dose 
enhancement was observed when using a high energy MV beam, with higher DEF values for Bi-
NPs (0.25 mM) treatment (1.26 in A549 cells and 1.23 in DU145 cells) as compared to DEF 
values with similar concentrations of Bi2S3-NPs (1.09 in A549 cells and 1.07 in DU145 cells). 
Using a linear quadratic model to analyse the radiobiological effect of the dose enhancement by 
NPs it were found that there was systematic changes of the alpha (α) value which increased by 
treating with the NPs, while there were very small changes for the beta (β) value.  
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Chapter 1 
1.Background and Literature Review 
1.1 Overview 
This chapter contains an introduction to principles and basic physics of X-rays in imaging and 
radiation therapy. It includes the production of X-rays by conventional clinical modalities. It also 
considers the basic interaction processes between X-rays and matter at an atomic scale and 
illustrates the effects of these interactions on biological materials (targets) such as tissue 
equivalent phantom and cells. An introduction into the basic biological cell structures and their 
functions is also provided in order to facilitate a better understanding of the damage caused by 
radiations. Furthermore, the radiobiological and physical parameters utilised to measure the 
radiation damage are also discussed. It also provides a description of the properties of metallic 
nanoparticles (NPs) as well as their biochemical effect in enhancing the subject contrast and 
radiosensitisation. This chapter concludes with a description of the objectives and outline of this 
thesis. 
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1.2 Introduction to literature review (Imaging and Radiotherapy) 
Although there have been significant advances in cancer treatment, cancer remains the second 
largest cause of mortality in developed countries. Worldwide, 1.7 million new cases of cancer 
were diagnosed in 2017 [1] and 134,174 cases of cancer were diagnosed in Australia with deaths 
totalling 47,753 [2]. Radiotherapy represents one of the major treatment methods for cancer, 
which is sometimes used in conjunction with surgery for better outcomes, as well as with 
chemotherapy. Approximately 50% of patients suffering from cancer have to be treated with 
radiotherapy at some stage of their illness [3, 4]. Radiotherapy treatment involves delivery of a 
pre-set dose of ionising radiations to a well specified target by radiologic imaging techniques. 
The ionising radiations have been used for over 100 years to treat a range of cancer types [5]. 
Initially, X-rays in the kilovoltage energy range (kVp) were employed to treat superficial 
cancerous tissues. However, low penetration of such X-rays limited their effect on deep-seated 
tumours and delivered high dose (sometimes being higher than the threshold value) to the tissues 
in their path when they pass through to the tumours, which leads to a low skin sparing effect. The 
major challenge faced by radiotherapy is the controlled delivery of a dose that is lethal for the 
treatment of the tumour while minimising any damage to the surrounding area [6, 7]. 
 Recently many advanced techniques have been included in radiotherapy to customise the 
dose to the target and to address the shortcomings. Most commonly in the field of clinical 
radiotherapy, electron linear accelerators (LINAC) are used to produce X-rays and electron 
beams of high energy in the megavoltage range of energy (MV). This technology has now 
become the most common source of ionising radiations and has replaced the kVp and 
orthovoltage X-rays that have been used in clinical centres to deliver the most common forms of 
radiotherapy to the patients. Using high energy X-rays has enhanced the dose distribution and 
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skin sparing, and improved the effectiveness of radiotherapy in treating cancer since an adequate 
dose can be delivered to tumours whilst minimising the radiation effects to the surrounding 
normal tissues. In addition, with modern LINACs it is possible to perform other techniques such 
as intensity modulation radiation therapy (IMRT), stereotactic radiotherapy (SRT) and 
volumetric modulated arc therapy (VMAT), that being the main common external beam 
therapies (EBRT) [8-10]. IMRT is common in radiotherapy of the central nervous system (CNS), 
whereas SRT is a very precise technique of delivery used for the delivery of large single dose 
fractionations within the brain. Furthermore, using imaging equipment precise delivery of 
radiation to the tumours can enable better localisation. This technique is based on the use of two 
and three-dimensional imaging during a course of radiation treatment in order to direct radiation 
therapy, utilising the imaging coordinates of the actual radiation treatment plan. This technology 
(image guided radiotherapy IGRT) is also available in various radiotherapy centres and can 
improve the accuracy of treatment, providing improved tumour control, reduced margins, 
reduced toxicity, and increased doses [11, 12]. LINACs are also the most common modality 
employed in radiotherapy centres; the gamma rays used are in the MV range and are released 
from a radioactive cobalt-60 source. Radioactive seeds such as iridium-192 (also used in 
brachytherapy) can also act as an alternative modality in radiotherapy and are effective in 
treating certain types of tumours and are less dependent on electrical energy [13]. Proton therapy 
is another type of radiotherapy which uses particles such as neutrons, protons, or heavy ions to 
treat cancer [14]. Particle radiotherapy has the power to provide better dose concentration at the 
tumour and has confirmed a role in the management of orbital tumours such as base of skull 
sarcoma. This therapy provides both physical as well as biological advantages, especially in the 
treatment of localised tumours as well as radioresistant tumours, and also those tumours that are 
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located near critical body structures (e.g. spinal cord) [15] . However, the high installation cost 
involved in particle radiotherapy that uses proton and heavy ion beams, make it less common.  
Improving the accuracy of tumour detection (diagnosis) will therefore facilitate more precise 
treatment/dose delivery and is clearly an important step towards more effective cancer 
treatments. Imaging technologies such as Magnetic Resonance Imaging (MRI), Computed 
Tomography (CT), Positron Emission Topography (PET) and Single Photon Emission Computed 
Tomography (SPECT) are routinely used in hospitals for cancer imaging during its treatment. 
These modalities have become a significant tool for visualising potential abnormalities to allow 
increased accuracy and precision. Computed tomography (CT) is the most common modality 
used in both diagnosis and radiation therapy imaging guidance due to availability, low cost and 
high effectiveness [16]. Specifically, it provides high resolution images of three-dimensional 
(3D) tissue details in a shorter time than other modalities, for example MRI. Moreover, the fast 
acquisition of data from structural tissues and the high reproducibility of CT enables continued 
comparison to occur, providing the tumour localisation, which is necessary for effective 
radiotherapy treatments [17]. However, while CT images contain a high level of detail, the CT 
modality is significantly limited due to its inability to distinguish soft tissue types. In order to 
address this limitation the use of a CM (iodine compounds) has been used to improve the CT’s 
ability to distinguish soft tissues from each other, to increase its sensitivity and to improve image 
contrast [16, 18]. It is the interaction between the incident radiations and the contrast agents 
which can generate such significant changes to the diagnostic image [19]. More importantly, the 
concomitant use of iodinated CM and radiation therapy can enhance X-rays absorption in 
endothelial cells and on other tissues; hence this can induce the deoxyribonucleic acid (DNA) 
cleavage. Iodine-based compounds in radiation therapy and tumour imaging were the first line of 
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investigations of improving therapeutic techniques [20-24]. However, it is necessary for 
administration of a large amount of CM to obtain the adequate CT contrast image, which is 
impossible due to the adverse effects on the patient [16, 25]. Moreover, these iodinated CM have 
some drawbacks such as their short blood pool circulation time (<10 minutes) [26, 27], their poor 
contrast in large patients [16, 28] as well as their serious adverse effects in some patients (e.g., 
hypersensitivity reactions) [29, 30]. 
Newly developed NPs have been proposed as a new direction of investigation, as 
diagnostic and therapeutic agents to overcome many of previous shortcomings of traditional 
iodinated CM. Several high Z elements such as Au-, Pt-, Ta-, and Bi-based NPs have received 
much attention as contrast agents for CT due to their high X-ray attenuation coefficient and their 
prolonged circulation over iodine (animal study) [16, 17, 27, 31-33]. In addition, there have been 
several attempts to use metallic NPs to enhance the therapeutic dose to cancerous tissue. Metallic 
NPs possess desirable properties and are good therapeutic candidates for application in the 
treatment of cancer using ionising radiation. Their high Z, physical density (ρm) and electron 
density (ρe) can increase radiation absorption because of the high cross section of the X-ray 
photon capture and Compton scattering (CS) [34]. Moreover, NPs have shown great promise in 
cancer therapy (in vitro and in vivo studies) due to the selective accumulation of NPs in the 
tumour tissue that result from to their ability for leveraging the enhanced permeability and 
retention (EPR) effect [35, 36]. Recent studies have reported that metallic NPs are capable of 
increasing the radiation energy absorbed to tumour tissue and can induce the chemical 
radiosensitivity of its DNA [37]. 
The general aim of this thesis is to use the bismuth compounds as dual-function agents for 
cancer; diagnostic agents as well as therapeutic agents. Using a single system to enhance the 
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effects of detection as well as boost therapeutic efficacy is likely to lead to a promising 
theranostic agents. Optimisation of the diagnostic and therapeutic strategies simultaneously can 
open the possibility of cancer control and improve survival rates. In both actions, as a diagnostic 
or therapeutic agent Bi-based NPs presents high Z and density atoms to the exposing radiations. 
Hence, it is vital to understand the interaction of the ionising radiations with the NPs on the 
atomic scale. 
1.3 Basic radiation physics  
In order to provide a comprehensive understanding of the effect of NPs in combination with 
imaging and radiotherapy, fundamental radiation physics principle are described in the following 
sections. 
1.3.1 Type of radiations  
Radiation is simply the emission of energetic waves/particles. It can be divided into two types; 
ionising and non-ionising radiation. These categories are based on whether the emitted particle 
has the ability to displace an electron from atomic orbitals around the nucleus and thereby ionise 
the atom. Examples of non-ionising radiation include photons categorised as visible light, 
radiowaves and microwaves, since the lower frequencies and longer wavelengths of these 
particles/radiations mean they have lower energy than that required for ionisation [7]. In contrast, 
X-rays and gamma rays are located on the high frequency and high energy end of the 
electromagnetic spectrum and therefore, can ionise atoms [38] (Figure 1-1). 
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Figure 1-1: Electromagnetic spectrum showing major categories as a function of wavelength, frequency 
and energy. X-rays form part of the high energy portion of the spectrum [38]. 
 
Ionising radiation can also be generated from the emission of particles other than 
photons, such as alpha and beta particles, neutrons, protons and heavy ions such as carbon. As 
the ionising radiation travels through matter, its energy can be lost in a large number of small 
increments. As a result, the interaction of ionising radiation with biological material can create a 
significant amount of tissue damage (via creation of free radicals), a property which makes 
ionising radiation well suited for use in the treatment of cancer. The most important result of 
ionisation effects on human tissue is the potential damage to DNA of the targeted tissue, which 
can be directly or indirectly conducted [39]. Direct ionisation can damage target tissue when the 
ionising charged particle interacts directly with the orbital electrons of atoms in DNA, causing its 
structure to break down. Indirect damage occurs mainly when particles with a neutral electric 
charge such as photons and neutrons interact with a water molecule, producing secondary 
ionising radiation (e.g., free radicals) which can then interact and damage DNA. Most of the 
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damage caused in the target is the result of the secondary effect; about 2/3 of the damage (using 
X-rays). This is due to this secondary ionising radiation depositing higher energy than that 
deposited by the ionising radiation directly [39].  
1.3.2 Production of X-rays  
Clinical X-ray beams used in imaging or radiotherapy typically have an energy range from 10 
kVp to 50 MV. This is achieved by accelerating charged particles to high energy (electrons) then 
causing these fast moving charged particles to interact with the target. Most of the kinetic energy 
of the generated electrons is transformed in the target into thermal energy, with only a small part 
of the energy being emitted as radiation in the form of X-rays. These X-rays are produced by two 
mechanisms and are therefore categorised as characteristic X- rays and bremsstrahlung X-rays 
(Figure 1-2) [7, 39, 40]. 
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Figure 1-2: Illustration of X-ray generation. (a) Bremsstrahlung radiation. (b) Characteristic X-rays and 
other processes that can occur such as Auger electron production.  
 
Characteristic X-rays result from Coulomb interaction between the accelerated electrons 
with high energy and the inner-shell electrons of the atoms in the anode (X-ray tube component 
where X-rays is produced). The incident electrons’ energy must be sufficient to ionise the target 
atom by total ejection of electrons in the inner shell. When this occurs, an outer shell electron 
from a higher energy level moves to fill the vacancy at a lower energy level. The difference 
between the two atomic orbitals’ energy may either be released at discrete energies in the form of 
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characteristic photons or transferred to the outer electron, which results on removal of this 
electron from the atom, referred to as an Auger electron [7, 39]. 
Bremsstrahlung X-rays or braking radiations result from Coulomb interactions between 
high-velocity electrons and the nucleus of an atom, which deflects their path because of its 
electric field. The kinetic energy that the incident electron loses is transmitted into 
electromagnetic energy in the form of X-ray photons with a continuous spectrum, and it is these 
X-rays which form as a result of this process, referred to as bremsstrahlung X-rays. A low energy 
incident electron is barely influenced by the electric field of the nucleus, which will produce low 
energy bremsstrahlung X-rays. When the energy of the electrons is increased, braking radiations 
become more intense and change toward higher frequencies. However, as the energy of X-rays 
increases, the intensity of photons decreases linearly with energy because the majority of the 
atomic volume is empty space and thus, the interaction cross section of the electrons with the 
nucleus is very small [39]. 
In addition, the peak kilovoltage (kVp) and the electric current (mA) used in the X-ray 
tube are significant factors in determining the photon energy and their number (keV). For 
bremsstrahlung radiation, the maximum kinetic energy of X-ray photons is related to the highest 
energy of the tube voltage. However, intermediate energy levels represent the highest X-rays 
emission spectrum due to absorption of low-energy photons by the anode [16]. As a result, there 
is a change in the poly-energetic spectrum to higher energies. This is referred to as the beam 
hardening effect and it leads to the creation of artefacts when X-rays are used for imaging. For 
this reason, X-ray beams are made to pass through a tin metal filter in order to reduce the beam 
hardening effect [16, 40]. For characteristic X-rays, the intensity of X-rays depends on the 
energy difference between the binding energy of inner-shell electrons and the applied voltage. If 
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the peak kilovoltage is less than the binding energy of the electron, no characteristic X-rays will 
be produced. Moreover, X-ray photon production is heavily reliant on Z and physical density of 
the material [7, 40]. 
1.3.3 Interaction of radiation with matter 
There are a number of possibilities that can occur when a photon interacts with the atoms of an 
attenuator; the cross-section for each interaction relies on the energy of the photon (hv) and the 
mass density, Z or electron density of the material. The photon collisions with atoms may be with 
inner-shell electron via the photoelectric effect, with the electrostatic field of the nuclei via pair 
production, or with an essentially free electron shell through the Compton scattering effect. As a 
result of the photoelectric effect and pair production, the photon may completely disappear or it 
may be scattered incoherently in the Compton effect [7]. Therefore, these interactions can be 
classified into two main categories scattering and absorption.  
1.3.3.1 Compton scattering 
Compton scattering is the dominant interaction of X-rays in the diagnostic range with soft tissue 
(significant at kVp >70) (Figure 1-3). In this interaction, the photon interacts with an outer shell 
electron (free electron). After the collision, a portion of the incident photon’s energy is shifted to 
the electron as kinetic energy and ejects it from the atom. This electron is termed the Compton 
electron. As a result of this interaction, the scattered photon is emitted with a reduction in 
energy. Since energy and momentum are conserved in Compton interactions, the incident 
photon's energy is divided between ejected electron and the scattered X-ray. In many cases, both 
of these particles have enough energy to ionise more atoms before losing all the energy. In the 
diagnostic range (lower energy) the majority of the incident X-rays’ energy is transferred to the 
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scattered electron, whereas in the treatment range (high energy), most of incident X-rays’ energy 
is transferred to the scattered electron [41]. This process depends on the number of electrons in 
the outer shell (the electron density), but is independent of the Z of the absorbing material. In 
addition, the probability of Compton interactions increases by increasing the physical mass 
density of the matter [40]. 
 
 
 
Figure 1-3: Illustration of Compton interaction. 
 
1.3.3.2 Photoelectric effect  
The photoelectric effect is a phenomenon that occurs when an incident X-ray with low energy 
interacts with an inner shell electron. Its energy is totally absorbed by the atom, with kinetic 
energy being transferred to the orbital electron. The removed electron called a photoelectron and 
its kinetic energy equals the difference between that of the initial photon’s energy and the 
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binding energy of the removed electron (Figure 1-4). After the collision, the ejected electron 
leaves the atom, creating a vacancy which can be filled by electrons in the K, L, M, or N shells 
[40, 41]. Filling this vacancy has one of two results; it either causes the emission of characteristic 
X-rays or the production of Auger electrons [16]. The energy of the characteristic X-rays 
produced in soft tissue is very low due to the low K-edge energy. Therefore, the characteristic X-
rays produced can be considered to be absorbed in short distance. Other tissues contain atoms 
with higher Z and higher K-edge energy; the characteristic photons are higher energy and deposit 
energy at a greater distance. Therefore, the probability of the photoelectric effect is heavily 
reliant on Z of the medium and its physical density (ρm). Also, this process is inversely 
proportional to the cube of the energy of the incident photons [39].   
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Figure 1-4: Illustration of photoelectric interaction and other processes that can occur as a result of 
photoelectric interactions (characteristic X-ray and Auger electron production). 
 
1.3.3.3 Pair production 
When the energy of the incident X-rays increases to 1.02 MeV, a photon interacting with the 
Coulomb field of the nucleus of an atom may annihilate, converting its energy to the production 
of a positron-electron pair (Figure 1-5). This process is referred to as “Pair Production”. In this 
mechanism, the entire energy of the photon is converted to the production of a pair. The 
equivalent energy of each electron mass is 0.51 MeV; thus the threshold for incident energy must 
be at least 1.02 MeV in order to be absorbed to produce pair production. Any further energy will 
be equally divided between the produced electron and positron in the form of kinetic energy. 
Both particles of the pair will travel through the matter, losing their energy by atomic ionisation 
and excitation [7, 39, 40]. 
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Figure 1-5: Illustration of the pair production process (hv is greater than 1.02). 
 
1.3.4 Attenuation of X-ray beams 
The interactions described in section 1.3.3 are responsible for a reduction in the number of 
photons in an X-ray beam as it travels through a medium. This is termed attenuation and can be 
understood as the reduction of the intensity of the X-ray beam which occurs after it passes 
through a medium, due to the X-ray absorption and scattering. Attenuation is defined by the 
equation [39]: 
         
    (1) 
Where I(x) is the intensity transmitted through a thickness x and I0 is the intensity of photons 
incident on the material with linear attenuation coefficient μ. The attenuation of a mono-
energetic beam is obtained as a straight line by plotting I(x) as a function of x for a narrow 
mono-energetic beam, which can be described as an exponential function [39].  
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The half-value layer (HVL) is the thickness of a specific absorber that will attenuate the 
intensity of the beam to one half of its original intensity (Figure 1-6). Thus, when the reduction 
in intensity becomes half its original value, the absorber thickness is called the half value layer 
by definition, as in the following equation [39]: 
     
   
 
 
     
 
 (2) 
The beam produced by an X-ray tube is not a mono-energetic beam and contains a 
spectrum of X-ray energies. Therefore, attenuation of such a beam is not exponential and can 
therefore not be plotted as a straight line. As the material thickness increases, the slope in the 
resultant attenuation curve decreases, due to the material’s removal of low energy photons by a 
filtering process as indicated in Figure 1-7. 
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Figure 1-6: Illustration of the reduction in the intensity of mono-energetic photon beam as a function of 
thickness of the material absorber. 
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Figure 1-7: Illustration of the transmission of the X-ray tube beam as a function of aluminum absorber.  
 
The first HVL reduces the incident X-ray beam intensity to 50%, whereas, the second 
HVL is the thickness of the absorber that attenuates the transmitted beam to half of its value after 
it passes the thickness equal to the first HVL. The third half layer is the thickness of the absorber 
required to reduce the intensity of the transmitted X-ray beam by 50% from the level it was after 
passing through the absorber of thickness equal to two HVLs. The beam becomes harder as the 
filter thickens; that is, the average photon’s energy increases [39]. 
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1.3.4.1 Attenuation coefficient 
Attenuation can be defined in relation to several different coefficients, but the main coefficient is 
the linear attenuation coefficient µ, expressed in the unit of inverse centimetre (cm
−1
). However, 
this linear attenuation coefficient is reliant on the energy of the photons and other properties such 
as density (ρ) because the attenuation produced in a given thicknesses of a material is dependent 
on the number of electrons which exist in that thickness. It is possible to normalize the linear 
attenuation coefficient with respect to unit density, and the resultant mass attenuation coefficient 
(µ/ρ) is independent of density [39, 41]. 
1.3.4.2 Energy transfer coefficient  
The interaction between X-rays and electron orbital shells in matter leads to loss of the incident 
photon’s energy which is given to the electron as kinetic energy and the photon is reflected with 
reduced energy. The energy of the scattered photon might be adequate to undergo multiple 
interactions as it passes through the matter. As a photon beam travels through a material, the loss 
of photon energy transferred to electrons as kinetic energy (the quantity kerma) per unit mass of 
absorber can be described by the energy transfer coefficient (µtr). This coefficient can be likened 
to the linear attenuation coefficient as in the following equation [39]: 
 
    
   
  
   
(3) 
Where Ētr indicates the average loss in a photon’s energy, per unit thickness of the absorber. This 
energy is transferred into the kinetic energy of ejected electrons. Similarly the mass energy 
transfer coefficient can be obtained by normalizing the linear attenuation coefficient with respect 
to unit density (µtr/ρ) [39, 40]. 
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1.3.4.3 Energy absorption coefficient  
The ejected electrons can also experience kinetic energy loss as they traverse a material by 
electron interactions with material atoms. The energy loss of electrons results from inelastic 
collision with atomic electrons of the material due to ionisation and excitation processes. 
Electrons also can lose their energy during bremsstrahlung interaction with nuclei. This 
interaction is negligible in low Z materials and electron energy; however, when the Z and 
electron energy increase, the electron energy loss increases producing high absorbed energy in 
the target material. Therefore, the energy absorption coefficient (µen) can be represented as the 
product of the energy transfer coefficient (1 – g) where g represents the average of secondary 
electron energy lost through the creation of bremsstrahlung in the absorber as in the following 
equation [39]: 
              (4) 
Since the energy absorption coefficient can evaluate the energy absorbed in target tissues 
and predict the biological impact of radiation, it is an influential quantity for prospective 
radiotherapy [7, 39]. 
1.3.5 Basic physics of CT (Imaging)  
This section focuses in the imaging techniques, such as conventional X-ray CT, Dual energy CT 
and spectral CT. It contains principles and the basic physics of CT scanners. 
1.3.5.1 Principles of CT scanning 
Conventional X-rays are used as an imaging technique for clinical diagnosis; however, the 
superimposition of structures remains the main limitation of this imaging modality. Structures 
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with high attenuation such as bone provide clearer images compared with low attenuation 
structures such as soft tissue, which is completely hidden in conventional film radiography. X-
ray computed tomography (CT) as a digital imaging modality provides depth information of soft 
tissue structures and overcomes the limitations of traditional radiography. Diagnostic CT images 
are obtained by rotating X-rays sources around the patient at a large number of angles by rotating 
X-rays tube around the body (Figure 1-8). The detector array is located on the opposite site of 
the patient to collect 3D slice images. Tomographic images (slice images) in CT offer higher 
contrast images compared to traditional X-ray modality [42] because CT measures the 
attenuation value produced from absorption or deflection by tissue structures along each ray 
from the source to detector in a multiple directions [16, 42]. 
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Figure 1-8: (a) CT image is obtained by rotating the X-ray tube and detectors. (b) Attenuation resulting 
from each volume element [16]. 
 
The intensity of the X-ray beam falls off exponentially on passing through the patient 
structure. The relationship is given by the following equation, where      is the measured 
attenuated intensity by body structures and (I0) is the primary intensity of the X-ray beam [16]. 
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∑        (5) 
 
I (χ) represent the voxels along the ray path; µi represents the linear attenuation coefficients of 
the structures within a voxel, and χi the absorber thickness of the voxel. 
A series of attenuation projections resulting from each ray path interval is obtained as the 
X-ray tube and array detectors are rotated through multiple angles. Subsequently, each picture 
element displays the sum off all attenuation coefficients. The integral of the attenuation 
components along the line which enables this is obtained using the algebraic reconstruction 
technique (ART). This enables the display of an appropriate grey scale with the special 
distribution of the physical quantity µ for each voxel by converting this to a CT number relative 
to the computed attenuation coefficient of water as in following equation [42]: 
 
   (
         
      
)        
(6) 
Where µt is the computed attenuation coefficient of a voxel along the ray track in the tissue and 
µw is the computed attenuation coefficient of water as a standard value. This equation is called 
the Hounsfield unit (HU) scale and it characterises the linear transformation of the computed 
attenuation coefficient measured in the tissue relative to the radiodensity of water at standard 
pressure and temperature (STP). Water equivalent tissue in this scale exhibit the zero Hounsfield 
units (HU), since µt = µwater, while -1000 HU is the CT value of air by definition. CT values of 
water and air constitute the fixed points in the scale, due their independence on the X-ray energy 
[42]. Human tissues that have higher physical density than water have a positive CT number, for 
example, liver and kidney, whereas tissue with a lower density than water, such as lung tissue 
and fat, return a negative CT value. Due to the higher Z of atoms in bone and its higher density, 
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it has a very high attenuation coefficient value, with possible values for the measured CT number 
being up to approximately +1000 HU on the scale. The CT value for bone is heavily reliant on 
X-ray energy. Therefore, CT numbers for human tissue range from −1024 HU for lung tissue to 
the highest value +3095 HU for compact bone [43]. This large range of numbers can be 
displayed at 4096 grey levels which cannot be evaluated in a single view (Figure 1-9). 
 
 
 
Figure 1-9: (a) The CT Hounsfield Scale. (b) CT windows for air, bone, and soft tissues as displayed in 
computer monitor. Each window can be adjusted on the screen by changing the window level and the 
range of grey scale [43].   
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1.3.5.2 Iodinated contrast agents 
Iodine has a long history of clinical use and is still widely used clinically as a CM for CT 
imaging due to the relatively high Z of this element (I = 53). This is the key parameter which 
makes iodine effective in producing a high computed attenuation coefficient. In addition, iodine 
compounds are the only kind of materials that can be injected into patients at a rate of grams per 
second, unlike other pharmaceuticals [44]. Iodinated CM is available in different molecular 
forms (Figure 1-10). Depending on the manufacturer, there may be slight variations in the 
modern versions; however, they share similar benzene ring structures that provide commendable 
stability, solubility and low toxicity. There are some complications associated with the use of 
these contrast materials. While these are less than their predecessors, the dangers still need to be 
taken into consideration. This is the reason that, until it is deemed diagnostically valuable, a 
clinician will not inject an entire dosage of iodinated CM into a healthy person. Therefore, any 
kind of improvement in toxicity is always welcome. In addition to this, efforts undertaken to 
improve quality of image and diagnostic specificity are valuable. There has been a wide range of 
scientific discoveries in iodinated CM which is evident through development of different 
molecular forms, reduction in toxicity and also changes in the applications related to radiology. 
These serve to guide those endeavouring to devise new species of CM and also provide solutions 
to overcome the hurdles that may be encountered with people who are interested in structures 
and pathologies in radiography. 
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Figure 1-10: Molecular structures of iodinated CT contrast agents: (a) ionic monomers, (b) nonionic 
monomers, (c) ionic dimer, and (d) nonionic dimer [16]. 
 
Urography is an area where iodinated CM has a wide range of uses. The radiographic 
procedure involved in this process involves injection of CM in the urinary tract via the urethra. 
The process is effective as it assists in images that are produced, however, for the long term, it is 
not considered as a practical method for invading the excretory system [45]. Hence, it is 
preferred to introduce a material known as radiopaque orally or through injection. Prior to 
imaging, it is essential to administer the excretion of iodinated salts and compounds from the 
blood stream to the urinary tract which occurs through kidneys. The administration assists the 
physicians to demarcate the margins of renal tissue, ureters, and bladder. This assists in diagnosis 
of conditions without the drawback of catheterisation that is required in retrograde pyelography. 
Syphilis patients exhibited early reports of enhancement in the urinary tract through the excretion 
of iodine when sodium iodide was prescribed as a part of their treatment regime [46]. In such 
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cases, image contrast has been found to be insufficient for diagnostically valuable which has 
resulted in further research in excretory use of iodinated CM. An iodinated compound was 
purposely used by Swick and von Lichtenberg in 1929, for solubility and tolerance in order to 
record a successful urogram which follows an intravenous injection [45, 47, 48]. Ionic iodinated 
contrast agent was the first generation to be used as a contrast agent; however, the amount of this 
contrast medium required to produce an adequate CT image was problematic because of the high 
osmolality of this material. Consequently, it was replaced by non-ionic iodinated media, 
resulting in a reduction in the osmolality of the media which in turn reduced the risk of adverse 
effects. The iodinated CM used earlier was based on sodium iodide and potassium iodide salts. 
While the salts were highly soluble, potassium iodide was the only species that did not exceed 
the desired level of toxicity in early trials [49, 50]. For intravenous administration, neither 
material was considered sufficiently tolerable. It was then that Swick along with his collaborators 
tested iodide that was bounded to benzene rings (Uroselectan). This was followed by variants 
that were di-iodinated resulting in further improvements in the solubility and to reduce the 
toxicity of the compound [45]. The next generation was tri-iodinated compounds such as 
diatrizoate [51]. 
However, the addition of more iodine atoms did not resolve the side-effects of iodinated 
CM. A study in 1969 brought forth the information that high osmolarity of the materials was 
responsible for a large contribution towards their toxicity [52]. These molecules were also 
hypotonic when compared to blood plasma. This had a result of an unnaturally large gradient that 
in turn attracted ions across the membrane of cells or through glomerular tissue in the kidneys. 
The older versions of CM provided distinct High Osmolar CM (HOCM). Salt forming carboxyl 
groups were removed and hydroxyl groups were added to maintain solubility. Thus, Almen was 
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able to produce a molecule that had a lower osmolarity than the previous iodinated species. The 
compound was called a Low Osmolar Contrast Media (LOCM) (iohexol). Furthermore, in order 
to reduce the viscosity of the highly concentrated solutions a synthesis of nearly spherical 
derivatives was suggested by Almen. This had a positive impact on the injection rate and also 
tolerability. 
The most advanced iodinated agents are the dimeric, iso-osmolar, non-ionic CM. Lessons 
from each step over the 75 year evolution of iodinated compounds have been incorporated. The 
compounds are dimeric, which refers to two almost identical copies of the tri-iodinated benzene 
rings. They are monomers to increase the number of iodine atoms per molecule (six present in 
total). The large size assists in reducing osmolarity as the radiopaque atoms are incorporated into 
fewer molecules of the solution’s volume. The osmolarity of the injected  M is similar to blood 
plasma in case of iso-osmolar CM and hence have minimal effects on the tonicity of the fluid 
space. The compound is non-ionic, which assists in improving osmolarity and also reduces pain 
upon injection [53].  
1.3.5.3 Adverse effects of iodinated contrast agents 
On considering the effect of CM, a separation between primary and secondary effects is 
considered. The primary effect of iodinated contrast agent is the attenuation of incident 
radiations. The secondary effect is generally undesirable and hence can be categorised as an 
adverse effect or event. The effects of iodinated CM in most patients are relatively minor and 
may not be manifested in a way that is detectable [54]. However, there is visible correlation 
between the administration of CM and also a decrease in renal function and also renal failure 
[55]. Nonetheless, it is still important to know of any other impacts on the functioning of the 
body that could result in a negative reaction.  
  
29 
 
Significant study and exploration has been done into the effects of CM [56-58]. 
Previously adverse effects were much more pronounced and serious than those today. There have 
been improvements due to the use of non-ionic, tri-iodinated compounds that have low 
osmolarity [59, 60]. The adverse effects can be considered to be dependent on the dosage 
provided. They are most commonly seen when a large volume of CM is provided, such as in 
cases of arteriography [53]. Therefore, the efforts that are undertaken to improve the quality of 
imaging and also reduce the quantity of iodinated CM used is valuable as it reduces the adverse 
effects.  
Renal malfunction mechanisms often follow the administration of iodinated CM, which is 
related to the solution’s hypertonicity and viscosity. On injection of HOCM, and also to some 
degree LOCM, the medium molecules are found to equilibrate within the intravascular 
compartment. These solutions are deemed to have a relatively higher osmolality than what is 
present in the human plasma and also across the capillary membranes into the vascular space 
[55]. The high dose of the solute and hypertonicity generates a strong gradient for the flow of the 
CM across the glomerular layers into the renal tubules [61]. Filtration and subsequent 
reabsorption marks the normal functioning of the kidney which is done by the renal tissue. The 
excretory volume which is collected by the contrast molecules exert osmotic forces that in turn 
reduce the reabsorption of water by these tissues [55]. A lower glomerular filtration rate (GRF) 
marks such decreases and changes, which is usually observed following contrast-aided 
radiography [62]. 
Most individuals are able to tolerate the effects of the intravenous iodinated CM without 
any such complications; however, there are some patients who have been observed to experience 
adverse effects of CM. These side effects have been related to risk factors such as the likelihood 
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of renal failure [63]. They involve pre-existing renal insufficiency, diabetes mellitus, 
dehydration, cardiovascular disease, concurrent use of diuretics, old age (>70 years), myeloma, 
hypertension, and hyperuricemia [63-65]. A low GFR related to renal insufficiency, which is 
tested by measuring a patient’s serum creatinine levels [59]. In such patients, it is recommended 
that appropriate precautions are taken before any radiocontrast examination. The precautions 
include hydration (which could be oral or intravenous), use of LOCM or iso-osmolar CM 
variants discontinued use of nephrotoxic drugs for a minimum of 24 h and consideration of 
alternate imaging techniques [66].  
1.3.5.4 Current trends  
During recent decades, adverse events related to the kidneys have been increasingly researched, 
although this has been much less extensive for non-ionic iso-osmolar CM [67]. In complex 
systems such as the human body, the mechanisms that result in the production of beneficial or 
detrimental effects have not been adequately researched. Further complicating this task is that 
treatments may show promising results in vitro which do not translated into tangible benefits 
when used in patients [68]. For instance, an experimental contrast agent may show a good safety 
profile in cultured nephron epithelial cells, which provide little information about the in vivo 
safety of the person. In reality, the cells do not simply exist in an environment with a 
concentrated foreign molecule but their function in clearing the substance across the boundaries 
of the renal medulla needs to be addressed [69]. The significant pathways that are present 
between surrounding tissues need to be considered [70]. Therefore, in fact there might be 
hundreds of hidden factors that can engage. 
Furthermore, despite the improvements which have been made to the use of iodinated 
contrast agents, some limitations to their effectiveness in CT imaging still exist. These 
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approaches have had limited success due to the high concentrations of iodinated contrast agents 
required for encapsulation and lengthy purification methods [71]. Additionally, targeted imaging 
with these nanoparticulate systems still remains a major challenge due to the difficulty in 
conjugating specifically targeted biological components to these materials and the subsequently 
low payloads/concentrations that are delivered to the target, resulting in low CT sensitivity [72, 
73]. More importantly, these iodinated CM have a short circulation time (less than 10 minutes 
for conventional iodinated compounds) due to the quick clearance by the kidney after 
administration. 
One approach used to mitigate contrast induced adverse events is to combine various 
CM. This is because each CM is individually safer when there is no chance that an excess dose is 
used. In other words, if the threshold of the dosage is passed, also the toxic effects of each of the 
CM are different. This approach ensures that the negative effects are not compounded. This has 
been studied by Badiola in a combination of gadolinium and iodinated CM for use in 
angiography [74]. Nonetheless, there still exists debate regarding the nephrotoxicity of 
gadolinium based contrast agents [68, 75, 76]. Gadolinium contrast agents are different as they 
have a shorter circulation time as compared to iodinated CM [77, 78]. Hence, they safer in 
patients with low tubuloglomerular filtration rates. However, research suggests that the 
pathological effects of using gadolinium-based CM are more severe and toxic.  
To improve the efficiency of CM is a constant process that results in noticeable benefits 
in terms of reduction of either the radiation dose to patient or administered contrast volume. In a 
study conducted by Badiola, limited contrast enhancement was visible by mass of radiopaque 
material administered (40 cc volume of 4 parts magnevist to 1 part optiray). Dual-energy 
subtraction angiography (DSA) (will be discuss in the following section 1.3.5.5) was used to 
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collect images which was present at potentials of 68 and 90 kVp. A method was proposed by 
Arvanitis and Speller to maximise the detection of iodine at low diagnostic tube potentials [79].  
In recent years, considerable progress has been made towards the production of NP-based CM 
[16, 80-83]. The goal is that if hundreds or thousands of radiopaque atoms are included in a 
single molecule then the inherent stress on the renal tissue can decrease during clearance. Such 
approach is applied with other heavy metals as well as iodine itself [80].  
1.3.5.5  Dual CT scanning 
Dual Source CT is an advanced CT procedure which uses two different X-ray tubes with 
different energies in a single scan to produce an image. Dual Energy CT (DE-CT) was initially 
performed in the 1970s; however, at that time it was achieved by employing different tube 
voltages over the same object in two scans to obtain two subsequent images [42, 84, 85]. Two 
scans with two different energy spectra are conducted in order to acquire separate attenuation 
values and extract accurate information for selected material from these data sets. For example, 
material density can be possibly obtained from material selective images which are based on 
measuring the difference on attenuation and material decomposition. The principle of DE-CT 
focuses on the advantages of using linear attenuation coefficients, which rely heavily on the 
energy of the X-rays used and on the Z of the material [42, 85-88]. The benefit of utilising X-
rays of different energy is evident when the effect of K-edge on mass attenuation coefficients is 
considered as illustrated for a few elements in Figure 1-11.  
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Figure 1-11: Illustration Mass attenuation coefficients as a function of material energy. 
 
The voltages applied across the rotating tubes on DE-CT range from a maximum of 140 
kVp to a minimum of 80 kVp, which can produce two different images resulting from the 
difference in attenuation between tissues (Figure 1-12). Since the average difference in energy 
between the two tubes is 60 kVp, including the characteristic X-ray of the anode, the smaller 
energy difference of the spectra can be 76 keV and 56 keV. In addition, a pre-filtration process is 
used in CT to remove X-ray photons with low energy (below 30 keV), and as a result, the overall 
average energy will increase to 92 keV [84].  
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Figure 1-12: Illustration of the energy spectra related to 80 and 140 kVp voltages and resultant energy 
spectrum after the filtration process [86]. 
 
Compton scattering is the predominate mechanism at moderate energy levels and is the 
main cause of the attenuation at this level. Whereas, the attenuation values of X-rays at lower 
energy results from the photoelectric effect. This means that the combination of these effects can 
produce the computed attenuation coefficient curve for any structure the following equation [42].  
                           (7) 
Where σ and τ represent  ompton scattering and the photoelectric effect, and a1 and a2 represent 
the weights of structural composition. The linear attenuation of two different materials can be 
acquired by contribution the effect of Compton scattering and the photoelectric effect within 
these materials. As a result, selected material attenuation will follow the equation 1-8: 
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                           (8) 
These materials’ Z and density should be sufficiently varied in two ranges; low and high which 
can be indicated as basis material with different subscript 1 and 2. Some elements within the 
body, such as calcium and water, that represents bone and soft tissues, have sufficient differences 
in their attenuation properties due to the difference in their Z and density and can therefore be 
selected as the basis materials for DE-CT. The main task in DE-CT is accurately estimating the 
values of C1 and C2 for each picture element in “basis material decomposition”[42]. 
1.3.5.6 The spectral CT scanning 
This section discusses and outlines the evolution of CT imaging techniques and the basis of the 
technology for spectral CT. CT imaging aims to measure the attenuation of X-rays properties in 
order to accurately characterise tissues. The evolution of the CT imaging technique is presented 
in Figure 1-13 from the conventional (single energy) CT scanning to a dual energy and spectral 
CT. 
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Figure 1-13: Illustration of the differences between CT techniques; starting with conventional CT, DE-CT 
and spectral CT [89-91]. The conventional CT scan measures the X-ray averaged attenuation over one 
spectrum using a single source, DE-CT measures the attenuation over two separate spectra using dual 
sources, and spectral CT measures the attenuation within multiple spectra of a single source. The multiple 
energies are measured by using spectral detectors (e.g., Medipix), which allow a complete measurement 
of energy of each photon and attenuation curves.  
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In conventional CT, the X-ray beams are passed through an object to form an image. This 
is done from multiple directions and the CT imaging measures the resultant reduction in the 
intensity of the beams. The material’s X-ray attenuation is directly dependant on the Z and the 
electronic density. The grey levels present in the CT slice can represent the attenuation in the X-
rays that displays the proportion of X-rays that were scattered or absorbed as they are passed 
through each voxel. Therefore, the conventional CT characterises tissues by providing the total 
attenuation in a voxel using a single scalar value in HU. However, it is not reliable to distinguish 
various types of tissue, due to its limit to measure the cumulative attenuation on the whole range 
for all the tissues present within the voxel but the tissues’ information about the energy 
dependence of the coefficient of attenuation is not obtained.  
On the contrary, the dual technique CT technique uses two X-ray energy spectra from a 
single source and repeated at different tube potential or by using different source filtrations or 
even both [85, 87, 88, 92]. This can be done using dual-source synchronous acquisition [93], 
single source sequential and single-source fast switching acquisition [94]. The additional 
measurement of the attenuation in DE-CT is retrieved at a second energy, which allows 
differentiation between two materials. A pair of images is produced using the different relative 
attenuation of the X-ray photons that are displayed by materials at different X-ray energies, 
which is used in separating structures.  
The attempt to test the feasibility and usefulness of DE-CT was done several years ago 
[85, 88, 95, 96]. The experimental prototypes usually required the acquisition of two separate CT 
data sets at different potentials. There are various clinical applications of DE-CT: (i) bone 
removal [97-99], (ii) computation of contrast-enhanced imaging [100], (iii) difference between 
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calcium and iodine [101], (iv) difference between blood, blood mixed with pus, bile and urine 
[102] and also the discrimination between the kidney stones [103].  
The now available technique of micro-CT imaging is capable of improved material 
characterisation through the use of spectral CT. The concept is based upon using a single 
standard X-ray beam and an energy resolving photon counting detector. A semiconductor sensor 
is used by the detector for the conversion of X-ray photons into the electron-hole pairs and then 
records the characteristics of the X-ray beam on a photon by photon basis. Therefore, multiple 
energy measurements are required for enhanced material identification and can be obtained from 
a conventional CT scan. The spectral CT is dividing a single, broad X-ray spectrum into energy 
bands that can be defined and separated. The spectral data can then be processed to increase the 
contrast among tissues or to enable material differentiation.  
The images produced by spectral CT are obtained through the use of multiple energies 
and these are then called spectroscopic or spectral CT images. The energy reliance on the linear 
x-ray attenuation coefficients are the function of the energy dependent probabilities of the 
Compton and photoelectric effects.  This is determined by the elemental composition and also 
the density of the material. Therefore, enhanced differentiation is possible using spectral CT for 
bones, muscle, and fat and even contrast agents. This is achieved either through the analysis of 
the relative contributions made by the Compton and photoelectric effects or of the composition 
of the element. Spectral CT can also be recognised as colour CT. The component images 
obtained using the spectral CT imaging can be combined together with the colour coding into a 
single composite image.  
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1.3.5.7 The MARS-CT scanning 
The design of CT systems has included high spatial resolution and spectral capability with the 
latest developments in the novel spectroscopic photon-counting detector technology. The 
technology has allowed for an extension in the capabilities of the previous generation of micro-
CT scanners. These types of scanners (spectral-CT) have several advantages over traditional CT 
scanners. Firstly, images with high resolution are produced. The spatial resolution is obtained by 
the focal spot size of the X-ray source, magnification factor and the pixel size of the detector. 
The spatial resolution of conventional CT systems is typically 0.3 mm [104]. Micro-CT systems 
utilise micro-focus X-ray tubes and high resolution imaging detectors, and are therefore able to 
produce images with high spatial resolution of the order of a few tens of microns. To evaluate the 
3D micro-structure of specimens, this resolution is deemed appropriate. Moreover, the 
spectroscopic photon-counting detectors are able to measure the energy distribution of photons 
without any additional weight or noise [105].  
These novel detectors are present in micro-CT scanners that have the ability for 
implementing advanced imaging techniques. The information obtained from the scanner can be 
used to provide enhanced contrast resolution and also to classify and quantify the relevant 
materials that are present within the target biological specimens [106].  With the aid of spectral 
micro-CT, it is possible to bring forth improvements in resolution, sensitivity and also 
quantitative accuracy for the specimen imaging. Anatomical, functional and molecular 
information can hence be obtained from such scanners. Therefore, these kinds of scanners are 
considered to be an alternative to the traditional clinical CT scanner [107]. 
A number of micro-CT scanners have been developed by New Zealand researchers [90, 
108-113]. These systems rely on the photon-counting detectors that have been developed by the 
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Medipix European collaboration. These detectors are used for several types of imaging as they 
have an advantage over charge integrating systems. The MARS-CT group at Otago University 
focuses on the application of these novel photon-counting detectors for pre-clinical research. The 
special micro-CT scanner provides well resolved spatial information and the data related to 
energies of X-rays with the help of the Medipix detector. The device is also known as the 
Medipix All Resolution System (MARS). In 2008, a MARS-CT1 proof-of-concept device was 
introduced. MARS-CT2 was developed a year later, but the limitations of both these systems 
were addressed in the subsequent MARS-CT3 system. The design of the latest version was 
advocated by the Department of Physics and Astronomy, University of Canterbury with 
assistance from University of Otago, Christchurch and local industry. The performance of the 
scanners was tested in the bioengineering laboratory in the Department of Radiology at 
Christchurch Hospital, New Zealand. This was done in accordance with the researcher 
application protocols.  
To date, these scanners have been used widely for pre-clinical applications such as imaging 
of various contrast agents [91, 110, 111, 114], atherosclerotic plaque imaging [89] and soft tissue 
imaging [115, 116]. As compared to the other CT scanners, MARS-CT provides more detailed 
information to the user, which allows for differentiation of tissues without the inherent 
drawbacks of the dual source approach.   
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1.4 Introduction to radiobiology in radiotherapy  
The word radiobiology refers to the study of the effect of ionising radiations on biological 
material [117]. When radiations are absorbed by biological tissues, cells or tissue damage can 
result, which can be repairable or unrepairable. Cell death results from unrepairable processes. 
The main aim of radiotherapy is to maximise the radiation dose delivered to tumours in order to 
achieve cell death. The subsequent section will explain how this occurs as well as some aspects 
of the biology of cells. 
1.4.1 Cells biology 
Cells are the main building blocks and the smallest living biological units of life. All living 
organism consist of enormous numbers of cells which are arranged together to build living 
structures such as the various forms of tissue in the organism. The principle of complementarity 
states that the activity of these structures depends on the chemical activity of individual cells as 
well as the multicellular organisms’ activity of its cells. The fundamental functional aspects of 
living things are demonstrated by cells, such as reproduction, growth and development, response 
to stimuli, metabolism and movement. Although there are differences between the function of 
the cells, they share some common features. All cells are enclosed by a plasma membrane which 
contains intracellular fluid (cytoplasm). The semifluid substances contain individual structures 
that work together to perform specific tasks and carry out specific functions. Cells contain 
chromosomes and genes in the form of DNA. Cells can be divided broadly into two types; 
prokaryotic and eukaryotic. The major difference between two types where is the chromosome is 
located. In prokaryotic cells, the genetic material is contained in the nuclide in the cytoplasm 
without a barrier separating it from other parts of the cell, in other words, these cells are without 
a nucleus [118, 119]. However, in eukaryotic cells, the location of the chromosome is in the 
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membrane bounded organelle called the nucleus which separates it from the cell’s other 
structure. In general, prokaryotic cells are small in size (1-10 microns in diameter) compared to 
eukaryotic cells (10-100 micron in diameter) [119]. Bacteria are an example of prokaryotic cells 
and eukaryote cells usually are found in multicellular organisms such as animals and plants. 
This thesis will focus in eukaryotic cells which contain three main components; membranes, 
nuclei, and other organelles, as shown in Figure 1-14. Table 1-1 summarise the main cellular 
structures and their functions in eukaryotic cells. 
 
 
 
Figure 1-14: Human lung adenocarcinoma epithelial (A549) cell line in culture.   
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Table 1-1: Description of cell components (organelles, suborganelles) and their functions [119]. 
Cell Element Structure Functions 
Plasma 
membrane 
It is composed of a double layer 
of lipids embedded with 
proteins. 
The selectively permeable membrane is an outer 
barrier that separates the structures of the cell 
from their outside environment and it transports 
what passes through and exits the cell. 
Cytoplasm 
The region inside the membrane 
but not the nucleus which 
consists of the fluid cytosol that 
is the jelly’s mixture containing 
dissolved organelles. 
Carries out specific functions. 
Mitochondria 
Relatively large organelle, 
bounded by double membrane 
structure, and   rodlike floating 
inside the cytosol. 
The sites of cellular respiration, which are 
responsible of the production of energy in the 
form of ATP from food molecules. 
Ribosome 
This particle contains two 
subunits; ribosomal RNA 
(rRNA) and proteins.  
Might be Free or linked to 
Rough endoplasmic reticulum. 
Synthesises all the cell’s proteins. 
 
Smooth 
endoplasmic 
reticulum 
Membrane systems of cavity. 
Has no ribosome on the surface. 
Synthesises lipids and steroids. 
Site of drug detoxification and calcium storage. 
Golgi apparatus 
Smooth membranes systems 
consist of flatten sacks called 
cisternae. 
Processes, modifies and packages the 
macromolecules such as protein and lipids in 
vesicle for secreting from the cells, it is 
involved in producing lysosomes and 
incorporated into the plasma membrane. 
Lysosomes 
A membrane system of sacs 
contains acid hydrolases. 
Major sites of intracellular digestion. 
Cytoskeleton 
An intracellular frame of fibre, it 
acts as muscle and a skeleton of 
the cells and extends throughout 
the cytoplasm. 
Contains of three types of fibres 
(microtubules, microfilament, 
and intermediate filament). 
Maintains the shape, support and movement 
inside the cells. 
Nucleus 
Central organelle enclosed by 
nuclear membrane and involves 
nucleoplasm, nucleoli and 
chromatin which contain DNA. 
Controls and regulates the cell’s activity. 
Responsible for controlling genetic information. 
Directs the multitude of protein synthesis tasks 
by producing messenger RNA (mRNA) based 
on instructions provided by the DNA. 
DNA replication during cells cycle. 
RNA synthesis (transcription). 
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Cells carry out different processes in order to generate the energy required to maintain a 
steady cellular state. They are two types of metabolic reactions that take place in the cell to 
enable cells to metabolise nutrients and organic molecules into energy: biosynthetic pathway 
(anabolism) and breaking down pathway (catabolism) [119]. In the catabolic process, cells 
undergo a series of derivative chemical reactions that break down complex substances into small 
units with the assistance of enzymes to release energy. The conversion of glucose during cellular 
respiration is one example of this destructive metabolism; glucose is turned into carbon dioxide 
and water. In anabolic metabolism, cells undergo a series of constructive chemical reactions that 
synthesises molecules to produce large molecules from small units, requiring energy in the 
process. Dipeptide synthesis from amino acids is one example of a biosynthetic metabolism 
[119]. 
Energy can be generated after breaking down complex sugars via a series of reactions 
called glycolysis. The process starts when cells absorb glucose and convert it into a substance 
called pyruvate with the production of two molecules of adenosine triphosphate (ATP). The 
following reactions, which are known as the Kreb’s citric acid cycle, take place when oxygen is 
available in cells [120]. Pyruvate is utilised to yield much more usable energy for the cells to 
maintain their functions. The nucleus is considered to be one of the most important organelle of 
eukaryotic cells as it governs all the important functions such as the information storage, 
retrieval and duplication of genetic information [118, 119].  
1.4.2 Cellular DNA target 
With reference to radiation damage, the most significant part of the cell is the nucleus which 
contains the DNA that controls the genetic information, and directs the synthesis of ribosomes 
and proteins; thus, it is the most important component of the cell that is responsible for all of the 
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cells’ activity. DNA is a large biopolymer containing many similar and smaller monomer units 
that are linked together (Figure 1-15). The monomers that create DNA are called nucleotides 
which can be considered as the building blocks. There is strong evidence that the biological 
effects of radiation such as cell death, carcinogenesis and mutation can be caused by breaking the 
DNA stands. Therefore, the principle target for ionising radiation is the DNA and chromosome 
structure inside the nucleus [117]. DNA has three main chemical components: a pentose sugar 
(deoxyribose), a nitrogenous base, and a phosphate group. Two categories of nitrogenous bases 
are purine and pyrimidine. DNA consists of two main purine bases (adenine (A) and guanine 
(G)) and two main pyrimidine bases (cytosine (C) and thymine (T)). The nucleotides hydrogen-
bond to each other (A with T, and G with C) to create base pairs, which connect the two DNA 
strands [121]. 
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Figure 1-15: Illustration showing DNA within the nucleus of the cell in the chromosomes and nucleotides 
as the building block of DNA [122].  
 
1.4.3 Radiation induced damage to DNA 
1.4.3.1 Radiation quality 
In radiation biology, radiation quality refers to the characteristics that determine interactions at 
the cellular level that may produce biological effects. In other words, radiation quality relates to 
beam characteristics that explain the spatial distribution of energy transfer by charged particles 
when other physical factors are kept constant (e.g., absorbed dose). 
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 Radiation absorbed dose 
Absorbed dose is the defined unit of measurement of the mean energy absorbed per unit mass. 
The SI unit of absorbed dose is the Gray (Gy), which is known as the absorption of 1 Joule of 
energy per kilogram of mass (J/kg). 
 Linear energy transfer (LET) 
Linear energy transfer (LET) is a physical quantity representing characteristic quality in 
radiobiology. The International Commission on Radiation Units and Measurements (ICRU) 
defines the LET as: the energy loss of the radiation in a medium, defined by the quotient dE/dl, 
where dE is the average energy locally absorbed in the medium by a charged particle of specified 
energy in traversing a distance of dl. The unit of LET is keV/μm. Since the energy lost is directly 
proportional to the density of the material traversed, LET can be approximated using the density 
of the material [123].  
 Relative Biological Effectiveness  
Relative Biological Effectiveness (RBE) is a comparison of test radiation with a standard 
radiation. It is the ratio of biological effectiveness of one type of ionising radiation in respect to 
another, given the same dose of absorbed energy.  
1.4.3.2 DNA damage by ionising radiation 
In biological materials, the absorption of energy from radiation can cause excitation or ionisation 
processes. The excitation process occurs when the energy imparted to the electron is sufficient to 
raise it to a higher energy level without causing the ejection of this electron. The ionisation 
process occurs when the incident radiation has sufficient energy to eject an electron out from its 
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orbital. Therefore, the interaction of ionisation radiation can result in the production of secondary 
electrons and free radicals in the biological system. When the radiation interacts directly with 
critical targets, such as DNA atoms, it may be ionised or excited to cause a biological change. 
This is referred to as a direct effect of the radiation and is usually the dominant process when the 
radiation has a high LET, such as neutrons and alpha particles. Alternatively, indirect action 
occurs when the radiation interacts indirectly with other atoms and molecules, such as water, 
producing free radicals that are capable damaging critical targets, such as the chemical bonds of 
proteins and DNA. X-rays and gamma rays have a low LET (sparsely ionising), and therefore 
interact through this indirect mechanism [117] (Figure 1-16). 
 
 
 
Figure 1-16: Distribution of ionisations and excitations along different particles tracks in H2O [124]. 
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When cells are irradiated, their vital functions can be affected by both free radicals and 
direct ionisation, which can break chemical bonds and create new bonds between molecules and 
macromolecules. This disruption can be repaired through several repair mechanisms, depending 
upon the degree of damage. DNA strand breakage caused by radiation can be classified into two 
types; single strand breakage (SSBs) or double strand breakage (DSBs). Single strand breakage 
occurs when only one of the strands of a double helix is damaged. This type of damage is of little 
biological consequence as the opposite unbroken strand can still be used as a template. When the 
repair is incorrect this may lead to minor biological consequences such as a mutation. Double 
strand breakage, however, occurs when both stands of DNA are broken resulting in cleavage of 
chromatin into parts. This type can cause significant biological consequences and is considered 
to be irreparable [117, 125]. As a result of the complete disruption, cell death, carcinogenesis or 
mutation occurs. Figure 1-17 illustrates the formation of radiation damage as results of single 
and double strand break. 
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Figure 1-17: Illustration of DNA stand breaks cause by radiation. (a) Single strand break. (b) Double 
strand break (adapted from [126])  
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The DNA molecule is folded and packaged into thread-like structures called 
chromosomes. Each chromosome consists of DNA molecules with ribonucleic acid (RNA) 
twisted into the shape of a helix and coiled many times around proteins. During mitosis or 
meiosis the two duplicated chromosomes are joined at the constriction point called the 
centromere producing chromatid [117]. If DSBs, the lethal form of ionising radiation-induced 
damage occurs at a large scale, this leads to chromosome or chromatid aberration (Figure 1-18). 
DSBs can be repaired by two competing processes: non-homologous end-joining (NHEJ) which 
and homologous recombination repair (HRR). The former does not require undamaged 
chromatid to repair but can mediate end to end joining, the latter requires an undamaged 
chromatid. Chromosome aberration occurs after nonhomologous recombination in the G1 phase 
and chromatid aberrations results from homologous re-joining occurring in the S and G2 phase 
of the cell cycle as shown in (Figure 1-19).  
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Figure 1-18: Diagram of chromosome aberration or breakage occurred by radiation. (a) Two chromosome 
breaks as a result from two separate free radical. (b) A single free radical produces the two chromosome 
breaks. 
 
Figure 1-19: Diagram of non-homologous end-joining (NHEJ) occurring in G1 phase of the cells cycle 
when there is no undamaged chromatid to be used as a template.  The S and G2 Phase of the cells cycle 
indicates the homologous recombination repair (HRR), when there is chromatid can be used as a 
template.  
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1.4.4 Cell survival curves  
The damage caused by ionising radiation to biological tissue is usually expressed by cell survival 
curves [117]. Cell survival curves illustrate the relationship between the absorbed dose and the 
fraction of cells that survive that dose and maintain their reproductive integrity. Survival curves 
are graphically presented in the form indicated in Figure 1-20, by plotting the surviving fraction 
on a logarithmic scale versus radiation dose on a linear scale [117, 125]. 
 
 
 
Figure 1-20: Proposed models for interpretation of the shape of cell survival curves for mammalian cells 
after they have been exposed to radiation. The fraction of cell survival is plotted on a logarithmic scale 
versus radiation dose on linear scale. (a) The multi-target hit model. (b) The linear quadratic model. 
 
The shape of the cell survival curves is highly dependent on several factors, such as the 
radiation type and the cell line. For example, survival curves for most mammalian cells that are 
exposed to low-LET radiation, such as X-rays and gamma rays, usually start with a straight line 
on the logarithm scale, followed by a shoulder and then tend to be exponential again at high 
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dose. By contrast, for densely ionising radiation such as neutrons that have high-LET, the cell 
survival curve exhibits a straight line along the entire dose range [117, 127]. There are various 
biological theories that have been proposed to interpret the shape of cell survival curves; the 
common models are the Multi-target model and the Linear-quadratic model [125]. The former 
model was widely used for decades and is illustrated in Figure 1-20a. In this model, the cell 
survival curve is explained in terms of the initial slope which represents the single hit event on 
cells (D0) and the final slope that represents the multiple event hit, therefore, the width of the 
shoulder is dependent on whether the radiation causes single or multiple killing events on the 
cells. Electrons or free radicals are liberated during the single event hit, killing cells through the 
interaction with DNA. As the radiation increases, the cellular repair processes increase, and 
therefore the cells’ resistance increases. At higher dose the multiple-event hit takes place 
reducing the cells’ ability to repair, which leads to the cellular lethality [127]. The width of the 
shoulder can be represented by the following equation: 
 
      
  
  
      
(9) 
Where, n represents the extrapolation number, which measures the width of the shoulder. Dq, is 
the quasi-threshold dose which is the radiation dose below which no influence is produced. 
However, not all of the survival data fits this model due to the insufficiently precise nature of the 
biological data. The second model (Figure 1-20b) is used as the current radiobiological model 
because it provides a satisfactory and practical interpretation of the survival curves observed at a 
clinical level. The linear quadratic model (LQ) assumes that there are two main components that 
can induce the cells inactivation by a free radical, one of which is proportional to dose as a result 
of a single ionising hit, and the second is proportional to the square root of the dose resulting 
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from two separate ionising events [117, 127]. In this model, the formulation of fraction of cells 
that survive the dose is expressed by the equation: 
          
 
 (10) 
Where, S is the fraction of cells surviving, D represents the dose, α describes the linear portion of 
the survival curve, which is the probability of a single ionising event that produces the two 
chromosome breakage at low dose. When the dose increases, the quadratic portion of the cell 
survival curve (β) takes place, producing the two chromosome breakage as a result of two 
separate electrons. The radiation induced cell death depends on number of radiation interactions 
and dose absorption occurring in the biological matter. The linear and quadric portions of the 
cells survival curve are equal when the absorbed dose is equal to the ratio ⍺/β, that is, the more 
linear the effect and less sensitive to the dose fraction. The interaction of low-LET radiation with 
high Z materials results in an increasing number of free radicals, which in turn can lead to 
significant biological damage of DNA [117]. Therefore, delivering a large amount of a high Z 
material into the biological target will enhance radiotherapy effects. Currently, nanostructures 
composed of atoms with high Z have been utilised to enhance the treatment of cancer using 
ionising radiation. Beside enhancement of energy absorption, it has recently been shown that the 
high Z NPs can increase the nuclear damage by inducing chemical radio-sensitivity of DNA 
[37]. This study focuses on the use of NPs to enhance the effect of radio sensitisation and dose in 
biological systems. 
1.4.5 Cell death  
Apoptosis or programmed cell death refers to a series of molecular steps to reach a distinct 
morphological characteristics and biochemical changes that results in the death of a cell. In 
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radiobiology, a cell is principally considered as dead when it no longer produces healthy cells, 
this is otherwise defined as a loss of proliferative potential [128]. In this study, loss of 
proliferating capacity has been used to consider the cells death.  
1.5 Introduction to nanotechnology 
This section contains a description of the properties of metallic NPs as well as their role in 
enhancing the subject contrast in CT and radiosensitisation in radiotherapy. 
1.5.1 Nanoscale properties 
The term ‘nanotechnology’ refers to the design, creation and manipulation of materials and 
particles with dimension of less than 100 nm. Thus, nanotechnology is concerned with particles 
that are less than 1/80 of the size of red blood cells [129] (Figure 1-21). Nanometre-sized 
particles (NPs) have unique properties, which are not evident in larger particles or materials 
[130, 131]. The atomic characteristics in nanoscale allows for achieving different shape, size, 
strength, conductivity, melting point, optical and magnetic characteristics [129, 131, 132]. 
Moreover, low dimension material can be taken up and maintained in cells to a greater extent 
than bulk materials [133]. The fundamental factors controlling these unique properties of 
nanoscale materials are their size and surface characteristics. These are interconnected, because 
as the size decrease, the surface area-to-volume ratio (SA/V) increases. The properties of 
nanoscale structures are dependent on size; however, the properties of bulk materials are only 
dependent on chemical composition. The size of NPs allows them to exhibit the unique 
phenomena, including quantum confinement effects. For example, for semiconductor materials, 
as the size of particles decrease below the Bohr radius of the bulk materials, the motion of the 
electrons becomes more confined to specific energy levels (discreteness) [134]. As results, the 
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energy levels become discrete and this, in turn, increases or widens the band gap. Eventually the 
valence and conduction bands will produce more discrete energy levels by decreasing the 
confining dimension [132]. The surface of the NPs is the second key factor controlling their 
properties. As the size decrease towards an atomic level, the surface of the NPs are chemically 
more active compared to the bulk material that has less close coordination and fewer dangling 
bonds [133, 135].  
 
 
Figure 1-21: Nanoscale comparison of nanoparticles [136]. 
 
There are a number of advantages for using NPs as diagnostic and therapeutic agents. Because of 
the large SA/V in NPs, one NP can deliver more atoms to the target and hence enhance the 
radiation interaction probability (Figure 1-22). 
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Figure 1-22: One nanoparticle contains hundreds or thousands of atoms that can be delivered to the target. 
 
It is also possible to functionalise the surface of the NPs to make them biocompatible, as 
well as to target the region of interest [137]. The small size of NPs  relative to the size of a cell 
gives them the potential to interact with cell membranes and become internalised (intracellular) 
[138]. Recently, some studies have reported the capability of some metallic NPs (e.g., Au and 
Bi) to serve as contrast agents for X-ray imaging application. Moreover, another advantage of 
NPs is that they can be used as therapeutic agents. The following subsections 1.5.1 and 1.5.3 
focus on the application of metallic NPs for diagnostic imaging and radiotherapy.  
1.5.2 Nanoparticles as CT contrast agents (Imaging) 
Recently, bismuth-based NPs have attracted a great deal of attention for CT imaging applications 
due to their high X-ray attenuation coefficients, which results from the large Z and physical 
density of bismuth. From the perspective of radiation (X-ray), bismuth and its compounds 
possess unique and desirable properties. Specifically, these parameters are its effective atomic 
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number (Zeff), physical density (ρm), and electron density (ρe). The Zeff  and ρe have been 
calculated using the following equation [39]: 
      √                                   
      
 (11) 
 
    
  
 
        
(12) 
 
Where fn is the portion of the total number of electrons, Z is the atomic number, NA is the 
Avogadro constant, ρm is the physical density and A is the average atomic mass. The Zeff, ρm and ρe 
of water and common bismuth-based compounds are provided in Table 1-2. The high values for 
bismuth-based compounds can increase the probability of photoelectric effects and Compton 
scatting, which leads to improved X-ray attenuation as well as absorption. The chemical 
characteristics of bismuth compounds are also important to anticipate the radiation effect as 
indicted in Table 1-3. 
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Table 1-2: Physical properties for bismuth compounds  
Compound Zeff ρm 
(kg m
-3 
) 
ρe  
(×10 
30
 em
-3)
 
H2O 7.42 1000 0.334 
BiI3 66.4 5780 1.43 
Bi2S3 76.2 6780 1.69 
Bi2O3 79.4 8900 2.18 
BiOI 
Bi 
63.4 
83 
7920 
9780 
1.95 
2.35 
 
Table 1-3: Chemical properties for bismuth compounds.   
 
Symbol 
 
Element 
 
Atomic weight 
 
Number of atoms 
 
Mass precent (%)  
BiI3 Bismuth 208.980 1 35.43  
Iodine 126.904 3 64.56  
Bi2S3 Bismuth 208.980 2 81.29  
Sulfur 32.0655 3 18.71  
Bi2O3 Bismuth 208.980 2 89.70  
Oxygen 15.999 3 10.30 
BiOI Bismuth 208.980 1 59.39 
Oxygen 15.999 1 4.45 
Iodine 126.904 1 36.06 
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Bismuth-based NP contrast agents for CT possess several advantages over conventional 
iodine-based and Au-NP contrast agents as a result of their high Z (I = 53, Au = 79, Bi = 83), 
high X-ray attenuation (I = 1.94; Au = 5.16; Bi = 5.74 cm
2
kg
-1 
at 100 keV) [16, 27, 31, 139, 
140], low cost (~ $ 0.02 g
-1
) [71, 141] and low toxicity [27]. Bi2S3 is one of the most promising 
NP contrast agents as a result of its high effective atomic number (Zeff = 76.2), physical density 
(ρm = 6780 Kg.m
-3
), and electron density (ρe = 1.69×10
30
 e.m
-3
) (Table 1-2). The high density of 
free electrons increases the probability for CS, which is of particular interest in X-ray 
applications. Besides these properties of bismuth, bismuth-based NPs have become a most 
promising candidate for use as a contrast agent for CT due to their unique nanoscale properties. 
For example, bismuth sulfide nanoparticles (Bi2S3-NPs) coated with poly (vinyl pyrrolidone) 
(PVP) and have been used in vivo as a contrast medium for CT. These nanoparticles were 
rectangular platelets ranging in size from 10 to 50 nm and displayed significantly longer 
circulation times (140 ±15 min) compared to iodinated agents (< 10 min). A comparative dose-
response cytotoxicity study between Bi2S3-NPs and clinical iodine agents was conducted, and 
revealed that the NPs had a similar toxicity profile to iodine in macrophage (U937) cells and a 
superior profile in hepatocyte (HepG2) cells. In addition, after the introduction of these 
nanoparticles to lymph nodes, CT images were clearly demonstrated [27]. These results have 
also been confirmed in similar studies [31]. In addition, Bi2S3-NPs have been labelled with cyclic 
peptides in order to target them towards breast cancer in mice. The targeted Bi2S3-NPs were 
prepared by coating Bi2S3-NPs with PEG5000-DSPE(1,2-distearoyl-sn-glycerol-3-phosphoetha-
nolamine-N-[amino(polyethylene glycol)-2000) and then conjugation with the lyp-1 peptide. The 
labelled Bi2S3-NPs show a higher CT number in the targeted region and a clearer image 
compared to non-labelled NPs after intravenous admission [139]. Micellar Bi-NPs have also 
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been synthesised with a phospholipid surface coating for use as a contrast agent for molecular 
imaging (spectral CT). Spectral CT is an advanced technique which enhances traditional CT 
images. It is based on K-edge energies for targeted elements. In this study, targeted bismuth, 
gold, and gadolinium NPs have been successfully utilised as a contrast agent for spectral CT to 
image fibrin clots [142]. Moreover, the encapsulation of bismuth as BiOCl/Bi2O3 within ultra-
short nano-tubes has been developed, with these particles labeled in mesenchymal stem cells 
(MSCs). Bi@US-tubes have a CT number 500 times greater than polymer coated Bi2S3-NPs and 
the clinical iodinated contrast agent [71]. Bismuth oxide nanoparticles (Bi2O3-NPs) also have 
been synthesised using thermal decomposition; then the surface modification was conducted 
with human serum albumin (HSA), by using a precipitation methods. The HSA surface coating 
plays an important role in improving the NPs stability in aqueous solution. The in vitro results 
indicated that the Bi2O3-NPs has 20% higher contrast enhancement compared to Bi2O3/HSA 
core-shell NPs. However, the safety and stability are much better in Bi2O3/HSA core-shell NPs. 
The in vivo study was conducted using rate model and proved that Bi2O3/HSA core-shell NPs 
have lower toxicity and higher contrast [71]. Another study reported the synthesis method of ⍺-
Bi2O3-NPs via a precipitation method, with the surface coating methotrexate (MTX) through (3-
aminopropyl) trimethoxysilane (APTMS). The ⍺-Bi2O3–APTMS–MTX has a better 
dispersibility, stability and less toxicity than uncoated Bi2O3. The ⍺-Bi2O3-NPs showed contrast 
enhancement capabilities [143]. A recent study reported the synthesis of Bi-NPs modified with 
dodecanethiol (DT-Bi-NPs). Such NPs have promising potential for high performance CT GI 
tract contrast agent (in vivo study) [144]. A second study involved the fabrication of ultrahigh 
payload Bi-NPs in 1,2-propanediol and their capability in enhancing the subject contrast for CT 
as a contrast agents [145]. 
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1.5.3  Nanoparticles as therapeutic agents (Radiotherapy)  
Bismuth is a material with a high Z, and this has been demonstrated to enhance radiation dose 
and improve therapeutic efficacy in radiotherapy. However, while extensive research has been 
conducted into radiation dose enhancement potential of Au-NPs, few studies have been carried 
out to investigate the effectiveness of Bi-based NPs. Bismuth and its compounds possess the 
desired properties that make it a candidate for use as a superior dose enhancing agent. The 
important parameters are Zeff, ρm, and ρe that can increase the probability of photoelectric effects 
and the Compton scatting effects leading to improve X-ray absorption as shown in Table 1-2. As 
a result of the interaction of X-rays with NPs, the emission of photo-electrons and Auger 
electrons and characteristic X-rays can generate reactive oxygen species (ROS), which become 
an additional tool in radiotherapy treatment [34]. Moreover, the percentage of bismuth atoms in 
bismuth compounds is also important to anticipate the radiation effect as indicted in Table 1-3. 
For example, the percentage of bismuth by mass in Bi2O3 (89.6%) is higher than in Bi2S3 
(81.2%), and it can therefore absorb a larger amount of energy. The radiation dose enhancement 
for commercial Bi2O3- and Bi2S3-NPs has been investigated using phantom studies, which 
revealed Bi2O3-NPs enhance the radiation dose to 12% higher than Au-NPs in the kVp. Whereas, 
the DEF for Bi2S3-NPs was 13% lower than gold NPs. The irradiation with a MV beam indicated 
similar results; however, DEF values were 15% lower than in the case of the kVp beam. The 
reason for this discrepancy is that, in a higher energy range, the photoelectric effect is not the 
dominant interaction process [146]. 
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1.5.3.1 Enhancement of radiation effect by high-Z elements 
Usage of photons in the kilo electron voltage (keV) range enhances the dose delivered as a result 
of the additional photoelectric interactions that result from the increase in cross sectional 
interaction, which are highly dependent on the Z of the material. Early studies were conducted to 
understand the enhancement of bromine atoms incorporated in phage DNA as 
bromodeoxyuridine, which displayed enhanced biological effects due to ionisation of the 
bromine K-shell and also Auger effects [147]. Another study has reported the induction of Auger 
effects in killing mammalian cells pre-labelled with 5-bromodeoxyuridine after irradiation with 
monochromatic synchrotron radiation [148]. Similar studies were done by sensitising 
mammalian cells with 5-bromodeoxyuridine [149] and with 5-iododeoxyuridine [150]. 
Furthermore, it was shown that when the energy of photons reaches the absorption edge of the 
inner shell of platinum, a platinum containing molecule can be used as a radiosensitising agent 
[151]. In this work we enhance the radiosensitivity of cells using NPs incorporating high Z-
atoms. 
1.5.3.1.1 Auger effect  
This phenomenon was first described by Pierre Victor Auger In 1925 [152]. The pattern of 
electron tracks that were produced by the irradiation of the cloud chamber of low energy X-rays 
were traced and the production of multiple electron tracks was also noted. A study concluded 
that the event was a result of the transition in electrons that was initiated by the low energy X-
rays photons that impinge the target atoms and release inner shell electrons [153]. The vacancy 
as a result of this causes the emission of characteristic X-rays and low energy Auger electrons, 
which leads to the emission of Auger, Coster-Kronig, and super Coster-Kronig electrons [153, 
154]. It was depicted that the Auger effect is a result of various radionuclides that decay due to 
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electron capture (EC) or internal conversion (IC) [155]. The photons utilised in this case – when 
the energy of the photons is greater than the energy of the inner shell electrons of the target atom 
– can be absorbed through the photoelectric effect resulting in a vacancy. The photoelectric 
interaction depends on the energy of the photon as well as the target element. An inner shell state 
can be ionised when it is effectively induced by appropriate energy of incident X-rays, 
synchrotron radiation being the only source of light to intensify the monoenergetic photon 
sources. However, Auger effects are frequently induced in X-ray irradiated samples even though 
poly-energetic X-ray beam are used [156].  
The significance of the Auger effect on biology was ignored for many years due to their 
low energy and also the short range when compared to the energy released from a decaying 
radionuclide. The distance travelled by Auger electrons range form 2-500 nm resulting in high-
LET radiation, which ranges from 2 – 25 keV/μm [155, 157, 158]. Due to the polychromatic 
nature of X-ray from X-ray tubes, the investigation and application associated with the photo 
absorption spectra at the X-rays energy level have failed. However, after a meeting in 1975 
organised by Ludwig Feinendegen in Jlich in Germany which considered the biological aspects 
of Auger effects, things changed [154]. 
This thesis will explore the radiobiological effects of Auger electrons which is are a 
consequence of the photoelectric effect (induced by external X-ray beams) in the presence of 
radiosensitiser nanomaterials containing high Z atoms that have been incorporated into cells to 
produce more lethal damage.  
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1.5.3.2 Theoretical calculation of radiation dose enhancement by 
nanoparticles 
Absorbed energy resulting from high Z NPs (radiosensitisers) can enhance the radiation dose in 
target tissue. The radiation dose enhancement can be obtained by the quantity DEF; that is, the 
dose enhancement factor, which is defined as the ratio of the average dose absorbed in a region 
of interest with NPs to that without NPs. The most effective way for DEF to be calculated is by 
estimating the ratio of mass energy absorption coefficient μen/ρ values for NPs to water using 
mono-energetic beams as in the following equation: 
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(13) 
Where μen/ρ represents the mass energy absorption coefficient, E is the energy of mono-energetic 
beam, NPs is nanoparticles and WNp is the weight of nanoparticles. The effect of high atomic 
number (Z) in enhancing ration dose is demonstrated by the following (Figure 1-23)  
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Figure 1-23: DEF as a function of Atomic number (Z) [159]. 
 
Using the previous equation, the theoretical expected DEF was calculated for different 
beam energies and concentration of the three elements iodine, gold and bismuth. Energy 
dependence of the DEF for different concentrations in water is presented in Figure 1-24. The 
iodine’s DEF result has increased from the K-edge of iodine (33.2 keV) up to about 80 keV and 
having its maximum around 50 keV for 100% concentration of iodine mixture. In contrast, the 
maximum energy range of energies resulting in the maximum dose value is found to be at energy 
way below the gold and bismuth’s K-edge value which is around 40 kev, value of DEF at that 
energy is about 160 for Au and 180 for Bi. For Au, the DEF is strikingly increases till it reaches 
peak at 40 keV and gradually reduces till it passes the K-edge energy where there is steep 
increase followed by a gradual decline as energy increases. This in agreement with previous 
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calculation for iodine [21] and gold [160]. Similar trend of DEF is obtained for Bi, however, 
after reaching the bismuth’s K-edge at 91 keV, the DEF trend is representing constant values 
then followed by a gradual decrease as energy increases. By comparing the three curves, it is 
noted that all the three elements represent a similar bell shape curve. DEF comparison for all 
elements at 50% concentration (50 mg/mL) has been represented in Figure 1-25. From 10 to 50 
keV, gold and bismuth produce a higher DEF compared to iodine. Around 60 to 80 keV, the 
DEF for iodine is found to be slightly higher than both gold and bismuth. At approximately 100 
keV and above, the DEF for gold and bismuth reaches there are higher than iodine. Thus, 
bismuth and gold have a higher DEF compared to iodine at most range of energies which are 
most suitable radiation levels for dose enhancer assisted radiotherapy. In addition, From the 
Figures 1-24 and 1-25, the expected DEF for bismuth is slightly higher at energy range from 50 
to 100 keV, when comperes to gold. 
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Figure 1-24: Energy dependence of the DEF for different elements iodine (a), gold (b), and bismuth (c) 
concentrations in H2O.  
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Figure 1-25: DEF comparison for iodine, gold and bismuth at 80% concentration.  
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1.6 Thesis overview 
This thesis is divided into two major sections: 
 Section A : Diagnosis using a phantom study  
 Section B: Therapeutic component using biological / cell culture study 
1.6.1 Objectives 
The idea of using NPs as contrast agents in CT imaging and dose enhancer agents in 
radiotherapy has been around for a long time. However, this research is based on a novel 
approach due to its strong theoretical basis for the design methodology and enhanced 
biocompatibility of the nanomaterials under investigation. The novelty is to examine the 
possibility of developing bismuth compound NPs as contrast agents by controlling their synthesis 
and surface modification to provide long circulation time, enhanced high quality imaging 
platform to show greater detail in CT images while simultaneously considering the 
biocompatibility factor. The hope for this development is to that it will not only be used for 
diagnostic purposes but also as a new therapy for cancerous tumours in order to be eventually 
used as “THERANOSTIC” agents. Therefore, development of novel and improved diagnostic and 
therapeutic agents in the nanoscale can help improve the visualisation of some previously 
undetectable pathology, refine the localisation of tumours and improve the therapeutic effect of 
radiotherapy. The use of these particles allows researchers to diagnose and treat cancer in its 
earliest stages of progression; it has enhanced established therapeutic approaches and has 
facilitated the development of novel therapies.  
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1.6.2 Hypothesis 
The two major hypothesises underlying the work presented in this thesis are that firstly, bismuth 
compounds (Bi2S3 and BiOI) NPs can improve CT application contrast sensitivity. Second 
hypothesis is that local tumour control can be improved by exploiting bismuth and bismuth 
compounds NPs (Bi and Bi2S3) NPs so as to increase the energy deposited in the tumour cells. 
Our research hypothesis is driven by idea of the influence of free radicals and the importance of 
cluster damage produced by these low energy electrons. The experimental approach, aims and 
objectives of each chapter are discussed in detail below: 
1.6.3 Thesis outlines  
Chapters in this thesis have been written as a stand-alone study of each main aim.  
 Chapter 1 includes an introduction to the basic radiation physics in CT and radiation 
therapy, radiobiology and nanotechnology. This chapter contains a review of previous 
studies and current studies on using high Z material in radiation effect enhancement in 
CT and radiotherapy. Detailed description of the interaction of radiation with different 
matter such as water, iodine, and high Z materials and the theoretical background of the 
subject contrast and dose enhancement effects are also provided.  
 Chapter 2 presents details of the general materials, instrumentation and experimental 
methodologies used in this research. 
 Chapter 3 presents the first part results of synthesis methods and surface modification 
of the Bi-based NPs for radiobiological applications. This chapter also includes the 
results of NPs characterisations using TEM, XRD, XPS, FT-IR, Zeta potential and 
TGA. 
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 Chapter 4 describes the diagnostic part including three parts: studying the X-ray 
attenuation profile for Bi2S3-NPs coated with PVP and compared to iodinated CM by 
increasing tube potential and secondly the comparison of X-ray attenuation in DE-CT 
and MARS-CT images resulted from the two BiOI-NPs and iodinated contrast agents. 
 Chapter 5 contains the radiobiological study of dose enhancement produced by NPs in 
cells study including the cytotoxicity results using colourimetric (MTS) and clonogenic 
assays. 
 Chapter 10 contains the concluding remarks and future direction of this study. 
1.6.4 Aims 
The research outlined in this thesis aimed to: 
1. Synthesise Bi and its compounds as biocompatible NPs such as Bi2S3 and BiOI.  
2. Characterise the NPs in terms of the following parameters: size, chemical composition, 
surface charge, and surface area using the characterisation techniques:  TEM, Zetasizer, 
XRD, XPS, TGA and FT-IR. 
3. Investigate the feasibility of employing Bi compounds as a contrast agent in a phantom 
study for computed tomography and quantifying the subject contrast enhancement 
relative to iodinated CM depending on the voltage applied to the X-ray tube using an 
image phantom.  
4. Provide the first direct experimental confirmation in enhancing the subject contrast of 
DE-CT and MARS spectral CT using BiOI-NPs. 
5. Establish tissue culture methods and techniques by growing cells, counting and splitting 
them and by setting up the colourimetric (MTS) and clonogenic assays. 
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6. Test the cytotoxicity of the NPs by measuring the cell viability. 
7. Assess the dose enhancement obtained by Bi-based NPs using cells lines irradiated with 
1-7 Gy range of fraction radiation doses with different type of radiation sources and at 
various concentrations of NPs. 
8. Determine the DEF using the cell survival curve analysis. In this study, the radiological 
model (LQ) was used to analyse the effects of NPs on radiation dose. LQ parameter from 
the cell survival curve such as alpha (α) and beta (β) were obtained 
9. Canvass the capability of employing these compound nanostructures as theranostic 
agents.  
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Chapter 2 
 2 Materials, Methods and Procedures 
2.1 Overview  
This chapter presents details of the materials, instrumentation and experimental methodologies 
used in this research. The experimental methods are divided into five major sections. The first 
section describes the synthesis of the bismuth and bismuth compound NPs with a suitable surface 
coating for biological study. The second section describes the techniques used to examine the 
shape, size, particle charges and chemical composition, including examination of the surface area 
and amount of surface coating. The third section mainly focuses on the diagnostic purpose of 
these NPs using phantom studies and is divided into two parts; (i) the X-ray attenuation profile 
for Bi2S3-NPs coated with the polymer PVP relative to iodinated contrast agents by increasing 
tube potential and (ii) the novel role of BiOI-NPs in enhancing the subject contrast of DE-CT 
and MARS CT. The fourth section mainly focuses on the therapeutic purpose and provides 
details of cell culture protocols and techniques for biological preparation and cytotoxicity of NPs 
in cells. This section investigated the therapeutic effect of NPs on the radiation response of cells 
lines.  
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2.2 Materials 
The materials considered in this research include synthesised NPs (by our group and our 
collaborators) purchased NPs, chemicals and materials. All chemicals were used without further 
purification unless otherwise stated. 
 Sources of Nanoparticles 
The source of NPs and purchased NPs are listed in Table 2-1. It gives general details for the 
materials source and specifications. 
Table 2-1: Source of Nanoparticles with specifications provided by synthesis laboratory or the suppliers. 
Nanoparticles Source Specifications 
Au-NPs Purchased from Nanoprobes Inc. (Yaphank, NY 
11980, U.S.A.). 
Powder; 1.9 nm particle 
diameter 
75wt%. 
PVP coated 
Bi2S3-NPs 
Synthesised, research lab of Prof Lu, in the 
Changchun Institute of Applied Chemistry (CIAC).  
Powder; 5-15 nm particle 
diameter 
20 wt% 
Bi-NPs Purchased from US Research Nanomaterials Inc. 
(3302 Twig Leaf Lane, Houston, TX 77084, 
U.S.A) 
Powder; 80-250 nm particle 
diameter 
80 wt%. 
Starch coated 
Bi-NPs 
Synthesised, research lab of Dr. Steven Best, 
Department of Chemistry, The University of 
Melbourne. 
Powder; 25 nm particle 
diameter 
80 wt%. 
PVP coated 
BiOI-NPs 
Synthesised, research lab of Dr. Anton Blencow, 
Department of Chemistry, The University of South 
Australia.  
Powder; 3-5 nm particle 
diameter 
 65 wt%. 
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 Source of Reagents 
The sources of reagents are listed in Table 2-2: 
Table 2-2: Source of reagents.  
Reagents Source Specifications 
Oleic acid (C18H34O2) Sigma Aldrich 99.9%, Colourless to Very Faint Yellow, 
Viscous Liquid, Weight; 282.46 g/mol 
Oleyl amine (C18H37N) Sigma Aldrich 70%, Colourless to Yellow, Liquid or 
Semi-Solid, Weight; 267.49 g/mol 
Octadecane (C18H38) Sigma Aldrich 99.9%, Colourless, Weight; 254.49 
g/mol 
Thioacetamide, ACS reagent 
 (C2H5NS) 
Sigma Aldrich 99.9%, Crystalline Powder, 
Weight;75.13 g/mol 
Bismuth neodecanoate (C30H57BiO6) Sigma Aldrich Colourless to Yellow, Viscous Liquid, 
Weight; 722.75 g/mol 
Poly(vinyl pyrrolidone)  
(C6H9NO)x 
Alfa Aesar Powder, White to Off-White, 
wt%;8,000 
Poly(vinyl pyrrolidone) (C6H9NO)x Alfa Aesar Powder, White to Off-White, 
wt%;10,000 
Starch, soluble ,CS reagent 
(C12H22O11) 
Sigma Aldrich Powder, White to Off-White, Weight; 
342.30 g/mol 
Bismuth(III) nitrate pentahydrate 
(BiN3O9.5H2O) 
Sigma Aldrich 98%, Crystalline Powder, Weight; 
485.07 g/mol 
N,N-Dimethylformamide (DMF) 
(C3H7NO) 
Sigma Aldrich 99.8%, Colourless, Weight; 73.09 
g/mol 
Dichloromethane (DCM) (CH2Cl2) 
 
Sigma Aldrich 99.8%, Colourless, Weight; 84.93 
g/mol 
Sodium borohydride (NaBH4) Sigma Aldrich 98%, Powder, White, Weight; 342.30 
g/mol 
Ammonium bismuth citrate 
(C12H22BiN3O14)  
Alfa Aesar Powder, White, Weight; 641.295 
g/mol 
Sodium iodide (NaI) Sigma Aldrich 98%, Powder, White, Weight; 149.89 
g/mol 
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Acetone General lab 
reagent 
99% 
Ethanol General lab 
reagent 
99% 
Omnipaque™ (iohexol)  GE Healthcare Concentration; 350 mg/mL 
CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (MTS)[3-(4,5-
dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner 
salt] 
Promega Liquid, Yellow, Colourimetric Viability 
Assays 
L-glutamine Sigma Aldrich Liquid, Colourless 
Penicillin Streptomycin (Pen Strep) Life Technologies 
Australia Pty Ltd. 
Liquid, Colourless 
Foetal bovine serum (FBS) In Vitro 
Technology. 
Liquid, Orange 
Dulbecco's Modified Eagle's medium 
(DMEM) 
Invitrogen Liquid, Red 
Minimum Essential Medium Alpha 
(𝛼-MEM) 
Life Technologies 
Australia Pty Ltd. 
Liquid, Red 
0.25 % Trypsin-EDTA (1X)  Life Technologies. Liquid, Red 
Roswell Park Memorial 
Institute 1640 Medium (RPMI) 
Life Technologies 
Australia Pty Ltd. 
Liquid, Red 
Dimethyl sulfoxide (DMSO) General lab 
reagent 
99% 
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2.3 Synthesis and characterisation of nanoparticles  
The following describes the synthesis and characterisation techniques for NPs. The first section 
was divided into three main parts including the fabrication of the Bi2S3, Bi and BiOI-NPs with a 
suitable surface coating for biological study. The following section presents the techniques used 
to examine the shape, size, particle charge and chemical composition, and the surface techniques 
utilised to examine the surface area and the amount of surface coating. 
2.3.1 Bismuth sulfide nanoparticles 
2.3.1.1 Preparation of NPs with PVP 
Spherical Bi2S3-NPs (5-15 nm in diameter) were synthesised as follows (Figure 2-1): Bismuth 
neodecanoate (7.2 g, 5 mmol) was added to octadecane (80 mL) and oleic acid (40 mL) and 
mixed together with sonication. This mixture was heated to 110 °C under argon for 20 min. 
Separately, thioacetamine (0.75 g, 10 mmol) was dissolved in oleylamine (7 mL) and injected 
into the reaction mixture with vigorous stirring. The mixture was kept at 110°C and mixed 
vigorously with stirring. After the injection of thioacetamine, the reaction mixture colour 
immediately changed to dark brown (Figure 2-2). The mixture was cooled after 1 min to room 
temperature and washed with ethanol (ratio of ethanol to Bi2S3-NP solution is 2:1). The NPs 
were isolated via centrifugation at 12,000 g for 3 min. The NP pellet was redispersed in 
dichloromethane (DCM) (10mL), and ethanol (10 mL) was added to re-precipitate the NPs, 
which were isolated via centrifugation (1 min, 12,000 g). The Bi2S3-NPs (~300 mg) were 
redispersed in DCM (200 mL) and poly(vinylpyrrolidone) (PVP) (2 g, MW 8,000) was added. 
The mixture was refluxed at 70 °C for 24 h, cooled to room temperature, and the solvent was 
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removed in vacuo. The residue was dissolved in Milli-Q water (50 mL) and dialysed (10 KDa 
cut-off) against Milli-Q water for 24 h. (Figure 2-3) The NPs were freeze-dried. 
 
 
 
 
Figure 2-1: Illustration of the synthesis and surface modification of Bi2S3-NPs with PVP [31]. 
 
 
Figure 2-2: Photograph showing (a) the synthesis of Bi2S3-NPs, and (b) a dispersion of nanoparticles in 
H2O. 
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Figure 2-3: Photograph of NP purification steps (dialysis). The NPs were placed in a dialysis membrane 
with a 10 kDa cut-off to allow any free polymers or chemicals to pass through but not NPs. 
 
2.3.2 Bismuth nanoparticles 
2.3.2.1 Preparation of NPs with PVP 
Bismuth NPs were synthesised using the method reported by Luo et al [161]. Briefly, bismuth 
nitrate (48.5 mg, 0.1 mmol) and PVP (55.5 mg, MW 10,000) were dissolved in DMF (10 mL). 
The mixture was degassed with argon for 15 min and mixed vigorously with stirring under an 
argon atmosphere. Separately, 1 M NaBH4 solution in water (300 µL) was mixed with DMF (10 
mL) and added to the reaction mixture under vigorous stirring. After 5 min, the NPs were 
precipitated and washed with 10 mL of acetone. The NPs were isolated via centrifugation at 447 
g for 3 min.  
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2.3.2.2 Preparation of NPs with starch 
Bi-NPs (10-25 nm in diameter) were synthesised as reported by [162] (Figure 2-4). A solution of 
ammonium bismuth citrate (ABC) (130 mg, 0.2 mmol) in distilled water (20 mL) containing 1 
mL of soluble starch (50 mg starch in 5 mL water) was vigorously stirred for 20 min at room 
temperature. The mixture was degassed with argon for 5 min, followed by fast injection of 300 
µL of 1 M NaBH4 solution (0.946 g in 25 mL H2O) in 20 mL of distilled H2O to the previous 
reaction. The mixture turned black immediately on injection of NaBH4 solution (Figure 2-5). 
The reaction was stirred vigorously for 2 h. The prepared NPs were washed with water (ratio 
water to Bi-NP solution was 1:1) twice. The NPs were then isolated by centrifuging at 12,000 g 
for 5 min. Ethanol (7 mL) was added to the NP pellet to break any cross-links between starch 
molecules. The mixture was stirred for 10 min at room temperature, followed by centrifugation 
at 12,000 g for 5 min. The ethanol was decanted off to afford NPs and any excess ethanol was 
removed using a heat gun.  
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Figure 2-4: Illustration of the synthesis and surface modification of Bi NPs with starch. 
 
 
Figure 2-5: Photograph showing (a) a colour image of the as synthesised Bi-NPs, and (b) Bi-NPs 
dispersed in H2O after 2 h.  
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2.3.3 Bismuth oxyiodide nanoparticles 
2.3.3.1 Preparation of NPs with PVP 
BiOI-NPs were prepared as follows [163]. The pH of water (400mL) was reduced to pH 2.7 
using 76 µL nitric acid (HNO3), and Bi(NO3)3 (194 mg, 1.0 mmol) and PVP (2.0 g, MW = 
10,000 Da) were added. A 20 mM NaI solution in water (20 mL) was injected at room 
temperature to obtain a clear colourless to pale yellow solution (Figure 2-6). The mixture was 
vigorously stirred for 30 min at room temperature. The resulting NPs were precipitated with 
acetone (ratio acetone to NP solution was 3:1) and collected by centrifugation at 4025 g for 15 
min. The NPs were dispersed in distilled water (~10 mL) and separated again by adding 10 mL 
acetone followed by centrifugation at 4025 g for 3 min. This process was repeated twice. 
 
 
Figure 2-6: Photograph showing (a) a colour image of the as synthesised BiOI-NPs, and (b) their 
dispersion in H2O.  
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2.3.4 Characterisation 
In order to characterise the prepared NPs, a number of analytical techniques were employed. The 
following subsections present these techniques and subsequent NPs sample preparation.  
2.3.4.1 Transmission electron microscopy (TEM) 
This technique allows the direct observation of the morphology and the size of the NPs. The NP 
distribution and insights into particle aggregation can be obtained to some degree. The NP 
samples were prepared by depositing dilute solutions of NPs from isopropyl alcohol (IPA) or 
water onto carbon coated grids and the liquid was allowed to evaporate. TEM images were 
performed using a JEOL TEM 1010 with an accelerating voltage of 100 keV and attached to a 
Gatan Orius SC600ACCD camera and Rontec EDX detector at RMIT Microscopy and 
Microanalysis Facility (RMMF), Melbourne, Australia. The images and measurement of the 
particle sizes of the NPs were processed using Gatan Microscopy Suite (GMS) 3 Software. 
2.3.4.2 X-ray diffraction (XRD) 
XRD allows determination of phase state and crystalline structure of materials. In XRD, 
electrons are released and accelerated onto sample atoms to produce X-rays. These resultant X-
rays are diffracted differently by different crystalline materials, based on the atomic arrangement 
in the crystal lattice. The diffracted X-ray pattern is the fingerprint for the identification of 
materials [164]. 
These measurements were carried out using an X-ray diffractometer (model D8 
Endeavor, BRUKER AXS Inc., Madison, WI, USA) with LynxEye
TM 
silicon strip detector at the 
Separation Science and Mass Spectrometry Facility, RMIT University, Melbourne, Australia. 
  
86 
 
Diffraction patterns were obtained using nickel-filtered Cu-Kα radiation with a wavelength of 
 . 40 0 Å, operating at a voltage of 30 kVp and a current of  0 mA. The samples were 
positioned in the XRD sample holder, and then the surface of the powdered sample was 
smoothed and the excess sample was removed with the edge of the holder. Qualitative phase 
identification was performed with Bruker-AXS Eva software, by comparison with database PDF-
2 release 2015, obtained by the International Council on Diffraction Data (ICDD). 
2.3.4.3  X-ray photoelectron spectroscopy (XPS) 
XPS allows the chemical composition of solid surfaces to be determined. XPS uses X-rays to 
eject electrons from the samples atoms and produces a photoelectron with characteristic binding 
energy which can be used to identify elements [165].  
Samples were prepared by pressing the nanopowder onto foil under vacuum and mounted 
onto carbon tape. XPS measurements were carried out using a Thermo K-alpha X-ray (Thermo 
Fisher Scientific Inc., Waltham, MA, USA) at RMIT Microscopy and Microanalysis Facility 
(RMMF), Melbourne, Australia. The measurement was using monochromatic AlKα radiation 
(1486.6 eV photons) at dwell time of 50 ms and a pass-energy of 50 eV. The binding energies for 
the materials were referenced to the photoelectron component peak of C1s at 284.8 eV. Curve 
fitting was conducted using Avantage Software and the XPS spectral line assignment was 
obtained and matched with the data on the LaSurface database.  
2.3.4.4 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR spectroscopy provides qualitative and quantitative details on specific functional groups 
and the bonding of organic components. It is based on the infrared vibrational absorption spectra 
of materials. The appearance of certain vibrational frequencies in the spectrum of any material 
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can provide important information about the structure and orientation of that particular molecule 
[166].  
FT-IR analysis was performed on Perkin Elmer Spectrum 100 instrument equipped with 
micro-ATR (diamond ATR crystal) at the Separation Science and Mass Spectrometry Facility, 
RMIT University, Melbourne, Australia. The measurements were carried out in the range of 400-
4000 cm
-1
 region with a 4 cm
−1
 resolution. Each spectrum is an average of 10 scans.  
2.3.4.5 Thermogravimetric analysis (TGA) 
TGA measures the changes in physical properties of a material as a function of increasing 
temperature. The principle behind TGA is the measurement of weight loss as a function of 
temperature or time, where the information on the thermal stability of the initial material and 
final residues can be determined from the TGA curve [167]. 
TGA measurements were performed using a Perkin Elmer Pyris 1 Thermoanalyzer 
instrument (Perkin Elmer Inc., Boston, Massachusetts, USA) at the Separation Science and Mass 
Spectrometry Facility, RMIT University, Melbourne, Australia and was used to determine the 
amount of metal present in a sample. The measurement was performing under flowing nitrogen 
at a heating rate of 30 °C /min up to 700 °C.  
2.3.4.6 Zeta potential analysis  
The zeta potential (ξ) is the electrokinetic potential difference between two phases (solid and 
liquid), or in other words, can measure the charge repulsion/attraction between particles and 
medium. It is one of the physical properties that are displayed by NPs that are dispersed in 
solvents. The zeta potential measurement can be used to optimise the NP synthesis and to predict 
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long-term stability of NP suspensions. The dispersed NPs in solution have a surface charge due 
to their intrinsic ionic properties and other dipolar characteristics, and are surrounded by the thin 
layer (fix layer) of ions of opposite charge to the NP surface. In the outside layer, a different 
composition of electrically oppositions forms the diffuse double layer outside layers (Figure 2-
7). When the particles have large negative or positive zeta potential values in a suspension, they 
are attracted to the opposite polarity electrode accompanied by the fixed layer and part of the 
diffuse double layer. For highly charged NPs aggregation is generally low. On the other hand, if 
the particles have small zeta potential values there is little repulsion between the NPs which can 
lead to greater aggregation. In general, NPs are considered charged when the zeta potential 
values are greater than +30 mV or smaller than -30 mV, but in between these values the particles 
are considered neutral [168, 169]. However, there are several factors that can slightly change this 
value such as density and pH of the suspension. The measurement of zeta potential values was 
carried out using a Zetasizer Nano ZS (Malvern) and the data are presented in millivolts (mV). 
Samples were prepared by resuspending the NPs to concentrations of 1 mg/mL in neutral (PH 7) 
phosphate-buffered saline (PBS). 
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Figure 2-7: Illustration showing zeta potential of a charged particle in a suspension. This parameter is 
important to calculate the electrostatic component of the interaction energy between two entities [170].  
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2.3.5 Dispersion of nanoparticles 
The dispersion of NPs in liquids remains a challenge due to the difficulty in separating the 
attractive inter-particle forces. The large surface area of NPs can result in strong attractive forces, 
resulting in the formation of large clusters (aggregation). This reduces the effect of the surface 
area and surface reaction which is an essential factor for nanosized particles. The inefficient 
dispersion of NPs in medium may reduce their size efficiency in terms of chemical properties 
and interactions from nano to micro scale by increasing their sizes and morphologies [171]. 
Therefore, efforts have been made to assure that the NPs used in this work were effectively 
dispersed.  
There are a number of useful methods to disperse NPs and eliminate their aggregation in 
liquids. The most commonly used tool is the vortex mixer, which creates a vortex to mix the NPs 
in the liquid. The second proven tool to homogenously disperse NPs is ultrasonication, which is 
a result of ultrasonic cavitation. In other words, the ultrasonic irradiation breaks up and splits the 
agglomerated particles apart. It is considered an effective tool due to its high ability to disperse 
NPs during and after particle synthesis, leading to smaller sizes and an increase in size 
uniformity. 
The NP solutions were sonicated using an ultrasonic bath (Branson 2510) operating at a 
frequency of 40 kHz and power of 100 W. The process was conducted by adding the desired 
concentrations of NPs to the desired volume of liquid and sonicating for 30 to 40 min.   
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2.4 SECTION I: Diagnosis procedures (Phantom Study) 
This section mainly focuses on using the prepared NPs for diagnostic modality CT using 
phantom studies: 
 The first study focused on using PVP coated Bi2S3-NPs as contrast agents for CT at tube 
potentials (80 to 140 kVp) relative to iodinated CM.  
 The second study focused on using BiOI-NPs as a contrast agent for DE-CT and MARS-
CT. 
2.4.1 Bismuth sulfide nanoparticles as contrast agents for CT 
2.4.1.1 Preparation of nanoparticle solution 
Bi2S3-NPs (134 mg) were suspended in Milli-Q water (4 mL) with sonication (100 W) for 30 
min. The resulting stock solution was diluted with Milli-Q water to obtain solutions with Bi 
concentrations ranging from 0 to 65 mM. 
2.4.1.2 Preparation of iodine solution 
Clinical iodinated CM (omnipaque 350 I mg/mL) was utilised for comparison in this study. The 
omnipaque stock was diluted with Milli-Q water to afford solutions with iodine concentrations 
ranging from 0 to 65 mM. 
2.4.1.3 CT scan protocol 
 T images were acquired using a Light Speed™ V T scanner (single-slice) (GE Healthcare, 
Waukesha, WI, USA) at the Heidelberg Repatriation Hospital, Australia. Samples were imaged 
in Perspex phantoms positioned at the iso-center of the CT gantry. Phantoms consisted of eight 
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holes filled with omnipaque and Bi2S3-NPs solutions (2 mL) at concentrations ranging from 0 to 
65 mM (Figure 2-8). The phantom consisted of five blocks in parallel to mimic 5 cm
2
 of 
equivalent attenuation. CT imaging was initially conducted at a tube potential of 80 kVp, current 
of 200 mA, with a slice thickness of 5 mm. Subsequently, CT scanning was repeated at tube 
potentials of 100, 120 and 140 kVp whilst keeping all other parameters constant. The CT value, 
in Hounsfield Units (HU), for each sample and tube potential was determined from three 
different slices (the top, middle and bottom) and then averaged. 
 
 
 
Figure 2-8: Perspex phantom containing contrast agent solutions, and (b) the phantom positioned at the 
iso-center of the CT gantry.  
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2.4.1.4 Analysis of contrast-to-noise ratio (CNR)  
The CNR (background Perspex to contrast agents) was selected as a standardisation method to 
compare the two contrast agents. The region of interest (ROI) in each sample image was 
indicated by a 4 mm diameter circle. The mean in pixels of each ROI in each sample, and the 
mean of the background area of the phantom were calculated. The CNR is expressed as: 
 
    
         
   
 
(14) 
The ROIm and ROIb represent the CT values of the contrast material in a ROI of the samples and 
in the background of the phantom, respectively. SDb represents the standard deviation of the CT 
number of the background. CNR values were collected for both contrast agents at each tube 
potential. 
2.4.2 Bismuth oxyiodide nanoparticles as a novel contrast agent for DE-CT 
2.4.2.1 Preparation of NP solution 
BiOI-NPs (12 mg) were dispersed in MilliQ water (2 mL) and diluted with Milli-Q water with 
sonication (30 min) to obtain 25 mM BiOI solutions. 
2.4.2.2 Preparation of iodine solution 
Clinical iodinated CM (omnipaque 350 I mg/mL) was utilised for comparison in this study. The 
omnipaque stock was diluted with Milli-Q water to afford solutions with iodine concentrations 
25 mM. 
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2.4.2.3 DE-CT scan protocol 
CT images were acquired using a Light Speed™ V T scanner (single-slice) (GE Healthcare, 
Waukesha, WI, USA) at Peter MacCallum Cancer Centre, Australia. Samples were imaged in 
Perspex phantoms positioned at the iso-center of the CT gentry. Phantoms consisted of 16 holes 
filled with Omnipaque and BiOI NP solutions (1 mL) at concentrations of 25 mM (Figure 2-9a). 
The phantom had a cylindrical shape and contained holes with diameters of 1, 2, 3 and 4 mm (4 
of each). CT imaging was initially conducted at a tube potential of 80 kVp, current of 200 mA, 
with a slice thickness of 5 mm. Subsequently, CT scanning was repeated at tube potentials of 
150, and 80/150 kVp whilst keeping all other parameters constant. The CT value, in Hounsfield 
Units (HU) for each sample and tube potential was determined from three different slices (the 
top, middle and bottom slices) and then averaged. 
 
 
 
Figure 2-9: Perspex phantom containing contrast agent solutions, and (b) the phantom positioned at the 
iso-center of the CT gantry. 
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2.4.2.4 Analysis of contrast-to-noise ratio (CNR)  
The CNR data were calculated as previously mentioned in section 2.4.1.4. 
2.4.3 Bismuth oxyiodide nanoparticles as a novel contrast agent for MARS –
CT 
2.4.3.1 Preparation of samples  
BiOI-NPs (4.3 mg) were dispersed in MilliQ water (2 mL) and diluted in Milli-Q water with 
sonication (30 min) to obtain solutions with concentrations of 2.7, 1.35 and 0.67 mg/mL (3.9, 
1.9, and 0.95 mM, respectively). Clinical iodinated CM (omnipaque 350 I mg/mL) was used for 
comparison in this study. The omnipaque stock was diluted with Milli-Q water to afford 
solutions with iodine concentrations of 18, 9 and 4.5, 0.76, 0.38 and 0.19 mg/mL. The phantom 
has a cylindrical shape consisting of a solid poly(methyl methacrylate) (PMMA) cylinder with 
four holes drilled in the middle and eight around the outer edge. The samples were placed in 
small PCR tubes and inserted into the holes of PMMA phantom as shown in Figure 2-10. Water 
and lipid were used as controls. 
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Figure 2-10: (a) PMMA phantom capillary contents, and (b) phantom containg the 6 mm inserts 
(Eppendorf PCR tubes) filled with samples and fixed in the MARS holder. 
 
2.4.3.2 MARS scan protocol 
Samples were imaged using a MARS small-animal scanner (MARS Bioimaging Ltd., 
Christchurch, New Zealand) (Figure 2-11). The X-ray tube was operated at a fixed 118 kVp 
with a tube current and exposure time of  4 μA and 200ms, respectively. Energy thresholds were 
set at 27, 37, 40 and 91 keV. A total of 720 projections were obtained using a 2 mm-thick-CdTe 
sensor (128×128) bump-bonded at   0 μm equipped with Medipix3RX readout chip; and 
Source-Ray SB-120-350 X-ray tube (SourceRay Inc., Ronkonkoma, NY) with a tungsten anode 
having brass or 1.8 mm Aluminium equivalent filtration. The focal spot of the X-rays has a size 
~ 0 μm. Three vertical positions of the  dTe Medipix3RX camera were used with a translational 
(vertical) overlap of 3.139 mm to cover the 30 mm field of view (FOV). The parameters: source 
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to detector distance (SDD), source to object distance (SOD) and the bias voltage applied to the 
sensor were set at 250 mm, 200 mm and 598 V, respectively. Camera readout was conducted 
using the MARS readout system [172].  
 
 
Figure 2-11: A photo of the MARS spectral molecular scanners at the University of Otago. (b) Inside 
view of the MARS gantry showing the MARS camera, X-ray source, and sample holder postioned 
between the camera and X-ray source in the scanner.  
 
  
98 
 
Before scanning samples, threshold equalization relative to the noise edge, and energy 
calibration of the detector, were conducted. For each energy bin, 200 flat-field images (open 
beam) and 20 dark fields (without X-rays) were taken to correct for variations in pixel response. 
The MARS Image Processing Suite was used to process the raw data in DICOM format after 
transferring the data from the scanner to the inbuilt patient archive communication system 
(PACS). Images were reconstructed into a 480 x 480 mm matrix at all four energy bins using the 
MARS Algebraic Reconstruction Technique (mART). The CT reconstruction was for the four 
energy bins (27–37 keV, 37–40 keV, 40–91 keV and 9–118 keV) separately to provide the 
photon counts for each energy bin. For data analysis, 16 bit Dicom reconstructed images were 
converted to 32 bit by multiplying and adding the rescaling slope and intercept values 
respectively, using ImageJ software (Figure 2-12). The CT attenuation (effective linear 
attenuation) values for each material in all four energy bins were measured and converted to 
Hounsfield unit (HU) by normalising linear attenuation values to the attenuation values of water 
and air. The results were then plotted graphically to evaluate the attenuation trend of each of the 
given materials at their corresponding K-edge energy bin.  
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Figure 2-12: The MARS-CT builder software. 
 
2.4.4 Statistical analysis 
The data were expressed as mean ± standard deviation (SD) of three independent experiments. 
One tail Student’s t-test (paired) was carried out, with p = 0.05 or less considered significant. 
Statistical analysis was performed with GraphPad (version 7.0; GraphPad Software,. Inc).   
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2.5 SECTION II: Therapeutic procedures (Cell Study) 
This section mainly focuses on therapeutic purpose and provides details of cell culture protocols 
and techniques for biological preparation and cytotoxicity of NP in tissue cultured cells. The 
therapeutic effect of NPs on the radiation response of cell lines was investigated. 
2.5.1 Cells culture methods 
2.5.1.1 Subculture cells  
In the first set of experiments, human prostate melanoma (PC3) and B16 mouse melanoma cells 
were cultured and maintained in RPMI media supplemented with 10% (v/v) heat inactivated 
foetal bovine serum (FBS) and 1% ( v/v) penicillin/streptomycin (Pen Strep) at 37 °C in a 
humidified 5% CO2 incubator. 
For the second set of experiments, A549, Bovine aorthic endothelial (BAOEC) and 
DU145 cells were used. The A549 and BAOEC cells were cultured and maintained in DMEM 
media supplemented with 10% (v/v) heat inactivated FBS at 37 °C in a humidified 5% CO2 
incubator. DU145 prostate cell lines were cultured in 𝛼-MEM, supplemented with L-glutamine, 
1% (v/v) penicillin/streptomycin, and 10% (v/v) heat-inactivated FBS at 37 °C in a humidified 
5% CO2 incubator. The various media supplemented with their specific growth factors and 
antibiotics are referred to as complete media. 
All of the above cell lines were grown in 75 cm
2
 flasks (Sigma-Aldrich Pty. Ltd., St Louis, 
Mo, USA) subcultured at approximately 80-90% confluence. The A549 cells were used in 
passages 7-32; DU145 cell lines were used in passaged 4-128. PC3 and B16 cell lines were 
passaged up to passages number 25. The BAOEC cells were used in passage number 6. For more 
details about cell lines see Appendix A and for cells culture see Appendix B.  
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2.5.1.2 Cell counting  
After cell subculturing (see section 2.5.1.1), the cells harvested with 0.25 % Trypsin-EDTA (1X) 
to detach. Cells are pelleted and resuspend with complete medium (see Appendix C for further 
information). Cells were counted manually using a Haemocytometer (counting chamber). 
Typically, this can be used after mixing a 10 µL volume of the cell suspension with 10 µL of the 
dye Trypan blue and placing a drop of this mixture in the space between the chamber and the 
glass slide. Trypan blue passes through the membrane of dead cells and stains them blue, while 
leaving the live cells clear. As viable cells are excluded from the blue stain, this method indicates 
the amount of live cells per mL. The details of this method are mentioned in Appendix D. 
2.5.1.3 Cryopreservation – Freezing and Thawing  
2.5.1.3.1 Freezing  
Briefly, cells were washed and trypsinised as described above in section 2.5.1.2. Then in a 
separate step, a freezing medium mixture was made for each type of cells to give (90% medium; 
10% DMSO) and was cryogenically placed in an ice vial. A small volume (~1-2 mL) of the cell 
suspension was pelleted by centrifugation (at 200 g for 5 min) and then resuspended with the 
freezing medium to obtain the final volume of 1 mL per cryogenic vial with cell concentration 2-
4x10
6
 cells/mL). All prepared vials were labelled (e.g., cell name, passage number, date), placed 
in freezer boy (Mr. Frosty™ Freezing Container, Thermo Scientific™ VI , Australia) and 
transferred to -80 °C freezer overnight. After 24 h, all vials were transferred to gas phase liquid 
nitrogen for long term storage. More details are provided in Appendix D. 
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2.5.1.3.2 Thawing  
The frozen cryogenic vial was removed from liquid nitrogen and placed on ice. The vial was 
then thawed by placing it in a 37 °C water bath with shaking till liquid. The thawed cells were 
transferred dropwise into a new sterile 75 cm
2
 flask contains 15 mL of appropriate pre-warmed 
complete culture medium. The cells were gently mixed via pipette then cultured in a 37 °C 
humidified 5% (v/v) CO2 cell culture incubator. After attaching the cells (2-3 days), the media 
was exchanged with fresh media (see Appendix D for further information).  
2.5.2 Preparation of NPs solutions for biological study 
The mass of all the NP types was calculated. The dried NP power was dispersed in an 
appropriate medium to provide the desired concentrations in mM to treat each cell line. In the 
first set of experiment, Au- and Bi2S3-NPs at concentration of 4 mM were suspended in RPMI 
for either PC3 or B16 cell lines. In the second set of experiment, Bi2S3-NPs (4 mM) were diluted 
in DMEM for A549 and BAOEC cell lines and in 𝛼-MEM for DU145 cell lines. Similarly, Bi-
NPs (1.2 mM) were dispersed in either in DMEM for A549 and in 𝛼-MEM for DU145 cell lines. 
The resulting NPs stocks were diluted with appropriate complete media in order to obtain the 
required concentrations. 
All of the above solutions with complete media were sterilised twice, firstly by passing 
through a 0.22 μm hydrophilic polysulfonic membrane (Sartorius, Goettingen, Germany) and 
secondly by sonication for 30 min.  
2.5.3 Bi2S3-NPs localisation in the cells 
The two cell lines B16-F0 and BAOEC were incubated in slide flasks (Nunc, Roskilde, 
Denmark) overnight with 1 mM of Bi2S3-NPs and were stained with crystal violet dye to aid in 
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visualising the cells. The cell plate was placed on ice and each well washed twice with ice-cold 
PBS before the cells were fixed with ice-cold methanol for 10 min. After this time, the tissue 
culture plate was placed on the bench and cells covered with crystal violet solution (in 75/25 
ethanol/water). The cells were incubated for 10 min before being carefully rinsed with distilled 
water until the dye stopped running off. The stained cells were viewed using an Olympus IX51 
inverted microscope (Olympus, USA) equipped with light illumination, using 10×, 20× and 40× 
objectives. Cell images were acquired using an Olympus CCD digital camera model RTV-R-
CLR-10) with Q-Capture Pro acquisition imaging software. 
2.5.4 Cytotoxicity assays  
2.5.4.1 Colourimetric assay 
In vitro cytotoxicity of NPs was assessed using PC3, B16 A549 and DU145 cells using CellTiter 
96
® 
AQueous One Solution Cell Proliferation Assay and PrestoBlue cell viability reagent (MTS 
assay). 
PC3 and B16 cells (10
4
 cells/well) were added to a 96 well plate. The cells were allowed 
to grow for 24 h before adding prepared Au- and Bi2S3-NPs (0-2 mM) solution (see section 
2.5.2) for up to 48 h.  
In the second part of the experiments, the A549 and DU145 cells (10
3
 cells/well) were 
added to the 96 well and allowed to grow for 24 h. Prepared Bi2S3-NP stock was diluted in an 
appropriate complete medium and added to the cells at final concentrations of 0-6.5 mM, then 
incubated for another 24 h. The same procedure was used with Bi-NPs: cell lines were exposed 
to NPs solutions (diluted in appropriate complete cell culture medium) at final concentrations of 
0-1 mM for 24 h. 
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After the incubation period, the cells were washed twice with a tissue culture medium 
and replaced with 200 µL of fresh tissue culture medium containing 20% of MTS reagent. The 
cells were further incubated in the presence of MTS solution for 1 h before reading the 
absorbance at 490 nm using a CLARIOstar® plate readers (BMG LABTECH, Mornington, 
Australia). The results from the above assays were also confirmed using the PrestoBlue cell 
viability reagent (enzyme-linked immunosorbent assay) according to the manufacturer’s 
instructions (in section 4.3). The emission ‎spectra for this dye are 615-590 nm. The 
measurements were again done on CLARIOstar
®
. Experiments were performed in triplicate, with 
four replicates for each treatment at each time point. Data were expressed as the percentage of 
the viable cell population for that treatment relative to that of the untreated controls at that time 
point, which was expressed as 100%.  
2.5.4.2 Clonogenic assay 
The colony formation assay was performed to assess the cytotoxicity of Bi2S3 and Bi NPs on 
A549 and DU145 cells. Cells were plated at a density of 1 x10
3
 cells/well in a six-well plate and 
allowed to adhere at 37 °C, 5% CO2 for 24 h, then incubated with NPs for 24 h. Treated cells 
were washed using a culture medium and allowed to grow until control plates formed large 
clones (50 cells or more), after approximately 7 to 12 days. The medium was removed from the 
plates, and the cells washed with PBS. Colonies were fixed with 3 mL of 10% neutral buffered 
formalin solution (Sigma-Aldrich Pty. Ltd., St Louis, Mo, USA) for 30 min then stained with a 
mixture of 0.5% (w/v) crystal violet in (3:1) ethanol/water for 30 min at room temperature before 
being washed with PBS. The plates were allowed to air dry, and then colonies were observed by 
microscopy using a Leica DMD 108 digital micro-imaging instrument (Leica Microsystems CMS 
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GmbH manufacture, Mannheim, Germany) at × 40 magnifications and then manually counted. 
Figure 2-13 shows the colony formation assay in a 6 well plate.  
 
 
 
Figure 2-13: Colony formation assay in a 6 well plate. 
 
2.5.5 Cellular irradiation methods 
The cytotoxic effect of NPs on enhancing the X-ray dose was assessed using the MTS assay. The 
PC3 and B16 cells (10
4
 cells/well) were added to well of a 96 well plate and allowed to adhere 
for 24 h. On the next day the cells were exposed to different concentrations of Au- and Bi2S3-
NPs (0-1 mM) for 24 h prior to being irradiated with kVp superficial radiotherapy beams using 
various radiation doses (0-7 Gy) at the William Buckland Radiotherapy Centre (Alfred Hospital, 
Melbourne, Australia). 
A549 and DU145 cell lines (2 x 10
3
 cells/well) were added to a well of a 96 well plate 
and allowed to grow for 24 h. The cells were then incubated with different concentrations of 
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Bi2S3- and Bi-NPs for 24 h. The cells were then irradiated using both kVp and MV energy 
photon beams using various radiation doses (0-5 Gy).  
In order to meet the full scatter conditions at the cell layer, a 20 × 20 cm slab of energy-
appropriate tissue equivalent phantom was used to surround the cell plates. A special holder for 
the 96 well plate was used to fulfil the full scatter conditions required to satisfy dose delivery 
conditions as described previously by Mackonis et al. [173]. Dose distribution was verified using 
radiochromic film in the phantoms holding the plates to ensure all the cells received a uniform 
radiation dose (see section 2.5.5.3). 
The dose enhancements of Bi2S3 and Bi NPs were also evaluated using the clonogenic 
survival assay (CSA). A schematic diagram of the overall procedure is illustrated in Figure 2-14. 
The A549 and DU145 cell lines (2 x 10
3
 cells/well) were seeded to well of a 6 well plate and 
allowed to adhere for 24 h. After which, cells were then treated with NPs (0-0.25 mM) for 24 h 
and then irradiated according to the specifications below (see section 2.5.5.1 and 2.5.5.2). 
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Figure 2-14: A schematic illustration of the clonogenic assay.  
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2.5.5.1 Kilovoltage superficial X-rays radiotherapy 
The PC3 and B16 cells were grown in a 96 well plate (see section 2.5.5) irradiated with 80 kVp 
from a superficial X-ray therapy (SXRT) machine (Therapax 3 Series, Pantak Inc., Branford, CT, 
U.S.A.), and receiving a dose between 0 and 7 Gy. The irradiation setup for 80 kVp, was as 
follows: cells were irradiated with a single fraction dose rate (1.079 Gy/min) using a 10 cm 
diameter collimator with a 2.2 mm Al filter HVL and a 25 source-to-surface distance (SSD). 
A549 and DU145 cells lines were grown in 96 well plate (see section 2.5.5) irradiated 
with 150 kVp X-ray energies from a superficial X-ray therapy (SXRT) machine, receiving a dose 
between 0 and 5 Gy. The irradiation setup for 150 kVp, was as follows: cells were irradiated 
with single fraction dose rate (1.112 Gy/min) using a 10 cm diameter collimator with a 1.0 mm 
Cu filter HVL and a 25 source-to-surface distance (SSD). The setup for kVp X-ray irradiation of 
the cells is demonstrated in Figure 2-15. 
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Figure 2-15: The schematic illustration of irradiation of cells using the SXRT machine. 
2.5.5.2 Megavoltage X-rays radiotherapy 
The experiment was performed using X-rays in the megavoltage range (6 MV) using LINAC 
(Clinac 2100C, Varian Associates Inc., Palo Alto, CA, U.S.A.). The plates were placed on water 
plastics at an SSD at 100 cm using a 10 x 10 cm
2
 field size and with a dose rate (100 MU/min) 
where the cells received between 0 to 5 Gy. In order to make sure that maximum dose was 
delivered to the cells, a Plastic water phantom was positioned on the top of plate. The setup for 
MV X-ray irradiation is shown in Figure 2-16. 
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Figure 2-16: The schematic illustration of irradiation of cells with MV X-ray generated from clinical 
LINAC. 
2.5.5.3 Verification of dose uniformity 
The uniformity of the X-ray dose distribution was verified using both the radiochromic film 
GafChromic EBT (International Specialty Products, Wayne, NJ, USA) and a 2570/1 Farmer 
dosimeter (NE Technology, Reading, United Kingdom). The radiochromic film can be used as 
reference dosimetry for biological studies with various irradiation setups, due to its low energy 
dependence and near tissue equivalence [174]. The relative dose distributions of the beam energy 
are shown in Figures 2-17 to 2-19.  
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Figure 2-17: The radiochromic film irradated (raw images) with (a) 3 Gy of 6 MV, and (b) 150 kVp X-
rays. 
 
 
Figure 2-18: The radiochromic film irradated (uniformity map implemented in imageJ software) with (a) 
3 Gy of 6 MV, and (b) 150 kVp X-ray. 
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Figure 2-19: Dose profiles from radiochromic film irradiated with 3 Gy of 6 MV, and 150 kVp X-rays.  
 
2.5.5.4 Dose enhancement effect of NPs on cell viability 
2.5.5.4.1 Colourimetric assay 
After irradiation in MTS assay, the tissue culture medium was replaced with 200 μL of fresh 
medium and the cells were incubated for 48 h, before viability was determined using the MT 
assay. Briefly, 20 µL of the reagent was added directly in each well and then incubated for 1 h at 
37 °C. Due to the MTS light sensitivity, the plates were covered by aluminium foil in order to 
avoid light absorption. In each experiment, the absorbance was recorded directly after adding the 
MTS (for background subtraction) and again after a 1 h incubation period. The number of 
surviving cells was determined by comparing the absorbance to that recorded against a standard 
curve of known cell concentration. The results are expressed as the percentage of viable cell with 
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different concentrations of NPs compared to that of the untreated controls which was taken as 
100%. The cell survival fractions (% survival) are plotted on a logarithmic scale versus radiation 
dose on linear scale and fitted with a linear-quadratic model. 
2.5.5.4.2 Clonogenic assay 
In the clonogenic assay, the cells were incubated with NPs for 24 h; afterwards, the cells were 
washed with an appropriate culture medium, and allowed to grow for 7 to 12 days, followed by 
fixation and staining procedures as mentioned above. Cell survival was measured by comparing 
the irradiated cell counts to cell counts for a control with a known concentration. The cell 
survival fractions were fit with a linear-quadratic model by plotting the data on a log (% 
survival) vs linear X-ray dose plot. 
2.5.6 Statistical analysis 
The data were expressed as the mean ± the standard error of the mean (SEM) of three 
independent experiments. One way analysis of variance (ANOVA) was used to obtain the 
significance of the difference between the control and treated group by comparing post-hoc 
analysis mean with Bonferroni’s test. A difference was considered to be statistically significant 
when p < 0.05. Statistical analysis was performed with GraphPad (version 7.0; GraphPad 
Software,. Inc).   
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Chapter3 
 3 Synthesis and Characterisation of 
Nanoparticles 
3.1 Overview 
This chapter presents the synthesis and characterisation of NPs used in this thesis, including 
Bi2S3-, Bi-, and BiOI-NPs. The size and morphology were obtained using transmission electron 
microscopy (TEM). The chemical compositions of synthesised NPs were investigated by various 
characterisation techniques, including X-ray photoelectron spectroscopy (XPS) and powder X-
ray diffraction (XRD). Important properties affecting cellular uptake of NPs include specific 
surface area, particle aggregation, and surface charge (zeta potential) were measured. The coated 
NPs were characterised using Fourier transform infrared spectroscopy (FT-IR) and thermal 
gravimetric analysis (TGA) to prove the existence of the surface coating and determine the 
amount of coating thickness in relation to the NPs. The purchased non-coated Bi-NPs were 
characterised also to compare the characterisation data for TEM, XPS, and XRD with 
synthesised NPs. 
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3.2 Bismuth sulfide nanoparticles  
3.2.1 Synthesis of nanoparticles 
The Bi2S3-NPs surfaces were coated with PVP and were synthesised using the previously 
described two-step process, whereby oleic acid coated Bi2S3-NPs were initially prepared and 
subsequently coated with PVP [31, 175]. Bi2S3-NPs were synthesised at two different 
temperatures to control the particle size. A high temperature reaction was conducted at 165 °C 
followed by 110 °C to afford NPs with a diameter of ~ 5 nm. A lower temperature reaction was 
maintained at 110 °C throughout (chapter 2, section 2.3.1) to facilitate the formation of slightly 
larger NPs (5 to 15 nm), in order to obtain the optimal size for CT attenuation. The NPs tend to 
have larger size, when the low temperature was used [31, 134]. The optimal NPs size for CT 
attenuation has been reported to be between 4 and 20 nm [176].  
The method of synthesis applied in this study [31] has several advantages over the 
previous methods. One of the previously reported methods was the hydrothermal method [177, 
178] that yields NPs of different sizes with poor monodispersity. In addition the second method 
reported in the literature to produce uniformly sized Bi2S3-NPs with oleyl amine (OAm) that 
used as both ligand and solvent [179, 180]. However there are two main drawbacks in the this 
method; first the reduction of Bi 
3 +
 ions to metallic Bi which makes the NPs unsuitable for 
biological application due to high chemical activity which is not unsuitable for in vivo 
applications due to its high chemical activity and second the weak bond between OAm and 
Bi2S3-NPs resulting in easily detaching the OAm from the surface of NPs during the washing 
processes as well as increasing the NPs aggregation. In contrast, The NPs in our study have an 
excellent size distribution and monodispersity due to the strong bond of the neodecanoate in the 
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bismuth source together with oleic acid to Bi
3+
 ions during the reaction. Using oleic acid instead 
of OAm as stabiliser can prevent the reduction of bismuth to the metallic Bi [31]. More 
importantly the surface of the NPs can be readily coated with biocompatible molecules. More 
importantly the surface of the NPs can be readily coated with biocompatible molecules.  
3.2.2 Characterisations 
3.2.2.1 Transmission electron microscopy (TEM) 
TEM revealed that PVP coated Bi2S3-NPs synthesised at 165 
o
C had a narrow size range from 4 
nm (Figure 3-1), whereas those synthesised at 110 
o
C had an average size 6 nm (Figure 3-2). 
The TEM images confirmed the morphology of the NPs as spherical. In addition, the NPs have 
low dispersity (less aggregation or glomeration).  
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Figure 3-1: TEM images for PVP coated Bi2S3-NPs, synthesised at temperature       (scale bar   200 
nm). 
 
Figure 3-2: TEM images for PVP coated Bi2S3-NPs showing (a) individual spherical NPs (scale bar = 200 
nm), and (b) (scale bar = 50 nm), and aggregates which may form as a result of the TEM sample 
preparation. 
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3.2.2.2 X-ray diffraction (XRD) 
The powder X-ray diffraction (XRD) pattern for the PVP coated Bi2S3-NPs (Figure 3-3) was 
measured and compared to the reflection peaks can be fitted to the bismuthinite (Bi2S3) structure 
(JCPDS card no: 17-0320) [180]. There are no relatively sharp features in the XRD pattern, 
which could form the crystalline of Bi2S3 and the presence of large amounts of the PVP polymer 
that could to some extend be responsible for overwhelming the signals from Bi2S3.  
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Figure 3-3: XRD pattern for PVP coated Bi2S3-NPs. 
 
3.2.2.3 X-ray photoelectron spectroscopy (XPS) 
The composition of the Bi2S3-NPs was characterised using XPS (Figure 3-4). The XPS spectrum 
for Bi2S3- NPs shows the two peaks located at 158.5 eV and 163.5 eV, which can be attributed to 
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the binding energy of Bi 4f 7/2 and Bi 4f 5/2, respectively. Moreover, the peak at 161.4 eV 
corresponds to that of S2p.These results are in agreement with previous data of Bi2S3-NPs [31].  
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Figure 3-4: XPS spectra showing region of Bi and S peaks in PVP coated Bi2S3-NPs.  
 
3.2.2.4 Fourier transform infrared spectroscopy (FT-IR) 
Figure 3-5 shows the FT-IR spectrum of pure PVP (MW, 8000) and PVP coated Bi2S3-NPs. The 
peaks present at 2924 cm
-1
 correspond to the asymmetric stretching vibration of C-H resulting 
from the backbone and pendent groups of the PVP. The strong absorption band at 1659.70 cm
-1
 
is assigned to the C=O stretching vibration of PVP, and indicates the coordination between the 
bismuth atoms and the oxygen in carbonyl group (Figure 3-5b), this can be indicated when this 
peak compared with the peak at 1645 cm
-1
 in pure PVP as shown in Figure 3-5a. The peaks 
present at 1494 and 1384 cm
-1 
indicated the C-H vibration from PVP. The absorption peak at 
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1289 cm
-1
 corresponds to the C–N bond in PVP. All of these peaks are associated with the 
formation of coordination bonds between bismuth atoms and nitrogen atoms arising from PVP 
units as these results compared with pure PVP in Figure 3-5a. In general, FT-IR spectra confirm 
that the PVP chain has successfully been replaced by oleic acid and had coated the Bi2S3-NPs. 
 
 
 
Figure 3-5: FT-IR spectra of (a) pure PVP (MW 8,000), and (b) PVP coated Bi2S3-NPs. 
 
3.2.2.5  Thermogravimetric analysis (TGA) 
The amount of surface coating present in the PVP coated Bi2S3-NPs was determined via thermal 
gravimetric analysis (TGA). It is observed from the curve that dominant weight loss of the PVP 
coated Bi2S3 NPs occurred in the temperature region between 200 and 400 °C, but there is no 
weight loss below 200 °C (Figure 3-6a). The weight of NPs is ~19 wt%, with the remainder 
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attributed to the PVP coating. This is observed from the TGA curve after heating to the 
temperature 600 °C where the finial weight loss of the sample is 81 wt% and the rest is the NPs. 
The amount of elemental Bi in the compound Bi2S3 is 81% by weight. Therefore, in each gram 
of Bi2S3 NPs used in this study there was 0.16 g of elemental Bi.  
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Figure 3-6: TGA curve for (a) PVP coated Bi2S3-NPs, and (b) pure PVP (MW 8,000). The weight loss of 
~81 % is ascribed to the PVP on the surface of the NPs. 
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3.2.2.6 Zeta potential analysis  
Zeta potential measurements were performed to investigate the process of electrostatic charging 
of the NP surface. As can be seen in Table 3-1, the zeta potential values of all of the synthesised 
NPs are between -20 and 0 mV, indicating a slight negative charge. We believe that in the 
present case, the reduced zeta potential does not reflect the actual stability of the NPs due to the 
following considerations: Firstly, the zeta potential is indicating the surface potential by 
determining the magnitude of the electrical double layer repulsion. By taking this into account, 
the total interaction between particles is the sum of the electrical double layer and the van der 
Waals interaction which is obtained by the magnitude of the Hamaker constant. When the 
difference is low in the refractive index between the particle and solvent, this leads to a small the 
Hamaker constant. Therefore, the low zeta potential can be sufficient to stop the capsules from 
aggregating. In addition, the zeta potential also refers to the potential at the plane of shear, in 
other words the potential at the point where the particle, solvent and double layer move in 
opposite directions in an electrical field. When the surface coating especially polymers is not at 
the surface but some point further away and creates adsorbed layer thickness, the zeta potential 
will be reduced. Moreover the polymer itself might introduce a further steric repulsion which 
would enhance the particle stability. In order to understand the affect in stability and cell uptake 
related to the zeta potentials, further studies should be considered by studying other factors such 
as different concentration, pH of the liquids, particle size, and surface coating. 
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Table 3-1: Zeta potenail values for NPs. 
Sample code ZP1 ZP2 ZP3 ZP(mean) SD 
Bi2S3-PVP -3.33 -5.01 -10.3 -6.213 3.637 
Bi-starch 
BiOI 
-17.3 
-1.30 
-17.9 
-1.16 
-19.1 
-1.09 
-18.1 
-1.18 
0.106 
3.61 
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3.3 Bismuth nanoparticles  
3.3.1 Synthesis of nanoparticles 
In this work, Bi-NPs were synthesised and coated with PVP according to a reported method 
[161]. However, our results show that the PVP surface coating does not prevent surface 
oxidation when it is added to water as the NPs changed colour from black to white as depicted in 
Figure 3-7a. When the prepared Bi-NPs were dissolved in ethanol the solution remained the 
same colour. These findings are in agreement with those reported by Xia, et al. who have also 
studied the XRD pattern of the phase structure of PVP coated Bi-NPs and found that it has 
unclear peaks [162].  
 
 
 
Figure 3-7: Photograph showing (a) PVP coated Bi-NPs dispersed in H2O after 0 and 2 h. (b) Bi NPs 
dispersed in ethanol after 0 and 2 h.  
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In the second part of this section (see 2.3.2.1), Bi-NPs were synthesised using an 
reduction method [162]; ammonium bismuth citrate was used in aqueous solution by reduction 
with sodium borohydride. The starch was used as stabiliser for the Bi-NPs and prevented 
aggregation and surface oxidation. The stability of the NP dispersion was approximately two 
months (Figure 3-8), which was in agreement with reported methods [162]. The good stability 
can be attributed to the hydroxyl functional groups on starch that coordinate with Bi
3+
 and create 
a denser layer of starch on the surface of the Bi NPs. Starch is also capable of acting as a 
reducing agent [181, 182], therefore may prevent surface oxidation. Bi-NPs were also prepared 
using the same method but without soluble starch, and the NPs quickly precipitated out of 
solution and became colourless, indicating that the stability of the dispersion of Bi-NPs is 
affected by soluble starch [162]. Therefore, soluble starch may act as an antioxidant, dispersant 
and stabilizer in the Bi NPs synthesis.  
 
 
 
Figure 3-8: Photograph showing starsh-coated Bi- NPs when dispersed in (a) H2O, and (b) in ethanol. 
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3.3.2 Characterisation 
3.3.2.1 Transmission electron microscopy (TEM) 
The Bi-NPs size and morphology were determined using TEM. The PVP coated Bi-NPs 
deposited on the TEM grid from an ethanol solution had an average size of 25 nm and a spherical 
shape (Figure 3-9). However, the shape of the PVP coated Bi-NPs NPs deposited from water 
changed to a flower-like formation with diameters of ~1 µm. As mentioned in section 3.3.1, 
modification of Bi-NPs using PVP was not sufficient to prevent surface oxidation when exposed 
to water. 
 
 
 
Figure 3-9: TEM images of PVP coated Bi-NPs in (a) H2O, and (b) ethanol (scale bar = 100, 200 and 500 
nm). 
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In the second part of this section, the NPs prepared in the presence of soluble starch were 
measured by TEM (Figure 3-10). Their average size is in the range of 15 nm in diameter and is 
spherical in shape. These results are in agreement with those reported previously [162]. 
 
 
Figure 3-10: TEM images of starch coated Bi-NPs in (a) H2O and, (b) ethanol (scale bar = 50, 200 and  
500 nm). 
 
3.3.2.2 X-ray diffraction (XRD) 
XRD was used to determine the phase purity and crystalline phase of the purchased and prepared 
Bi-NPs (Figure 3-11). Both XRD patterns reveal peaks that can be indexed as the rhombohedral 
bismuth phase (JCPDS File No. 85-1329). No other diffraction peaks are attributed to an oxide 
or impurity from the observed XRD pattern indicating that the resulting product from the 
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synthesised NPs is high purity crystallised elemental bismuth. The synthesised sample is 
considerably broadened with a wide background compared to purchase sample. Similar to that 
previously mentioned, the non-sharp peaks can be attributed to the small size of the NPs and the 
nanocrystalline component [183]. The results match those reported in the literature [162, 184, 
185]. 
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Figure 3-11: XRD spectra of (a) for purchased Bi-NPs, and (b) synthesised startch coated Bi-NPs. 
 
  
129 
 
3.3.2.3 X-ray photoelectron spectroscopy (XPS) 
High-resolution XPS spectra of the Bi 4f region of the prepared and purchased Bi-NPs were 
obtained (Figure 3-12). Spectra of the prepared sample show two peaks at 163.7 and 158.6 eV 
which are assigned to Bi 4f5/2 and Bi 4f7/2, respectively. These results are consistent with 
previous reports [186]. The purchased sample has two peaks, with the one located at 164.5 eV 
corresponding to the binding energy Bi 4f5/2 and the second at 159.3 eV attributed to Bi 4f7/2. 
These peaks reveal that there is a slight amount of Bi2O3 in the purchased NPs, which is in close 
agreement to that reported in the literature [185, 187]. However, the lower binding energy of the 
Bi 4f peaks may be due to less oxygen present in synthesised NPs. Bismuth oxide formation can 
also be related to the adsorption from the air during sample preparation for XPS analysis.  
  
130 
 
1 4 0 1 5 0 1 6 0 1 7 0 1 8 0
B in d in g  e n e r g y  ( e V )
I
n
t
e
n
s
it
y
 (
a
.u
.)
B i  4 f 7 / 2 B i  4 f 5 / 2
(b )
1 4 0 1 5 0 1 6 0 1 7 0 1 8 0
B in d in g  e n e r g y  ( e V )
I
n
t
e
n
s
it
y
 (
a
.u
.)
B i  4 f 7 / 2 B i  4 f 5 / 2
(a)
 
 
Figure 3-12: XPS spectra showing region of Bi peaks in the (a) synthesised startch coated Bi-NPs, and (b) 
purchased Bi-NPs.  
3.3.2.4 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR spectra were also recorded for starch coated Bi-NPs in order to ensure the presence of 
starch as a surface coating (Figure 3-13b) and then compared with pure starch spectra in Figure 
3-13a [188]. The spectra show various peaks: the peaks at about 3271 and 3400 cm
−1
 correspond 
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to the –OH stretching vibrations, indicating the coordination between bismuth and neat starch. 
The position of the –OH stretch has shifted to 3400 cm−1, indicating the strong interaction of 
hydrogen bonds between the soluble starch and surface of the Bi-NPs [189, 190]. The peaks 
present at around 2928 cm
−1
 can be attributed to  −H stretching vibrations the CH2 groups of the 
soluble starch CH2 [191]. The two peaks positioned at 988 and 1168 cm
−1
 are associated with to 
the  −O bond stretching of  −O−  and  −O−H groups in starch, respectively. There is a peak 
shift from the peak at 993 cm
−1
 to 1026 cm
−1
 in the Bi-NPs spectra, which can be resulting from 
the interaction of Bi-NPs and starch. These results confirmed that that starch molecules are 
adsorbed on the surface of Bi-NPs. 
  
132 
 
 
 
 
Figure 3-13: FT-IR spectrum of (a) pure starch, and (b) starch coated Bi-NPs. 
 
3.3.2.5 Thermogravimetric analysis (TGA) 
The amount of Bi present in the prepared NPs was determined via TGA (Figure 3-14a). It was 
observed that a weight loss of 19.06 % occurred in the temperature region between 200 and 300 
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°C, which is the weight precent attributed to starch, that has degrades over the same temperature 
range (Figure 3-14b), and therefore the remaining mass percent attributed to Bi was is 80.94%. 
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Figure 3-14: TGA curve for (a) starch coated Bi-NPs, and (b) pure starch. The weight loss of 19.06 % was 
ascribed to the starch on the surface of the NPs.  
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3.3.2.6 Zeta potential analysis  
The zeta potential measurement was outlined in section (3.2.2.6).  
3.4 Bismuth oxyiodide nanoparticles  
3.4.1 Synthesis of nanoparticles 
PVP-coated BiOI-NPs were prepared by a simple aqueous solution-based synthetic procedure as 
previously described [163]. This method involves the hydrolysis of the hydrated Bi3+ ion under 
acidic conditions to form BiOI from the reaction between BiO+ and I− ions. This reaction was 
conducted in the presence of a polymer coating agent (PVP), to insure such a hydrolysis reaction 
occurred in an acidic solution and therefore the nucleation of BiOI-NPs was limited. In such a 
method, PVP is capable of acting as stabiliser and macromolecular surface modifier.  
3.4.2 Characterisations 
3.4.2.1 Transmission electron microscopy (TEM) 
TEM images reveal that PVP coated BiOI-NPs have an average size range of 4 nm and the 
morphology of these NPs is nearly spherical (Figure 3-15).  
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Figure 3-15: TEM images of PVP coated BiOI-NPs in H2O (scale bar = 20 and 50 nm). 
 
3.4.2.2 X-ray diffraction (XRD) 
The typical XRD spectrum of the BiOI-NPs (Figure 3-16) indicated that all of the reflection 
peaks fit to the orthorhombic phase structure for BiOI, as expected (JCPDS NO.10-0445) [163, 
192]. It is observed that the diffraction peaks are not sharp in relation to the powder XRD pattern 
for the BiOI-NPs which could be attributed to the uniformity of the non-crystalline component 
and the effect of PVP.  
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Figure 3-16: (a) XRD for PVP coated BiOI-NPs. 
3.4.2.3 X-ray photoelectron spectroscopy (XPS) 
The chemical composition and oxidation state of the elements in the BiOI-NPs was obtained 
using XPS, with the results presented in Figure 3-17. All of the expected elements (Bi, O and I) 
were successfully detected in the sample. The O 1s profile of BiOI is asymmetric and can be be 
fitted with two peaks. One peak at 529.70 eV is characteristic of oxygen in BiOI and a second 
peak at 534.88 eV corresponds to the oxygen containing components adsorbed on the surface of 
BiOI such as the hydroxyl groups [193]. The peaks of Bi 4f7/2 and Bi 4f5/2 are located at 158.8 
and 164.3 eV (Figure 3-17b), respectively, which are assigned to Bi
3+
 ions in BiOI [194]. The 
peaks at 630.11 eV and 618.14 eV are ascribed to I 3d3/2 and I 3d5/2, respectively, corresponding 
to I−of BiOI [193]. These results are in agreement with previous data of BiOI-NPs.  
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Figure 3-17: XPS spectra showing region of (a) O 1s, (b) Bi 4f, and (c) I 3d. 
3.4.2.4 Fourier transform infrared spectroscopy (FT-IR) 
Figure 3-18 shows the FT-IR spectrum of pure PVP (MW, 10000) and PVP coated BiOI-NPs. 
The bands at 2933 and 2869 cm
-1
 are assigned to the asymmetric and symmetric stretching 
vibrations of methylene (CH2). The peaks present at 1660 cm
-1
 originate from the C=O stretching 
vibration of in PVP, which exhibits the coordination between bismuth atoms and oxygen in the 
carbonyl group, this can be approved when this peak comperes with the peak at 1665 cm
-1
 in 
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pure PVP as shown in Figure 3-18b. The strong band at 1318 cm 
-1
 corresponds to the C–N 
stretching vibration of PVP. The nitrogen arising from PVP and oxygen atoms can coordinate 
with the metal ions, leading to PVP molecules attached to the surfaces of BiOI NPs as this peak 
was 1289 cm 
-1 
in the pure PVP as shown in Figure 3-18b . There is slight shift from the peaks 
existing in the pure PVP to PVP coated BiOI FT-IR indicates the interaction between BiOI and 
PVP, thus the characteristic absorption bands confirmed the presence of PVP. 
 
 
 
Figure 3-18: FT-IR spectra of (a) pure PVP (MW 10,000), and (b) PVP coated BiOI-NPs. 
 
3.4.2.5 Thermogravimetric analysis (TGA) 
The weight loss as a function of temperature: 9% loss between room temperature and 300 °C, 
followed by 26% between 300 and 494 °C (Figure 3-19). The first step can be related to the loss 
of volatile solvent. The second significant weight loss can be attributed to the loss of the PVP 
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chains. The weight loss of pure PVP polymer began to occur at approximately 342 °C and was 
completed at about 470 °C [195]. The higher thermal stability of PVP−BiOI NPs might be 
attributed to the higher chain compactness due to the interaction between the PVP and BiOI-NPs 
.Therefore the average surface loading of PVP to be 35 wt%. 
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Figure 3-19: TGA curve for BiOI-PVP NPs and TGA curve for pure PVP (MW 8,000). The weight loss 
of 35% is ascribed to the loss of PVP from the surface of the NPs. 
3.4.2.6 Zeta potential analysis  
The zeta potential measurement was outlined in section (3.2.2.6). 
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3.5 Conclusion 
The work presented in this chapter highlights a variety of methods related to NP characterisation. 
The work in this chapter was an example of the complete characterisation of NP properties that 
are essential in the applications of NPs in radiology and radiobiology such as size, shape, state of 
dispersion, physical and chemical properties (e.g., electron and physical density and chemical 
composition), surface area, and surface chemistry. The characterisation of bismuth and bismuth 
compound NPs demonstrates how the application of appropriate fabrication and surface coating 
methods can provide additional information to more accurately specify their properties as their 
biocompatibility is yet to be established and are not commercially available. This 
characterisation study can also identify their suitability for X-ray applications; enable further 
optimisation and the intended application. Characterisation of size, morphology and chemical 
composition of NPs can provide essential information to evaluate their interaction with 
subcellular organelles, cells, tissues, and organisms as well as their radiobiological impact. More 
importantly, these studies demonstrated that the uncoated NPs are not suitable in the biological 
application of the material. Therefore, the characterisation of the biological surface coating has a 
crucial role to optimise the applications of bio-NP agents in terms of in vivo stability and 
dispersion resulting in longer circulation times in the body. In addition, the high amount of Bi 
atoms compared to the amount of surface coating in synthesised bismuth and bismuth compound 
NPs can generate high numbers of free radicals via both photoelectric and Compton interactions. 
Therefore synthesised bismuth and bismuth compound NP characterisation highlights the need 
for fundamental studies of NP surface effects to understand the radiological effect and radiation 
interactions that can influence particle behaviour and performance in X-ray applications. This 
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characterisation data would be beneficial to many researchers in a wide variety of different 
fields.   
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Chapter 4 
 4 SECTION I: Bismuth Nano-compounds as 
Contrast Agents in X-ray Computed 
Tomography (CT)  
4.1 Overview 
The previous chapter presented the complete characterisation of synthesised NP properties that 
are essential for use in diagnostic imaging applications. This chapter aims to investigate the 
feasibility of employing bismuth compounds as a diagnostic agent for CT imaging. This work 
has multiple sub-aims that are related to the furthering and improvement of subject contrast by 
the inclusion of bismuth compound NPs such as Bi2S3- and BiOI-NPs into the radiologic targets. 
The first study was conducted to identify the appropriate energy range to maximise the detection 
of Bi2S3-NPs in CT images and hence improve image contrast. Images are compared to samples 
of conventional iodinated CM to provide a reference against a material that is already clinically 
viable and commonly employed. Results are compared with the theoretical calculations based on 
linear attenuation coefficients for both Bi and I. The second novel study determined the role of 
BiOI-NPs in enhancing the subject contrast of DE-CT and MARS-CT. The benefits of both 
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distinctive K-edge energies for Bi and I simultaneously are considered. As before, comparison 
with the theoretical calculations based on linear attenuation coefficients for Bi, I and BiOI were 
conducted. The final section summarises the main points of this chapter. 
4.2 Introduction 
Medical imaging modalities, such as magnetic resonance imaging (MRI), computed tomography 
(CT), positron emission topography (PET) and single photon emission computed tomography 
(SPECT) are commonly used to diagnose and guide treatment. X-ray CT is the most frequently 
employed, owing to its availability, low cost, deep tissue penetration, and ability to provide high-
resolution 3D images of anatomical structures in a short timeframe [196]. However, while CT 
can generate highly detailed tomographic images of electron-dense materials, its ability to 
differentiate subtle changes between soft tissues is limited. This is because most soft tissues have 
very similar CT numbers, ranging from -100 to 100 Hounsfield units (HU), which are a measure 
of X-ray attenuation in CT images [43]. Consequently, CT contrast agents with high X-ray 
attenuation coefficients are necessary for contrast enhancement in regions of interest which are 
of low subject contrast [16, 43, 197]. The interaction between the incident radiation and the CM 
results in significant contrast improvements for diagnostic imaging of soft tissues. 
Contrast agents for X-ray imaging based on iodinated compounds have been used 
extensively in radiologic imaging since the 1920s [16, 198]. Despite effective attenuation, 
versatile synthesis methods, high solubility and body tissue tolerance, iodinated contrast agents 
suffer from several drawbacks, especially for certain groups of patients [16, 25, 199, 200]. The 
main limitation of iodinated contrast agents is their short circulation times (< 10 min) resulting 
from renal clearance by the kidneys, and thus rapid CT image acquisition is required [27]. In 
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addition, iodinated contrast agents have a non-specific bio-distribution throughout the 
intravascular and extravascular spaces resulting in poor contrast due to its dilution, especially in 
larger patients [16, 201]. Generally, large doses of contrast agents are required to counteract their 
rapid renal elimination, which can induce hypersensitivity reactions and can have other serious 
adverse effects which are well documented in the literature [29, 30]. Recently, several strategies 
have been introduced to improve the efficiency and reduce the toxicity of iodinated contrast 
agents. For example, polymeric and lipid nanoparticulate systems have been used to encapsulate 
iodinated contrast agents [16, 18, 202, 203]. However, these approaches have had limited success 
due to the high concentrations of iodinated contrast agents required for encapsulation and 
lengthy purification methods [71]. Furthermore, targeted imaging with these contrast agents still 
remains a major challenge due to the difficulty in conjugating specifically targeted biological 
components to these materials and the subsequently low payloads/concentrations that are 
delivered to the target, resulting in low CT sensitivity [72, 73].  
In CT scans, the majority of photons used are of high energy (> 120 kVp). However, the 
Z (I = 53) and K-edge value (33.2 keV) of iodine makes it only sensitive to low energy X-rays. 
This is due to the high absorption of low-energy photons through PEs, which results in a beam-
hardening artefact. In other words, the low energy photons that are absorbed have less 
contribution to the CT diagnostic energy range and add only to the already high patient’s dose 
[28]. The result of this is that iodine has its optimal effect only at relatively low energy. Thus, 
higher Z elements are more desirable to enhance the CT efficiency.  
The development of various nanoscale metal-based contrast agents has been proposed as 
a means to overcome the shortcomings of traditional iodinated contrast agents [16, 72, 197, 204]. 
In particular, NP-based CM deliver heavy atoms with greater biocompatibility, higher contrast 
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densities and longer circulation times to targets more efficiently than conventional contrast 
agents. These longer circulation times facilitate the imaging process and allow better 
visualisation of blood vessels and tumours. Recently, high density metals such as gold (Au) and 
bismuth (Bi) have been formulated as NPs and have been shown to have relatively long blood 
circulation times compared to iodinated contrast agents. Au-NPs with diameters of 1.9 and 30 
nm have been reported to have circulation times > 4 h. in mice [205, 206], whereas Bi2S3-NPs 
(50 nm) have demonstrated circulation times > 2 h [27], both significant improvements on 
clinical iodinated contrast agents (< 10 min). There have also been numerous advances in the 
preparation of Au-NPs as contrast agents for CT, with their size, shape and surface coating being 
tunable parameters [81, 133, 207, 208]. However, the widespread use of Au remains low due the 
high costs involved. 
Bismuth is low in toxicity and a cost effective alternative to Au-NPs. Bismuth-based 
compounds (non-NPs) have also been used for many years for the treatment of various 
conditions and diseases. For example, bismuth containing pharmaceuticals are used for the 
treatment of gastrointestinal disorders [209-211], such as the eradication of Helicobacter pylori 
in peptic ulcers [209, 212-214], syphilis, tumours [215] and for reducing the renal toxicity 
caused by cisplatin [216]. Bismuth-based NP contrast agents for CT possess several advantages 
over conventional iodinated and Au-based NP contrast agents as a result of their high Z (I = 53, 
Au = 79, Bi = 83), high X-ray attenuation [27, 31, 71, 145], low cost [71, 141] and low toxicity 
[27]. Bi2S3 is one of the most promising NPs contrast agents due to its high Zeff, ρm, and ρe. The 
high density of free electrons increases the probability for Compton interaction, which is of 
particular interest in CT imaging. 
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Rabin et al. demonstrated that polyvinylpyrrolidone (PVP) coated Bi2S3-NPs displayed a 
five-fold increase in CT signal enhancement at a tube potential of ~50 kVp and a lower-
cytotoxicity profile compared to the iodine contrast agent (iopromide) in liver hepatocyte 
(HepG2) cells and similar cytotoxicity profiles were also reported in macrophage (U937) cells 
[27]. Cytotoxicity studies comparing Bi2S3-NPs and Bi subsalicylate in these cell lines 
demonstrated higher cytocompatibility with the former. Kinsella et al, conjugated Bi2S3-NPs 
with Lyp-1 cyclic peptides, a specific target for breast cancer in mice. Following intravenous 
administration and CT scanning, the conjugated Bi2S3-NPs were found to produce clearer images 
and higher CT numbers in the target tumours compared to non-targeted NPs [139]. The 
evaluation of contrast enhancement resulting from Bi2S3-NPs at a wide range of diagnostic tube 
potentials has not yet been studied.  
In addition to the use of nanosized contrast agents, recent advances in CT systems have 
gained considerable interest. One exciting new imaging technique is DE-CT. While conventional 
CT offers information of the cumulative attenuation over the entire energy range for the scanned 
tissues within the voxel. The capability of distinguishing the tissues is limited in standard CT due 
to the fact that the image only responds to the entire energy range but not to a specific energy. 
On contrast, the DE-CT technique uses two X-ray energies from a single source or by using 
different source filtrations [85, 87, 88, 92]. This can be done using dual-source synchronous 
acquisition [93], single source sequential and single-source fast switching acquisition [94]. The 
additional measurement of the attenuation in the DE-CT is retrieved at a second energy, which 
allows differentiation between two materials. A pair of images is produced using the different 
relative attenuation of the X-ray photons that are displayed by material at different X-ray 
energies, which is used in separating structures. There are various clinical application of this DE-
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CT: (i) bone removal [97-99, 217], computation of contrast-enhanced imaging [100], difference 
between calcium and iodine [101], between blood, blood mixed with pus, bile and urine [102] 
and also the discrimination between the kidney and urinary stones [103, 218, 219]. Material 
quantification by using the deference between virtual non-enhanced images and contrast-
enhanced images allows the calculation of the iodine [100, 220]. Such imaging methods have 
valuable advantages in vascular [221, 222], liver or kidney imaging by decreasing the level of 
radiation used [218, 219] or by quantifying iodine uptake [100, 223, 224]. A recent study 
reported on the ability of DE-CT to determine the mass fraction of three materials using 
reconstructed images (calcium, hydroxyapatite and iron nitrate) in one voxel [225], as opposed to 
a conventional CT scanner. However, the major limitation of DE-CT is that materials with 
similar attenuation curves cannot be discriminated due to the overlapping attenuation spectra 
[91]. A recent in vivo study in the dual energy micro-CT (DEmicro-CT), presents a novel 
solution to overcome this problem by using two different contrast agents (gold and liposomal 
iodine NPs) injected at different times to quantitatively map concentrations of extravasated Au 
and intravascular iodine [226]. A simulation study was performed to determine the performance 
of the two elements (Au and I) when both were considered as contrast agents in DE-CT. The Au 
showed higher performance compared to I [227]. The idea of using a single compound with two 
elements that have non-overlapping spectra has not yet been investigated. 
To overcome the drawbacks of dual sources, multi-energy imaging has been established 
to expand the potential of the clinical application of materials differentiation. The photon 
counting devices  Medipix2 [228] and Medipix3 [229] detectors were introduced by the 
European Centre for Nuclear Research (CERN) and allow up to eight points of an attenuation 
curves to be reconstructed from only one exposure, thus preventing the overlap in the 
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measurement [229]. The limitations of both the designs were addressed in the next version, 
MARS-CT3, which have recently established by Firsching et al. [114]. This technique is known 
by K-edge imaging [230, 231]. The K-edge imaging method involves imaging on either side of 
the sharp edge in the in the absorption spectrum of relatively high Z elements [91]. 
The general purpose of our study was to determine the feasibility of applying bismuth 
compound NPs as contrast agents for conventional CT, DE-CT and MARS-CT. In the first 
section 4.3, we aimed to validate previous work and demonstrate that Bi2S3-NPs provide 
significant increases in X-ray attenuation rates (conventional CT) at clinical tube potentials 
ranging from 80 to 140 kVp, in comparison to conventional iodinated contrast agents. In the 
second sections 4.4 and 4.5, we aimed to determine the feasibility of BiOI-NPs as a novel 
contrast agent in DE-CT and MARS-CT by considering the benefit of both distinctive K-edge 
energies for Bi and I. In section 4.5, we analysed the ability of the MARS spectral scanner to 
distinguish I and Bi in a single agent simultaneously. This work highlights the potential role of 
Bi2S3- and BiOI-NPs NPs to provide higher contrast and more detailed CT and CT application 
images.  
4.3 Bismuth sulfide nanoparticles at various tube potentials 
This section highlights the potential of Bi2S3-NPs to provide higher contrast and more detailed 
CT images at clinical tube potentials ranging from 80 to 140 kVp. In this study we examine the 
effect of X-ray tube potential on the characteristics of Bi2S3-NPs as contrast agents in 
comparison to conventional iodinated CM at various tube potentials. The CT contrast 
enhancement and CNR of all scanned images were calculated. The image enhancement and CNR 
values were plotted as a function of tube potential and concentrations were then analysed. 
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4.3.1 Results and discussion 
The range of tube potentials selected in this study (80 to 140 kVp) represents the range normally 
used in clinical CT scanners with contrast agents. The X-ray absorption of Bi2S3-NPs was 
compared to the clinical iodinated contrast agent (iohexol) at various concentrations and X-ray 
tube potentials as shown in (Figure 4-1). As expected, CT numbers (report as Hounsfield units 
(HU)) increased linearly with increasing concentrations of both Bi2S3-NPs and the iodinated 
contrast agent. This is due to the introduction of larger number of heavy atoms (Bi and I) into the 
solution, which increases the X-ray attenuation rate and subsequently increases the HU density 
during CT imaging. At all tube potentials (80 to 140 kVp), the CT numbers (HU) are greater for 
Bi2S3-NPs than the iodinated contrast agent at about the same concentrations, indicating higher 
absorption X-rays. Both contrast agents (I and Bi) display the same trend with respect to tube 
potential. This is also displayed in CT cross-sectional slices of Bi2S3-NPs and iodinated contrast 
agent solutions at concentrations of 65 mM and increasing tube potentials (Figure 4-2). The 
regions that contained Bi2S3-NPs have higher attenuation compared to iodine at all tube 
potentials, indicating enhanced contrast. This is related to the differences in interaction between 
X-rays and the two contrast agents, that is, the difference in the measured CT number between 
the contrast agents (I and Bi). This can be clearly explained from equation 6 (see chapter 1, 
section 1.3.5.1). The difference in subject contrast is mainly due to the value µt which is the 
computed attenuation coefficient of a voxel along the ray track in the tissue with and without the 
contrast agents. After taking into account the impact of the dominant interaction of X-rays that 
influence this value (µt), the difference between the CT numbers of two contrast agents can be 
explained. The dominant interaction of X-rays at > 80 kVp with tissue and water results only 
from Compton scattering (CS) [232]. In contrast, for high Z elements, PE would be more 
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significant than for low Z elements as PE depends strongly on a material’s Z (⍺Z3). Therefore, 
the CT number of high Z elements (I or Bi) is greater when compared to the attenuation of water 
(or soft tissue). Since, the iodine’s K-edge (33.2 keV) occurs just below 80 kVp and the highest 
attenuation rate for iodine is expected to be in this energy range. The attenuation of X-rays in CT 
decreases with increasing energy (80 to 140 kVp) due to the reduction of the probability of both 
PE and CS since these energies are beyond the K-edge value of I. In contrast, the difference in 
the attenuation number of Bi atoms compared to water molecules is expected to be higher than 
iodine and water. This is because the X-rays interaction probability with Bi decreases much 
slower than I due to the existing impact of bismuth’s K-edge value which increases the PE 
interaction with X-rays. Therefore, across all the range of energies the difference in attenuation 
between Bi and water is larger compared to that of I and water. It is well known that the 
probability of X-ray interaction is highly dependent on ρm, ρe and Z. Thus, it is logical that Bi2S3-
NP displays much greater attenuation for applications employing tube potentials between 80 to 
140 kVp. It is also noted that Bi2S3-NPs exhibits stronger attenuation in CT imaging at 80 kVp 
than at other potentials. However, there is only a slight change between 100 and 140 kVp. The 
cross-sectional CT images from the contrast phantoms also show similar results, where the area 
containing Bi at 80 kVp has a higher attenuation value than at other X-ray tube voltages. This is 
due to the high probability of interaction with photons (both PE and CS) at 80 kVp. The 
interaction probability is lower at potentials from 100 to 140 kVp (see the following section for 
more explanations). 
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Figure 4-1: CT numbers for Bi2S3-NPs and the iodinated contrast agent as a function of concentration at tube potentials of (a) 80, (b) 100, (C) 120, 
and (d) 140 kVp. Differences between the CT values for Bi2S3 and I contrast agents at tube potenatils are considered to be statistically significant 
at p values of less than 0.05 (* p < 0.05). 
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Figure 4-2: Cross sectional CT images of contrast phantoms containing Bi2S3-NP and iodinated contrast 
agents. Samples were imaged at equimolar concentrations (65 mM) and tube potentials of 80, 100, 120, 
and 140 kVp. 
The CNR of Bi2S3-NP and iodinated contrast agents is determined at equivalent 
concentrations of 26, 35, 51 and 65 mM (Figure 4-3). The CNR results are directly dependent on 
the X-ray CT attenuation of the contrast agents. The value of CNR increases with increasing 
concentrations of Bi and I within the system, as more atoms are available for interaction at 
higher concentrations. Hence, higher attenuation coefficients are obtained leading to bigger 
differences in attenuation between the solution and the Perspex (container). For the iodinated 
contrast agent, the CNR is found to decrease with increasing tube potentials at all concentrations. 
A higher image contrast enhancement for the iodinated contrast agent is observed at a lower tube 
potentials due to the high attenuation value produced from the effect of its K-edge (33.2 keV) at 
low energies. The CNR results for the iodinated contrast agent shows signal reduction which are 
consistent with the results of previous studies [28, 232]. For Bi there is a slight signal reduction 
from 80 to 140 kVp. The CNR data for NPs follows a similar trend to the iodinated contrast 
agent. However, at potentials higher than 80 kVp, the Bi2S3-NPs CNR shows a pattern of 
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reduction. This could be due to the photon interaction having a much more pronounced impact at 
80 kVp and then decreasing with potentials from 100 to 140 kVp. The effect of the tube potential 
on contrast enhancement is validated by calculating the differences in CNR between contrast 
agents from lower to higher tube potentials at a concentration of 65 mM. Comparison of the 
CNRs of both contrast agents as a function of tube potential is represented in Figure 4-4.  
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Figure 4-3: Calculated CNR for (a) iodinated, and (b) Bi2S3-NP contrast agents at different concentrations 
and tube potentials. Difference between the of Bi2S3 and I results are considered to be statistically 
significant at p values of less than 0.05 (* p < 0.05). 
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Figure 4-4: CNR obtained from CT images as a function of the tube voltage for Bi2S3-NP and iodinated 
contrast agents.  
 
At all tube potentials, Bi2S3-NP exhibits higher a  NR because of the material’s 
comparatively high Z, ρm, and ρe. The difference in contrast enhancement between Bi2S3 NP and 
iodinated contrast agents increases with tube potential. At lower kVp, Bi2S3-NP shows a one to 
two-fold increase in contrast enhancement compared to the iodinated contrast agent. This 
enhancement difference continued to increase and is greatest (three to four times) at 140 kVp. 
These findings of a four-fold signal enhancement of Bi2S3-NPs over CM at 140 kVp are in close 
agreement to studies by Ai Kelong et al., where a two-fold increase in X-ray attenuation was 
reported at 100 kVp [31]. Theoretical mass attenuation data are obtained using the NIST mass 
attenuation plots [233] (Table 4-1).  
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Table 4-1: Mass attenuation coefficients (µ) of measured X-ray energy spectra using published NIST 
mass attenuation plots. CT values for Bi and I were calculated using published NIST mass attenuation 
data. 
kVp keV µ Bi µ I µ water CT # for Bi  
(×10
3
) 
CT # for I 
(×10
3
) 
80 46 88 14 0.24 364 55 
100 60 53 8.0 0.21 247 39 
120 67 38 5.6 0.20 186 27 
140 80 27 3.3 0.18 149 17 
160 91 70 2.5 0.17 411 14 
 
The mass attenuation coefficient curves of Bi and I are plotted versus photon energy in 
Figure 4-5. The total mass attenuation coefficients for both I and Bi are a result of the 
contribution of both PEs and CS. The K-edge value represents an enhancement level threshold in 
the attenuation of Bi and I at a particular energy. This increased attenuation occurs at 33.2 keV 
for I and 90.5 keV for Bi, due to the binding energy of the K-shell electrons when the 
photoelectric absorption occurs. The CT data are selected for equivalent energies to the 
corresponding kVp (keV lies between one third and one half of the selected tube potential [40]). 
The mass attenuation coefficient decreases as kVp increases for both Bi and I. Interestingly, the 
attenuation trend for Bi is observed to sharply increase at 160 kVp due to the profound impact of 
bismuth’s K-edge value (91 keV). The calculated CT numbers followed the same trend as the 
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mass attenuation coefficient. There is close agreement between these results and the calculated 
theoretical data. The measured mass attenuation coefficient of both agents is strongest at 80 kVp, 
and as the X-ray tube potential increased, the attenuation decreases. Iodine’s K-edge occurs at 
photon energy of 33.2 keV, when the tube potential is about 60 kVp and as that potentials 
increases, the attenuation gradually deceases. At 80 kVp, iodine’s attenuative properties are 
maximised but are not further improved at higher tube potentials. At a high tube potential (>160 
kVp), bismuth’s K-edge optimum occurs at (91 keV), where it absorbs a high number of photons. 
Below this range (80 to 140 kVp), the strongest HU density for Bi occurs at 80 kVp due to the 
high number of X-ray photons contributing to the PE and CS and once more, less contribution 
occurs at higher potentials.  
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Figure 4-5: Mass attenuation coefficient as a function of energy showing the K-edge values for (a) iodine 
and (b) bismuth. Theoretical mass attenuation data were obtained using published NIST mass attenuation 
plots.  
 
The results presented in this study clearly demonstrate the potential for Bi-based NP to 
represent a contrast agent at the clinically relevant tube potentials as compared to conventional 
iodinated contrast agents. A lower concentration of Bi2S3-NPs can be also be used without 
resulting in viscosity issues [31]. While it is possible to use higher concentrations of iodinated 
contrast agents for greater image enhancement, this also increases the risk of adverse reactions in 
some patients [200]. Taking into consideration these factors, Bi2S3-NPs are a promising potential 
complement contrast agent at the studied tube potentials. This is especially relevant for cases 
where conventional iodine based CM cannot be used due to patient incompatibility (e.g., 
hypersensitivity reactions). Also importantly, the NPs have a longer blood circulation time, thus 
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improving their value as targeted agents by maintaining a relatively high blood concentration at 
the targeted tissue.  
4.3.2 Conclusion  
This phantom based study has shown that the inclusion of Bi2S3-NPs provides higher contrast 
efficacy than iodinated contrast agents at tube potentials of 80 to 140 kVp. The contrast 
enhancement is concentration dependent and also depends on the applied potential to the anode 
of the X-ray tub (i.e, the average beam energy). At low X-ray energy (80 kVp), Bi NPs display a 
one to two-fold enhancement in attenuation  compared to clinical contrast agents. Increasing the 
tube potential to 140 kVp resulted in even further improved attenuation levels, with Bi NPs 
displaying three to four-fold greater contrast enhancement over clinical iodinated contrast agents.  
This research clearly shows the potential for Bi-based contrast agents as an alternative to 
conventional iodinated contrast agents, particularly in cases where patients have had adverse 
reactions to conventional iodine-based CM and when higher contrast levels are required. As an 
added advantage, the long vascular half-life of Bi-based contrast agents further improves their 
value as a replacement to iodine in targeted imaging when prolonged circulation times are 
necessary.  
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4.4 Bismuth oxyiodide nanoparticles in DE-CT  
This study aims to determine the feasibility of BiOI-NPs as a novel contrast agent in DE-CT 
scanner by considering the benefit of both distinctive K-edge energies for Bi and I. In this study, 
BiOI-NPs and iodinated CM were evaluated for contrast enhancement at various X-ray tube 
potentials (80, 150 and DE-CT (80/150) kVp) in an imaging phantom. The CT number and CNR 
of all scanned images were calculated and were plotted as a function of tube potential and then 
analysed. This section also includes the cytotoxicity level of the NPs in lung adenocarcinoma 
epithelial (A549) cells line. 
4.4.1 Results and discussion 
To assess CT contrast efficacy of BiOI-NPs, the in vitro cytotoxicity of such NPs was examined 
using the colourimetric (MTS) assay. The effect of NPs on the viability of A549 cells was 
investigated to compare their toxic effects in order to obtain the maximum concentration at 
which the NPs are still nontoxic. The effect of 48 h treatment to different concentrations of NPs 
on cell viability can be seen in Figure 4-6. It is observed that 0.25 mM of NPs shows no 
significant effects on cell viability. After incubation with the highest concentration 4 mM (3.5 
mg/mL) of NPs, the cell viability was found to be ∼89 %, indicating that such NPs display no 
significant cytotoxicity in A549 cells line at such concentration. Similar results were found by 
Kandanapitiye et al; the HeLa cell viability was over ~92% even at relatively high dose of NPs 
(4.15 mg/mL) [163]. 
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Figure 4-6: Cell viability of A549 incubated with BiOI-NPs of different concentrations measured at 48 h. 
The data mean comparisons for different concentration are considered to be statistically significant at p 
values of less than 0.05 (* p < 0.05). The errors are the standard error of the mean from three independent 
experiments (mean ± SEM, n=3). 
 
Given that the attenuation value is energy depended, each of the elements in BiOI (Bi and 
I) has a specific attenuation curve. The energies (80 and 150 kVp) were selected to (i) represent 
the range of energies commonly used in clinical CT scanners with contrast agents and to (ii) 
cover the K-edge values for both Bi and I (plotted mass attenuation coefficient curves of BiOI) as 
shown in Figure 4-7 and as has been mentioned in section 4.3. In comparison with the standard 
CT, DE-CT has many advantages mainly its ability for material differentiation based on the 
material-dependent PE and CS probability of interaction. In this study, the DE- CT (80/150 kVp) 
was first validated against normal CT used at two distinct energies 80 and 150 kVp separately, 
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with both I and BiOI-NPs contrast agents. More importantly, the novelty of this study was to 
determine the feasibility of imaging BiOI-NPs as contrast agent in DE-CT. Using the DE-CT 
(80/150) kVp in order to enhance the combined X-ray attenuation effects of the two elements (I 
and Bi) in one compound, gives rise to a favorable compound platform with an X-ray attenuation 
power. The X-ray absorption of BiOI-NPs was compared to the clinical iodinated contrast agent 
(iohexol) at the selected X-ray tube potentials as shown in Figure 4-8. The BiOI-NPs attenuate 
X-ray stronger than CM in all the tested scans. This is also observed in CT cross-sectional slices 
of NPs and iodinated contrast agent solutions at tested tube potentials as displayed in Figure 4-9. 
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 Figure 4-7: Mass attenuation coefficient as a function of energy showing the K-edge values for BiOI. 
Theoretical mass attenuation data were obtained using published NIST mass attenuation plots . 
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Figure 4-8: CT numbers for BiOI-NPs and the iodinated contrast agent as a function of tube potentials 
(80.150 and DE-CT 80/150 kVp). Differences between the BiOI and I results are considered to be 
statistically significant at p values of less than 0.05 (* p < 0.05). 
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Figure 4-9: Cross sectional CT images of contrast phantoms containing BiOI-NP and iodinated contrast 
agents. Samples were imaged at equimolar concentrations (40 mM) and tube potentials of 80, 150 and 
DE-CT 80/150 kVp. 
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At 80 kVp, the X-ray attenuation caused by BiOI is higher than that of iohexol due to the 
fact that the attenuation coefficients of BiOI has the combined X-ray attenuation effect of both 
elements Bi and I as single agents. The high density and Z of Bi lead to an increase in PE and CS 
interactions and result in higher X-ray attenuation. Moreover, at such kVp the second element 
iodine increases the value of X-ray attenuation due to the effect of its K-edge value that has a 
pronounced effect at lower tube potentials. As expected, at the tube potential 150 kVp near the 
K-edge value of Bi but far than that of I, the X-ray attenuation caused by BiOI-NPs are greater 
than for the iodinated contrast agent at the same concentration, due the higher absorption of X-
rays via both CS and PEs for Bi. The X-ray attenuation value caused by the second element I at 
150 kVp has less contribution to the final X-ray attenuation resulting from the compound BiOI, 
as a results of iodine’s K-edge (33.2 keV) occurring just below 80 kVp. It is noticeable that BiOI 
at 80 kVp has a higher attenuation value than at the other X-ray tube voltages 150 and 80/150 
kVp. This is due to the fact that X-ray attenuation occurs primarily by PE from I and both PE and 
CS from Bi at 80 kVp, hence, the combined effect of both Bi and I leads to the higher attenuation 
enhancement. Our results show such an effect is lower at 150 kVp and DE-CT, due to the 
reduction of photons interaction in the case of I (this has been shown for Bi and I separately in 
section 4.3). The DE-CT results have confirmed that BiOI-NPs exhibit higher attenuation 
compared to iodinated contrast agents. This is due to maximising the interaction between X-rays 
and Bi atoms (at high energy), and I atoms (at low energy) in a single compound compared to 
iodinated contrast agents. A previous study has shown that one of the major benefits of DE-CT is 
that the attenuation of iodine is enhanced by approximately a factor of two compared to CT with 
low kVp [234]. Greater CT information can be achieved by considering the effect of I as well as 
the effect of Bi atoms at the higher energy of 150 kVp in DE-CT images. 
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The CNR for the CT images after scanning the BiOI-NP and iodinated CM were 
calculated at equivalent concentrations of 40 mM and at different sizes of ROI (4, 3, and 2 mm) 
(Figure 4-10). The CNR results directly rely on the X-ray attenuation number of the contrast 
agents. When comparing the CNR of BiOI-NPs to that of iodine at the reference energies, it is 
seen to be approximately 3.22 times greater at 80 kVp. At 150 kVp, the results for BiOI-NPs 
show a CNR enhancement of approximately 3.86 times and at DE-CT show a 3.79 times signal 
enhancement. Therefore, higher attenuation coefficients are obtained leading to greater 
differences in attenuation between the solution and the Perspex (container). For the iodinated 
contrast agent, the CNR is found to be higher at 80 kVp than for 150 kVp, due to the high 
attenuation value as a result of its K-edge (33.2 KeV); this is in agreement with previous studies 
in CM compounds [28, 232], and is also confirmed in section 4.3.1. The higher image contrast 
enhancement for the iodinated contrast agent that is observed at the lower tube potential of 80 
kVp, can also enhance the attenuation effect in DE-CT. In Figure 4-10b ( CT images for BiOI), 
the CNR value is greater at 80 kVp and in DE-CT than at the tube potential of 150 kVp, due to 
the combined effect of both Bi and I at the same time, which has the maximum effect at these 
energies. This could be due to the photon interaction (PE and CS) having a much more 
pronounced impact at 80 kVp and 150 kVp simultaneously and then decreasing with only the 
effect of Bi at the potential 150 kVp. In addition, it appears that CNR results show no significant 
difference between the different sizes of holes (4, 3 and 2 mm) in the phantom (ROI). 
An important consideration is that the compound BiOI-NPs contains 65 wt% elemental 
BiOI as measured in section 3.4.2.5. Hence, the total amount of elemental Bi and I in these NPs 
is calculated to be ~38 and 23 wt% respectively (refer to Table 1-3 for further information). 
When comparing these NPs to determine their CT contrast enhancement, the actual amount of 
  
167 
 
elemental I or BiOI should be compared. However, in terms of the K-edge effect, the significant 
factor is the percentage of I and Bi atoms. In this study, the concentrations of the whole element 
and compound with their coatings were used to measure their molarity and compared to 
iodinated contrast agent concentration. However, even when the 65 wt% of BiOI was compared 
to about 100 wt% of I in normal iodine based contrast agents, NPs can still rival those of iodine. 
Moreover, the X-ray attenuation efficiency of BiOI is greater than those of the previous reported 
inorganic NPs such as the PEGylated Au-NPs [205] and PVP-coated Bi2S3 [27, 31, 163]. This 
can be explained by the higher Zeff , and ρe compared to Bi2S3 and Au (see Table 1-2). Another 
significant factor is that the smaller the size of the NP, the larger the proportion of atoms on its 
surface. Therefore a smaller size has a larger SA/V which impacts on the cross section to 
radiation. The optimal nano metal (gold) size for CT attenuation has been reported to be between 
4 and 20 nm [176]. For this work, the optimal size was found to be about 4 nm for BiOI. 
This work provides proof of concept for a dual contrast agent for DE-CT using one single 
agent “BiOI-NPs”. One previous study has reported the use of Au-NPs and liposomal iodine NPs 
to detect each element in tumour vasculature; however this method is based on two separate 
injections and scans [226]. Our study provides a less time consuming methodology (requiring 
only one injection) with the added benefit of requiring fewer X-ray scans, which can reduce 
radiation doses. BiOI contrast agents can provide a new approach in subtraction of either I or Bi, 
or both, from the contrast enhanced image to obtain more detailed images. Considering these 
benefits and the prolonged circulation time for the bismuth-based NPs, this study opens the door 
for the study of promising agents for molecular CT imaging using different targeting strategies. 
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Figure 4-10: Calculated contrast-to-noise ratios (CNR) for (a) iodinated and, (b) BiOI-NP contrast agents 
at tube potentials (80, 150 and DE-CT 80/150 kVp). Differences between BiOI and I results are 
considered to be statistically significant at p values of less than 0.05 (* p < 0.05). 
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4.4.2 Conclusion  
This section demonstrates that novel concept of a dual contrast agent for DE-CT using bismuth 
and iodine in a single compound “BiOI-NPs” is advantageous. The phantom study has shown 
that the use of BiOI-NPs provides higher contrast efficacy than iodinated contrast agents at tube 
potentials of 80 and 150 kVp. The DE-CT images generated combine the benefits of both the K-
edge value for Bi and I. The contrast enhancement of BiOI (65%) has superior results over the 
iodinated contrast agents even with non-equal concentration of I (100%) elemental. At low 
energy (80 kVp), the CNR of BiOI-NPs was a factor of approximately 3.21 times greater. The 
contrast enhancements increase at the tube potential 150 kVp to a factor of 3.86 and to a factor of 
3.79 for DE-CT images over clinical iodinated contrast agents. The cytotoxicity study of BiOI-
NPs shows that such NPs have a good safety profile (~80 % at 4 mM). Therefore, this NP is a 
valuable contrast agent that can expand the use of X-ray CT and may have an important role in 
CT cellular imaging and image-guided drug delivery applications. 
This research clearly shows the potential for BiOI-NPs as contrast agents for DE-CT. The 
benefits include the non-overlap of the attenuation curves for both elements Bi and I and the long 
vascular half-life of Bi-based contrast agents that improve their value as a replacement to iodine 
in targeted imaging when prolonged circulation times are necessary.  
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4.5 Bismuth oxyiodide nanoparticles in MARS-CT  
This section focuses in the potential role of BiOI-NPs in enhancing the subject contrast for the 
spectral MARS-CT scanner. BiOI-NPs and iodinated CM were evaluated for contrast 
enhancement at various X-ray photon energy bins (27-37, 37-47, 47-60 and 60-91 keV) in an 
imaging phantom. The spectral CT numbers of scanned images were plotted as a function of 
photon energy bins were then analysed. This section also determines the ability of MARS-CT to 
discriminate the two elements I and Bi in BiOI-NPs agent simultaneously. 
4.5.1 Results and discussion 
Spectral MARS-CT imaging or K-edge imaging enables us to easily identify and distinguish 
elements in the target within the diagnostic energy range. Contrast agents typically involve 
elements with K-edge values ranging between 30 to 140 keV in radiology. The impact of these 
K-edge features can be explicitly explored and are valuable in the spectral energy measurements. 
Therefore, towards this aim the mass attenuation coefficient curves of Bi, I and BiOI are plotted 
versus photon energy bins (27-37, 37-47, 47-60 and 60-91 keV) in Figures 4-11. The mass 
attenuation coefficients values for Bi, I and BiOI demonstrate that the Bi and BiOI have greater 
mass coefficient values at the energy bins (27-37 and 60-9 keV) than iodine due to higher Z and 
density. Iodine represents an enhanced level of mass attenuation coefficients in the 27-47 keV 
energy bins due to the binding energy of the K-shell electrons when the photoelectric absorption 
occurs. The attenuation trend decreases with increasing photon energy. The mass attenuation 
coefficient curve for BiOI followed the same trend to iodine below 60 keV, but encounters 
another sudden increase at the energy bin 60-91 keV, as result of K-edge X-ray absorption of Bi. 
For the Bi element, the mass attenuation curve is following the same trend as BiOI curve at the 
last photon energy bin 60-91 keV due to the Bi absorption edge. It is noticeable that the mass 
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attenuation values for Bi is greater than BiOI at the first and last energy bins due to higher Z, ρm 
and ρe as calculated in Table 1-2. Accordingly, the selected energy bins (27-37, 37-47, 47-60, 
60-91 and 91- 118 keV) were used in spectral scans in order to scan and distinguish between I, 
Bi and BiOI. 
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Figure 4-11: Mass attenuation coefficient as a function of energy bins for the elements Bi, I and BiOI.  
 
The multi-energy reconstructions of the phantom scan for four energy bins are shown in 
Figure 4-12. All contrast concentrations of iodine, BiOI, lipid like and water are able to be 
identified and discriminated from each other. The X-ray attenuation in HU is ranging from -1000 
to 1500 as represented by the coloured bar. As shown from the figure, the HU density for air is-
1000 HU (minimum HU value), water is 0 HU and lipid is slightly higher than water; these 
samples represents the controls. The lower concentrations (0.76, 0.38 and 0.19 mg/mL) of iodine 
contrast agents have higher CT number compared to the controls. The following higher CT 
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attenuation values are BiOI-NPs with concentrations ranging from 2.7, 1.35 and 0.67 mg/mL. 
The highest CT attenuation in this study are obtained for the higher concentrations (18, 9 and 4.5 
mg/mL) of iodine contrast agents. The X-ray attenuation value for I is decreasing, with 
increasing photon energy bins from 27 to 118 keV, due to the reduction in PE interaction 
probability for higher energy bins. Similar observations in X-ray attenuation are obtained for 
BiOI-NPs, being highest at the lower energy bins, followed by a slight photon reduction, though 
not as obvious as iodine contrast agent due to the impact of PE which rises  to maximum  
probability at the last photon energy bin 60-91 keV.   
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Figure 4-12: (a) Illustration of 30 mm PMMA phantom with 6 mm diameter holses containing 200 μL 
vials of BiOI-NPs, iodine (I), H2O and lipid with different concentrations. (b) Reconstructed CT image 
(transverse view) (slice#147) with four energy bins, showing the attenuation in relation to energy for the 
high-Z materials. 
 
The mean values of the spectral Hounsfield trend along the increasing photon energy bins 
were obtained over the reconstructed voxels in their respective regions of iodinated CM and 
BiOI. The mean values of the HU were plotted as a function of the photon energy bins as shown 
in Figure 4-13. The maximum X-ray attenuation (K-edge absorption) in the iodine signal was 
captured between the 37 to 47 keV energy bins (Figure 4-13a and b). Then attenuation values 
decrease with increasing photon energy bins. The iodine attenuation trend was compared with 
high concentrations (Figure 4-13b). The higher concentrations of CM were used in this study for 
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comparison purpose due to the MARS-CT limitation to scan lower concentrations of CM. The 
spectral Hounsfield attenuation for BiOI has two enhancement levels; one is observed between 
the 37 to 47 keV, most likely as result of the I K-edge value (this in agreement with iodinated 
CM X-ray attenuation values), and the second is observed between the 60 to 91 keV due to the 
Bi K-edge value. It is clear from Figure 4-13c that the spectral X-ray attenuation at all energy 
bins for BiOI-NPs is higher compared to that for iodine contrast agents at close concentrations 
value. For example, at the photon energy bin 27-37 keV, the X-ray attenuation of BiOI is ~45 
HU and iodine CM is 20 HU. At the higher photon bins 37-47 and 47-60 keV, BiOI has the CT 
values of 47 and 31 HU and I has only 25 and 18 HU.  When the energy bin comes closer to the 
bismuth K-edge value 60-90 keV, the X-ray attenuation number is ~50 HU and I has 14 HU, 
indicating 3.5 times higher contrast enhancement when BiOI-NPs is used. The MARS-CT 
images contrast enhancement obtained from BiOI-NPs can be attributed to the combined 
attenuation effect of both I and Bi elements in BiOI-NPs, which has the greater influence at the 
two photon bins 37-47 and 60-90 keV. This can be explained by the higher rate of photon 
interaction as results of the three parameters Zeff, ρm and ρe as calculated in Table 1-2. 
Experimental observation confirmed that even with low concentrations the two K-edges 
absorptions can be detected in the MARS X-ray attenuation curves. Our study suggests that such 
agents have two benefits: (i) to act as dual contrast agents for MARC-CT and (ii) to reduce the 
need for high concentrations of iodine which has higher accuracy to be detected in the MARS-
CT images.  
The results presented in this study clearly demonstrate the novel role of the single BiOI-
NP to act as dual-contrast agent for MARS spectral scanner imaging. Unlike conventional CT 
and DE-CT, spectral CT can provide spectral data which has ability in differentiation and 
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classification of tissues to obtain material-specific images. Combining the benefit of using K-
edge imaging techniques with the promising contrast agents BiOI-NPs, it can be possible to 
quantify the amount and location of the either I and Bi or both particle with less need for other 
contrast agents. 
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 Figure 4-13: (a) X-ray attenuation number of small concentrations of I (0.76, 0.38 and 0.19 mg/mL), (b) X-ray attenuation number of high 
concentrations of I (18.9, 9 and 4.5 mg/mL), showing the X-ray image enhancement at 37-47 keV. (c) X-ray attenuation number of small 
concentrations of BiOI-NPs (2.7, 1.35 and 0.67 mg/mL) showing X-ray image enhancement at 37-47 keV and at 60-90 keV. The standard error in 
the measurement of all attenuation is ±2-5 HU. mg/mL). 
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4.5.2 Conclusion 
This phantom study has shown that the multi-energy spectral CT system has the ability to 
simultaneously discriminate the two elements in BiOI-NPs as well as to discriminate iodine 
contrast agents, lipid, and water as tissue equivalent, from each other. In the spectral CT scanner, 
the K-edge information is used to differentiate I and BiOI-NPs as well as both elements in BiOI-
NPs. This study has shown that the superior attenuation of BiOI-NPs at all the selected four 
photon energy bins over iodinated contrast. Experimental findings for all energy bins for BiOI 
and I attenuation curves correlate well with the theoretical calculations based on mass 
attenuation coefficients.  
The significance of this study is to demonstrate that two high-Z materials (I and Bi) in 
combination with multi-energy CT imaging (MARS) can provide better intrinsic tissue contrast 
to characterise tissues. These findings, when considered with the prolonged circulation time of 
bismuth-based NP, provide evidence for further applications of BiOI in contrast-aided 
procedures. The potential role of these agents can be expanded from non-targeted agents to use 
the I and Bi densities to quantify contrast uptake in the different tissues. This approach of 
combining two elements in a single agent can also allow simultaneous measurement of 
permeability factors within tumours and the separation of two elements as a viable paradigm for 
a wide variety of other applications including targeted therapy  
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Part of this chapter with content formatted for publication has been published as: Algethami, M., et al. (2015). 
"Radiation dose enhancement using Bi2S3 nanoparticles in cultured mouse PC3 prostate and B16 melanoma cells." 
NanoWorld Journal 1(3): 97-102. (see Appendix F for copyright permission)  
Chapter 5 
 5 SECTION II: Bismuth Nano-compounds 
as Radiosensitisers in Radiotherapy 
5.1 Overview 
The results displayed in the previous chapter clearly indicates the capability of bismuth-based NPs in 
enhancing the subject contrast for imaging CT in the conventional clinical energy ranges used 
with contrast agents. The previous chapter also documented the first experimental confirmation 
of the NP-enhanced subject contrast for DE-CT and MARS-CT scanners. Due to the benefits of 
such high Z NPs resulted from the high X-ray attenuation and absorption coefficients, low 
toxicity, a long blood circulation time, and be cost effectiveness. In this chapter it will be shown 
that, they can also enhance radiations in cell killing hence cause more efficient dose delivery 
acting as therapeutic agents.  Therefore, this chapter concludes that, these two benefits are reaped 
from one bismuth-based NP. Hence they can be termed theranostic agents. This work aims at 
investigating the possibility of using bismuth-based NPs as high Z elements as radio-enhancer 
agents using kilovoltage (kVp) and megavolage (MV) photon beams. In the first study, a 
comparison between Bi2S3 and Au-NPs as radiosensitiser agents was conducted in two cells 
lines, mouse prostate (PC3) and breast cancer (B16). Second section comprises the 
radiobiological study of dose enhancement effects produced by Bi2S3 and the novel Bi-NPs in 
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two cells lines, lung adenocarcinoma epithelial (A549) and prostate carcinoma (DU145). This 
chapter also includes the cytotoxicity level of the NPs in studied cells lines. It should be noticed 
that the terms of dose enhancement and radiosensitisation are used interchangeably to represent 
the effects of the particles on cells irradiated with X-ray beams. 
5.2 Introduction 
The chief aim of radiotherapy is to maximise the radiation dose delivered to tumours and at the 
same time minimise the level of damage to the surrounding healthy tissues by reducing the dose 
they receive. The methods to achieve this aim have mainly focused on employing the latest 
technologies and computers such as intensity modulated radiotherapy (IMRT) and volumetric 
modulated arc therapy (VMAT) [9, 10, 235]. A complementary approach for potentially 
achieving this aim involves localisation of high Z type medium at the target “tumour” prior to 
irradiations. The presence of high Z atoms in the target leads to an increase in the photoelectric 
effects cross section and the generation of low energy free radicals (photoelectrons and Auger 
electrons)[20, 34, 236]. These low energy free radicals have high linear energy transfer (LET) 
values [7] as a result can also cause DNA damage via the generation of reactive oxygen species 
(ROS). Moreover, it has been recently reported that metallic NPs sensitise the DNA molecules 
chemically and make them more sensitive to radiation damage [37]. If the cell sustains sufficient 
DNA damage it can impair its ability to replicate and/or activate cell death pathways. This line of 
investigation started with the use of iodine-based compounds of the type normally used as 
contrast agents for imaging in radiology [20]. Subsequently, this was fully studied using SQ20B 
human cells, and the levels of anticipated dose enhancement were formulated [21].  
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Recently, metallic NPs have been used for this purpose. NPs possess two advantages over 
iodine; (i) they have higher Z atoms and therefore a higher probability of photoelectric 
interactions, which depends approximately on Z
3 
[34], and; (ii) they accumulate more readily and 
to a greater extent atoms [237-239], and (iii) sensitise the DNA molecules [37]. One of the most 
commonly used metallic NPs for dose enhancement has been gold (Au) [160, 207, 240-244]. 
Gold has a high Z (79) and density (19.32 g/cm
3
), this leads to higher interaction and scattering 
probabilities with radiations, higher absorption via photoelectric (which depends strongly on the 
Z of the target (Z3)), and higher Compton interactions due to the high density of its atoms. Gold 
also has a low relative toxicity [243, 245-247]. Dose enhancement has been observed by 
inclusion of Au NPs with low energy X-ray beams (of the levels obtained from typical X-ray 
tubes) and to a much lower extent with higher energy beams (of the type generated by linear 
accelerators used in radiotherapy) [81, 207, 239]. Detailed descriptions of the outcomes of 
various studies have been recently reported by McMahon et al. [248] as well as full theoretical 
studies of such methods for radiation dose enhancement [249, 250]. Few studies have been 
documented in the literature describing alternatives to Au-NPs [240].  
Among these high Z candidates are bismuth NPs which have currently has been 
established in biomedical applications due to their favourable properties. Bismuth has a higher Z 
[Bi-83], resulting in a higher cross section for radiation absorption via the photoelectric effect, 
which depends strongly on the target atom’s Z value. It has a higher density of free electrons 
increasing the probability for Compton scattering, which involves outer shell electrons. It is also 
considered one of the least expensive heavy metal-based NPs and is significantly cheaper than 
gold. As mentioned before (section 4.2) bismuth is one of the least toxic heavy metals; it has 
been used in biological applications particularly in form of  bismuth salts [210, 212-215, 251] 
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and in form of NPs [16]. A few studies were conducted recently, one been conducted by our 
group in using bismuth-based NPs (Bi2O3 and Bi2S3) to enhance radiation dose and improve 
therapeutic efficacy in radiotherapy using phantom study [252]. Continue investigation study in 
Bi2O3-NPs as dose enhancer agents were conducted in cell study and Monte Carlo simulation 
also [253]. Another an analytical study demonstrated that Bi-NPs are excellent radiation 
enhancing agents by considering contributions from both photoelectrons and Auger electrons for 
tumour cells and their nuclei [254]. Moreover, Stewart et al. showed that improving the synthesis 
method of Bi2O3-NP by reduction in oxygen concentration can make them to scavenge reactive 
oxygen species (ROS), resulting in the higher ROS production in cells which leads to high 
cancer cell death rate [255].   
The aim of this chapter was to demonstrate the potential of bismuth-based NPs for the 
enhancement of kVp and MV radiotherapy beams. In the first section 5.3, we aimed to conduct a 
head-to-head comparison of Bi2S3- and Au-NPs and have demonstrated that the level of radiation 
dose enhancement inflicted by the former is higher than that reported for the latter. These studies 
were conducted using two mice tumour cell lines (PC3 and B16) in vitro, which were exposed to 
X-ray beams in the kVp range. In the second section 5.4, we extend to investigate the 
radiosensitisation efficiency of Bi2S3-NPs in A549 and DU145 cell lines. Radiation dose 
enhancement caused by NPs s when irradiated with kVp and MV range radiotherapy beams was 
measured using two methods for cell survival measurements colourimetric and clonogenic 
assays. The following section 5.5 was aimed to investigate the novel application of pure Bi-NPs 
as radiosensitiser agents in combination with kVp and MV range radiotherapy beams and in the 
two cells lines A549 and DU145. Similarly, two methods were implemented for cell survival 
measurements. This work with previous chapter can support the capability of employing 
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bismuth-based NPs as dual-function agents for cancer; diagnostic agents as well as therapeutic 
agents. Using a single system to enhance the effect of detection as well as boost therapeutic 
efficacy leads to the Promising platform called “theranostics”. Optimisation the diagnostic and 
therapeutic strategies simultaneously can open the possibility of cancer control and raise the 
survival.  
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5.3 Effect of bismuth sulfide compared to gold nanoparticles on PC3 mouse 
prostate and B16 melanoma cancer cells. 
In this section, an X-ray radiotherapy beam in kVp energy range was employed to obtain the 
radiosensitisation caused by both Au- and Bi2S3-NPs in two types of cells, mouse prostate (PC3) 
and breast cancer (B16) cells. The cell survival curves were used to calculate the dose 
enhancement factor (DEF) and the radiobiological parameters. This section also included the 
cytotoxicity level of the NPs in studied cells lines. 
5.3.1  Results 
5.3.1.1 Determination of elemental Bi and Au concentrations  
As mentioned previously in chapter 3 (section 3.2.2.5), the amount of elemental Bi2S3 present 
was determined via TGA to be 20 wt%, with the remainder being the stabilising coating. The 
amount of elemental Bi in the compound Bi2S3 is 81 wt%. Therefore 1 g of Bi2S3 NPs used in 
this study contains 0.16 g of elemental Bi. Au NPs (75 wt% Au) For Au NPs, the amount of 
elemental gold present is 75 wt% (as determined by the supplier).  
5.3.1.2 Bi2S3-NPs localisation in cells 
An investigation of the cellular uptake of Bi2S3-NPs and its localisation inside the cell lines 
(B16-F0 and BAOEC) was performed to determine the distribution of those NPs. After 
incubation with the Bi2S3-NPs for 24 h, it was shown that the NPs were clustered in the 
cytoplasm of the cells. The clusters of NPs are clearly observed in Figures 5-1 and 5-2 which 
shows the NPs have aggregated and are localised in the vesicles (black dote) within the 
cytoplasm. 
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Figure 5-1: (a) B16 cells with no particles and, (b) Bi2S3-NPs are internalised within cells, images taken at 
400 X magnifications. 
  
185 
 
 
 
 
Figure 5-2: BAOEC cells with no particles, and (b) Bi2S3-NPs are internalised within cells, images taken 
at 400 X magnifications.  
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5.3.1.3 Au- and Bi2S3-NPs cytotoxicity  
The effect of Au and Bi2S3-PVP NPs on the viability of PC3 cells was investigated. The main 
purpose of this experiment was to compare the cytotoxic effect of these NPs and to determine the 
maximal concentration of these NPs that was not cytotoxic. In order to quantify the effect of the 
NPs, the cells were exposed to different concentrations of NPs over a 48 h period as seen in 
Figure 5-3 .The absorbance of the cultures treated with different concentrations of NPs were 
expressed as a ratio of that of the untreated controls (0 mM) at the same time point, which were 
given a value of unity [256]. It can be seen that the cytotoxic level started to increase at the 
higher concentration 2 mM for both NPs.  
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Figure 5-3: Cytotoxicity of Au- and (b) Bi2S3-NPs in PC3 cells. The errors are standard deviation from 
three independent experiments (mean ± SD, n=3). The data mean comparisons for different concentration 
are considered to be statistically significant at p values of less than 0.05 (* p < 0.05).  
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5.3.1.4 Dose enhancement 
The dose enhancement factor (DEF) represents the level of dose amplifications and is used to 
quantify the effects of NPs as dose modifiers.The effect of Au-and Bi2S3-NPs on the viability of 
PC3 and B16 cells was investigated after being irradiated with 80 kVp to determine the DEF. 
The effects of different concentrations of Au- and Bi2S3-NPs on the cell survival curves for 
irradiated PC3 and B16 cells are displayed in Figures 5-4 and 5-5. The results demonstrate that 
there is a significant decrease in the cell survival of treated cells with both NPs compared with 
those without particles. The biological effects of Bi2S3-NPs on enhancing dose are slightly higher 
in PC3 cells and similar in B16 cells to Au-NPs. The DEF is determined from the ratio of the 
doses required to decrease cell survival to 80% in the presence or absence of added NPs. The 
DEF for Au- and Bi2S3-NPs in both cell lines were extrapolated from the survival curves 
(Figures 5-4 and 5-5) and the results are displayed in Table 5-1. The DEF was shown to be 
concentration dependent, and was higher in those cells treated with 1 mM NPs compared to those 
treated with 0.5 mM. PC3 cells were more sensitive to dose enhancement than were B16 cells 
under all conditions tested. Following irradiation, the Bi2S3-NPs generated a higher DEF than did 
Au NPs at the same concentration. The results suggest that Bi2S3-NPs would be more beneficial 
as a dose enhancer that Au-NPs, and as it is cheaper to manufacture, it may be a viable 
alternative to use in clinical applications.  
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Figure 5-4: Effect of 80 kVp X-rays on the survival of PC3 cells treated either with (a) Au-NPs or (b) 
Bi2S3-NPs. The errors are standard error of the mean from three independent experiments (mean ± SEM, 
n=3). The difference between the control (without NPs) and experimental group (with NPs) are 
considered to be statistically significant at p values of less than 0.05 (* p < 0.05). Survival data was fitted 
to the linear-quadratic model using regression analysis: log [% survival] = ⍺ *[dose] + β *[dose]2. 
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Figure 5-5: Effect of 80 kVp X-rays on the survival of B16 cells treated either with (a) Au-NPs or (b) 
Bi2S3 NPs. The errors are standard error of the mean from three independent experiments (mean ± SEM, 
n=3). The difference between the control (without NPs) and experimental group (with NPs) are 
considered to be statistically significant at p values of less than 0.05 (* p < 0.05). Survival data was fitted 
to the linear-quadratic model using regression analysis: log [% survival] = ⍺ *[dose] + β *[dose]2. 
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Table 5-1: Comparison of the Au- and Bi2S3-NPs dose enhancement factors at 80% cell survival in PC3 
and B16 cell lines exposed to 80 kVp. N/A = Not Applicable.  
 
Table 5-2: The radiobiological analysis of alpha (α) and beta (β) parameters derived from the linear 
quadratic fits of the survival curves for PC3 and B16 cell lines treated with different concentrations of 
Bi2S3- and Au-NPs and irradiating by 80 kVp. 
Radiation Type of 
cells 
NPs concentration (mM) 
Au Bi2S3 
0.5 1 0.5 1 
80 kVp PC3 1.45 2.65 1.6 3.07 
B16 N/A 2.13 N/A 2.24 
Radiations Type of cells NPs NPs 
concentration 
(mM) 
MTS assay 
α (Gy-1) β (Gy-2) 
80 kVp PC3 Au Control 0.003 0.026 
0.5 0.091 0.016 
1 0.278 0.017 
B16 Control 0. 073 0.001 
0.5 0.232 0.019 
PC3 Bi2S3 Control 0.024 0.029 
0.5 0.123 0.014 
1 0.383 0.031 
B16 Control 0.063 0.003 
0.5 0.227 0.017 
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5.3.2 Discussion  
Both the Au and Bi2S3-NPs are coated in a stabilising layer (also known as passivating layer) that 
prevents the NPs from irreversibly aggregating which allows them to be easily dispersed in 
aqueous solutions. For Au-NPs this stabilising coating is composed of (1-mercaptoundec-11-yl) 
tetraethylene glycol. Whereas for the Bi2S3-NPs a PVP coating was used. The interaction of 
radiation with this organic coating is negligible and can be ignored in dose enhancement 
calculations. However, to directly compare the contribution of elemental Au and Bi it is 
important to consider the weight percentage contribution of the organic coating and any other 
elements in calculations. For Au NPs, the amount of elemental gold present is 75 wt% (as 
determined by the supplier (Aurovist™; Nanoprobes, Inc., Yaphank, NY)), with the remaining 
25 wt% attributed to the organic coating. The amount of elemental bismuth in the Bi2S3-NPs was 
determined to be 16 wt% as given in chapter 3 (section 3.2.2.5). Therefore, when comparing 
these NPs to determine their dose enhancement effects, the actual amount of elemental Au or Bi 
should be compared. For Au- and Bi2S3-NPs, the concentrations of the whole element and 
compound with their coatings should be taken into account with respect to their molarity. 
However, in the perspective of radiation, the significant factor is the percentage of Au and Bi 
atoms.  
In order to compare the dose enhancement effect of Bi2S3-NPs to that of Au-NPs we used 
two tumour cell lines (mouse PC3 prostate and B16 melanoma cells). Both tumour cells were 
chosen because they can form both primary and secondary tumours in vivo, and as such are a 
good model to use for investigation of the dose enhancement effect of these NPs. This study 
indicated that at 0.5 mM both Au- and Bi2S3-NPs elicited a hormetic effect at 12, 24 and 48 h 
(Figure 5-3). While 1 mM Au- NPs also enhanced cell growth over the 48 h period, 1 mM 
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Bi2S3-NPs did not. At 2 mM, Au NPs were shown to elicit a slight cytotoxic effect on these cells 
(15% at 12 h) but by 48 h the cultures appeared to have fully recovered. On the other hand Bi2S3 
only displayed a hormetic effect at 0.5 mM, but at higher concentrations it was shown to be 
cytotoxic. At 2 mM Bi2S3-NPs caused a 20% reduction in the number of cells in culture after 12 
h, which was similar to that seen for Au NPs, but by 48 h these cells had not recovered unlike 
those treated with the gold NPs. 
 This study shows that the incubation of cells with Bi2S3-Nps for about 24 h leads to the 
inclusion of the NPs and is clustered in subcellular compartments in the cells’ cytoplasm and did 
not enter the nucleus (Figures 5-1 and 5-2). This is in agreement with the findings documented 
in other studies [31, 145]. Brown et. al. observed accumulation of Bi2S3-NPs inside mouse 
macrophages (J774A.1) cell line and HeLa cells after 24 h of incubation and the Bi-NPs were 
found to be taken up in endosomal/lysosomal compartments in both cells [145]. Several studies 
also have documented the internalisation of Au-NPs [238, 240, 257-260]. Both typed NPs are 
internalised by cells via endocytosis, and in some cases have been found ‘clustered’ around the 
membrane or in subcellular compartments within the cytoplasm. Therefore, the NPs are expected 
to be internalised and enclosed inside the cells enhancing the radiation effect.  
The survival curve of those cells treated with either typed (Bi or Au) NP is steeper than 
the untreated control and showed that the NPs enhanced the cytotoxic effects of the X-rays 
(Figures 5-4 and 5-5). This shift of the curve to the left is a measure of the dose enhancement 
caused by the inclusion of the NPs into the cells prior to them being exposed to the X-rays. This 
can be attributed to the fact that the inclusion of high electron density and high Z compounds in 
the cells is expected to generate high numbers of free radicals via both photoelectric and 
Compton interactions. These extra free radicals would increase the likelihood of DNA damage 
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and subsequent cell death (this will be further explained in the following section 5.4.2). More 
importantly, the Bi2S3-NPs used in this study only contained 16 wt% Bi (from Bi2S3), which 
generated a similar dose enhancement effect to that of Au NPs (75 wt% Au) in B16 cells. A 
significant finding is that Bi2S3-NPs generated a greater dose enhancement effect to that of Au 
NPs in irradiated PC3 cells. The results suggest that Bi2S3-NPs represent a cheaper viable 
alternative to the use of Au-NPs as effective dose enhancing agents when used in clinical 
applications. 
5.3.3 Conclusion  
This section provides the first experimental evidence of the efficacy of bismuth-based NPs as 
radiation dose enhancement agents in cells. It also demonstrates the first direct comparison of the 
level of radiation dose enhancement inflicted by Bi2S3- and Au-NPs. The results from this study 
suggest that Bi2S3-NPs containing ~16 wt% elemental Bi have a similar, or even slightly higher 
radiological effect, to that of Au NPs which are comprised of 75 wt% elemental Au at the same 
concentration when taking into account their surface coatings. Bi2S3-NPs have been shown to be 
suitable contrast agents for radiologic imaging and this work proves their value in radio-
sensitisation, in particular, dose enhancement at the kVp range of X-ray energies. Therefore, they 
can be considered as valuable theranostic agents that can improve image quality and at the same 
time enhance the effects of radiation on the target tissue. Another advantage of Bi2S3-NPs as 
theranostic agents is their proven long blood circulation, rendering them suitable agents for 
lengthy therapeutic and diagnostic radiation-based procedures. It should be noted that Au-NPs 
are extensively investigated as a radiosensitisers while this research represents pioneer work on 
Bi compound NPs (Bi2S3).   
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5.4 Effect of bismuth sulfide and bismuth nanoparticles on A549 human lung 
and DU145 prostate cancer cells  
In this section, X-ray radiotherapy beams in the kVp and MV energy ranges were employed to 
obtain the radiosensitisation caused by Bi2S3- and Bi-NPs in two types of cells, lung 
adenocarcinoma epithelial (A549) and prostate carcinoma (DU145). In this study, the toxicity 
induced by NPs in studied cell lines was obtained by measuring cell viability using two cell-
based assays; the colourimetric (MTS) and clonogenic. In addition, the cell survival curves were 
used to analyse the radiosensitisation effects by calculating the dose enhancement factor (DEF) 
and radiobiological parameters such as α and β values. 
5.4.1 Results  
5.4.1.1 Determination of elemental Bi concentrations in Bi2S3 and Bi-NPs 
As mentioned previously in chapter 3 (sections 3.2.2.5 and 3.3.2.5), the amount of elemental Bi 
in Bi2S3 is determined to be ~16 wt%, and in Bi-NPs is 65 wt%, with the remainder being the 
contribution of surface coating. 
5.4.1.2 The cytotoxicity of Bi2S3-NPs 
The cytotoxic effect of Bi2S3-NPs on the viability of A549 and DU145 cells is investigated. The 
cell viability was measured using two methods; colourimetric and clonogenic assays as displayed 
in Figures 5-6 and 5-7. In the MTS assay, cytotoxicity was determined by comparing the light 
absorbance of the cultures treated with different concentrations of NPs as explained in chapter 2, 
section 2.5.4.1. These measurements were expressed as a ratio to that of the untreated controls, 
which were given a value of 100%. It can be seen that cell viability starts to decrease following 
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exposure to 1 mM Bi2S3-NPs in both cell lines (Figures 5-6a and 5-7a). However, it is observed 
that Bi2S3-NPs becomes slightly cytotoxic at concentrations of 6.5 mM (4 mg/mL) or greater in 
both cell lines. When the A549 and DU145 cells were treated with Bi2S3-NPs at 1.6 mM (0.82 
mg/mL), the cell viability is observed to be approximately ~82% and ~77%, respectively. The 
cell viability decreased to ~81% in A549 and ~69% in DU145 cells when the concentration of 
the NPs was 3.25 mM (1.7 mg/mL). 
The cytotoxic effect of the NPs on the long-term cell viability for both cell lines was also 
measured by a clonogenic assay (method was explained in chapter 2, section 2.5.4.2). The results 
of the cells viability measured for different concentrations of NPs are seen in Figures 5-6b and 
5-7b. The clonogenic assays showed there was no statistically significant difference in colony 
numbers when the cells were treated with NPs of 0.5 mM but the numbers decreased at 
concentrations > 1 mM. The results of the clonogenic assay were similar to those obtained via 
measurement at concentrations from 0.125 to 1 mM. The A549 cell lines were less sensitive to 
the NPs compared to the DU145 cell lines. When cells were treated with the 1 mM NPs, the 
percentage of colonies formed in A549 cells was ~86% while for DU145 cells it was ~76%. In 
the clonogenic assay the average plating efficiencies for the A549 and DU145 cells were 35% 
and 25%, respectively.  
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Figure 5-6: Cytotoxicity of Bi2S3-NPs in A549 cells using (a) colourimetric assay (MTS), and (b) 
clonogenic assay. The errors are standard error of the mean from three independent experiments (mean ± 
SEM, n=3). The data mean comparisons for different concentration are considered to be statistically 
significant at p values of less than 0.05 (* p < 0.05). 
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 Figure 5-7: Cytotoxicity of Bi2S3-NPs in DU145 cells using (a) colourimetric assay (MTS), and (b) 
clonogenic assay. The errors are the standard error of the mean from three independent experiments 
(mean ± SEM, n=3). The data mean comparisons for different concentration are considered to be 
statistically significant at p values of less than 0.05 (* p < 0.05).  
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5.4.1.3 The cytotoxicity of Bi-NPs 
The effects of Bi-NPs on cell viability in the DU145 and A549 cell lines are seen in Figures 5-8 
and 5-9. The effect of 48 h exposure to different concentrations of NPs on cell viability as 
measured by MTS can be seen in Figures 5-8a and 5-8a.  Untreated control cells were given a 
value of 100%. A significant decrease in the number of viable cells (~20%) was observed when 
cells were treated with the Bi-NPs at 0.5 mM. Above 0.5 mM, the NPs produced a pronounced 
cytotoxic effect. At 1 mM (208 µg/ml), the viability of A549 and DU145cells was ~68% and 
~73%, respectfully. 
The effect of the NPs on cell viability was also determined using a clonogenic assay in 
both cell lines as seen in Figures 5-8b and 5-9b. The results from the clonogenic assays were 
similar to those obtained by colourimetric assay. There is a significant reduction in colony 
numbers when cells are treated with at least 0.5 mM Bi-NPs. At 1 mM colony formation in the 
A549 cells was ~62% and in the DU145 cells was ~56%. In the clonogenic assay, the average 
plating efficiencies for the A549 and DU145 cells were 35% and 25%, respectively. This study 
clearly indicates that 0.5 mM and lower concentrations are suitable for biological applications of 
Bi-NPs.  
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Figure 5-8: Cytotoxicity of Bi-NPs in A549 cells using (a) colourimetric assay (MTS), and (b) similar 
conditions using clonogenic assay. The errors are the standard error of the mean from three independent 
experiments (mean ± SEM, n=3). The data mean comparisons for different concentration are considered 
to be statistically significant at p values of less than 0.05 (* p < 0.05). 
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Figure 5-9: Cytotoxicity of Bi-NPs in DU145 cells using (a) colourimetric assay (MTS), and (b) similar 
conditions using clonogenic assay. The errors are the standard error of the mean from three independent 
experiments (mean ± SEM, n=3). The data mean comparisons for different concentration are considered 
to be statistically significant at p values of less than 0.05 (* p < 0.05). 
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5.4.1.4 Dose enhancement by Bi2S3-NPs 
This section presents the level of dose enhancement induced by Bi2S3-NPs using X-ray 
radiotherapy beams with energies in kVp and MV. 
5.4.1.4.1 Kilovoltage superficial X-ray radiotherapy 
The DEF is obtained from the cell survival curve and it is the ratio of the X-ray dose given to the 
untreated cell culture that produces 80% survival divided by the dose given to the same cells 
treated with NPs that produces 80% survival. The results of such DEFs with various beams are 
listed in the next section (see section 5.4.1.6). The dose enhancement effects of Bi2S3-NPs on the 
viability of A549 and DU145 cells were measured after they were irradiated with superficial X-
ray beams of 150 kVp X-rays. This was performed in order to estimate the DEF of the NPs at 
different concentrations. Survival curves for the exposed cells to different radiation doses can be 
seen in Figures 5-10 and 5-11. The survival curve of the irradiated cells incubated with NPs is 
steeper than that of the irradiated cells above. The results show that the cytotoxic effects of the 
X-rays are enhanced by the inclusion of the Bi2S3-NPs into the cells. At 80% cell survival in the 
colourmetric (MTS) assay (Figures 5-10a and 5-11a), 0.5 mM NPs caused ~24% 
radiosensitivity enhancement (DEF = 1.24) to the exposed A549 cells. The results indicate that 
the DEF increases with increasing concentrations of NPs; at 1 mM the NPs cause an average 
DEF of 1.41 (~41%). A similar result was observed in the DU145 cells that were irradiated with 
150 kVp; the 0.5 mM NPs dose enhancement was 1.38 (~38%) and DEF of 1 mM was 1.63 
(~63%).  
Similar results were observed in the clonogenic assays where NPs at 0.25 and 0.5 mM 
caused about 11% and 45% increased cell death in the A549 cells, respectfully. In the DU145 
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cells, the DEFs at the same concentrations (0.25 and 0.5 mM) were 1.19 (~19%) and 1.54 
(~54%), respectively. Therefore, the addition of NPs significantly decreased the survival of both 
irradiated cell lines. The toxic effect of Bi2S3 on enhancing the X-ray dose is slightly higher in 
DU145 cells. The values for the clonogenic assays were slightly higher than that calculated from 
the colourimetric assays in both cell lines. 
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Figure 5-10: Effect of 150 kVp X-rays on the survival of A549 cells treated with Bi2S3-NPs at different 
concentration using the (a) MTS assay, and the (b) clonogenic assay. The errors are the standard error of 
the mean from three independent experiments (mean ± SEM, n=3). The difference between the control 
(without NPs) and experimental group (with NPs) are considered to be statistically significant at p values 
of less than 0.05 (* p < 0.05). Survival data was fitted to the linear-quadratic model using regression 
analysis: log [% survival] = ⍺ *[dose] + β *[dose]2.  
  
205 
 
0 2 4 6
0 .5
1 .0
D o s e  ( G y )
S
u
r
v
iv
a
l 
f
r
a
c
t
io
n
0 .0 0  m M
0 .5 0  m M
1 .0 0  m M
E  =  1 5 0  k V p
(a)
0 2 4 6
0 .5
1 .0
D o s e  ( G y )
S
u
r
v
iv
a
l 
f
r
a
c
t
io
n
0 .0 0  m M
0 .5 0  m M
0 .2 5  m M
E  =  1 5 0  k V p
(b )
 
 
Figure 5-11: Effect of 150 kV X-rays on the survival of DU145 cells treated with Bi2S3-NPs at different 
concentration using (a) MTS assay, and (b) clonogenic assay. The errors are the standard error of the 
mean from three independent experiments (mean ± SEM, n=3). The difference between the control 
(without NPs) and experimental group (with NPs) are considered to be statistically significant at p values 
of less than 0.05 (* p < 0.05). Survival data was fitted to the linear-quadratic model using regression 
analysis: log [% survival] = ⍺ *[dose] + β *[dose]2.  
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5.4.1.4.2  Megavoltage X-rays radiotherapy 
The biological effect of Bi2S3-NPs on enhancing the dose for the MV beam using A549 and 
DU145 cell lines are seen in Figures 5-12 and 5-13. The calculation method for the DEF is 
similar that used for kVp X-rays. DEF results from the MV beam were extrapolated at 80% cell 
survival. The irradiated cells, at different radiation doses, are made slightly more sensitive to 
radiation than control cells by incubating the cells with Bi2S3-NPs. In the MTS assay, 0.25 and 
0.5 mM Bi2S3-NPs caused a 1.09 (~9%) and 1.15 (~15%) increase in A549 cell deaths, 
respectfully (Figures 5-12a and 5-13a). The DEFs in DU145 cells were 1.07 (~7%) and 1.14 
(~14%) for the same NP concentration, respectfully.  
Similar results are obtained in clonogenic based study assays as shown in Figures 5-12b 
and 5-13b. At 80% cell survival, the NPs dose enhancement at 0.5 mM for A549 and DU145 
cells was 1.19 (~19%) and 1.17 (~17%), respectively. Therefore, the addition of NPs to both cell 
lines generated similar dose enhancement effect, and decreased the survival of these irradiated 
cells. It is noticed that the biological effect on the both types of cells by Bi2S3-NPs utilising 
external MV X-ray beam are significantly lower than those obtained in kVp X-ray beam as 
presented in section 5.4.1.4.1.  
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Figure 5-12: Effect of 6 MV X-rays on the survival of A549 cells treated with Bi2S3-NPs at different 
concentration using (a) MTS assay, and (b) clonogenic assay. The errors are the standard error of the 
mean from three independent experiments (mean ± SEM, n=3). The difference between the control 
(without NPs) and experimental group (with NPs) are considered to be statistically significant at p values 
of less than 0.05 (* p < 0.05). Survival data was fitted to the linear-quadratic model using regression 
analysis: log [% survival] = ⍺ *[dose] + β *[dose]2. 
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Figure 5-13: Effect of 6 MV X-rays on the survival of DU145 cells treated with Bi2S3-NPs at different 
concentration using (a) MTS assay, and (b) clonogenic assay. The errors are the standard error of the 
mean from three independent experiments (mean ± SEM, n=3). The difference between the control 
(without NPs) and experimental group (with NPs) are considered to be statistically significant at p values 
of less than 0.05 (* p < 0.05). Survival data was fitted to the linear-quadratic model using regression 
analysis: log [% survival] = ⍺ *[dose] + β *[dose]2.  
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5.4.1.5 Dose enhancement by Bi-NPs 
In this section, X-ray radiotherapy energy beams ranging from kVp to MV were employed to 
obtain the radiosensitisation caused by Bi-NPs in the same type of cells. 
5.4.1.5.1  Kilovoltage superficial X-rays radiotherapy 
Figures 5-14 and 5-15 show the survival curves for exposed cells with different radiation doses 
of 150 kVp X-rays. The enhancement of radiation effects of the Bi-NPs was studied on the 
viability of A549 and DU145 cells after irradiation by 150 kVp X-rays using two different 
methods (MTS and clonogenic assays) as seen in Figures 5-14 and 5-15. At 80% cell survival in 
the MTS assay (Figures 5-14a and 5-15a), 0. 125 mM NPs caused a ~1.69 (~69%) and 1.30 
(~30%) increase in cell deaths to the A549 and DU145 cells exposed to 150 kVp X-ray, 
respectively. The results indicate that at 0.25 mM of the NPs, the DEF increases and causes an 
average DEF of 2.29 (229%) and 1.56 (~65%). to the A549 and DU145 cells exposed to 150 
kVp X-rays, respectively. 
Enhancement effects were also assessed using a clonogenic assay as seen in Figures 5-
14b and 5-15b). The NPs at 0.125 mM caused 1.81 (~81%) and 1.41 (~41%) %) increase in cell 
deaths to the exposed A549 and DU145 cells, respectfully. The DEF value at 0.25 NPs was 2.50 
(~250%) in the A549 cells and it was 1.91 (~91%) in the DU145 cells, when these cells exposed 
with 150 kVp X-rays. Our results indicate that A549 cells are more susceptible to cytotoxicity of 
Bi-NPs in combination with kVp beams than DU145 cells. It was also observed that the DEFs 
measurements in clonogenic assays are slightly higher than that obtained by MTS assays. 
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Figure 5-14: Effect of 150 kVp X-rays on the survival of A549 cells treated with Bi-NPs at different 
concentration using (a) MTS assay, and (b) clonogenic assay. The errors are the standard error of the 
mean from three independent experiments (mean ± SEM, n=3). The difference between the control 
(without NPs) and experimental group (with NPs) are considered to be statistically significant at p values 
of less than 0.05 (* p < 0.05). Survival data was fitted to the linear-quadratic model using regression 
analysis: log [% survival] = ⍺ *[dose] + β *[dose]2. 
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Figure 5-15: Effect of 150 kVp X-rays on the survival of DU145 cells treated with Bi-NPs at different 
concentration using (a) MTS assay, and (b) clonogenic assay. The errors are the standard error of the 
mean from three independent experiments (mean ± SEM, n=3). The difference between the control 
(without NPs) and experimental group (with NPs) are considered to be statistically significant at p values 
of less than 0.05 (* p < 0.05). Survival data was fitted to the linear-quadratic model using regression 
analysis: log [% survival] = ⍺ *[dose] + β *[dose]2.  
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5.4.1.5.2  Megavoltage X-rays radiotherapy 
The potential increase of cellular damage induced by NPs with MV X-rays beam irradiation can 
be calculated from the cell survival curves shown in Figures 5-16a-b and 5-17a-b. Similar to 
that seen for the kVp X-rays, the radiosensitivity of NPs with 6 MV X-ray beam were obtained 
by measuring the DEF. At 80% cell survival, 0.25 mM of NPs caused 1.26 (~26%) and 1.23 
(~23%) increase in cell deaths to A549 and DU145 exposed cells, respectively, as measured by 
the MTS assays. 
In the clonogenic assays, the DEF measurements were 1.39 (~39%) and 1.28 (~28%) in 
the A549 and DU145 cells, respectively. In both cell lines the survival curve of the irradiated 
cells after incubation with NPs is steeper than that seen in irradiated cells alone. Therefore, the 
results show that the cytotoxic effects of the X-rays on the cells can be enhanced by the inclusion 
of Bi-NPs. The DEFs obtained for MV X-rays beams are useful but lower than those obtained 
from kVp X-ray beams (section 5.4.1.5.1). The results also indicate that the A549 cells ha greater 
enhancement effect than the DU145 cells when treated with Bi-NPs.  
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Figure 5-16: Effect of 6 MV X-rays on the survival of A549 cells treated with Bi-NPs at different 
concentration using (a) MTS assay, and (b) clonogenic assay. The errors are the standard error of the 
mean from three independent experiments (mean ± SEM, n=3). The difference between the control 
(without NPs) and experimental group (with NPs) are considered to be statistically significant at p values 
of less than 0.05 (* p < 0.05). Survival data was fitted to the linear-quadric model using regression 
analysis: log [% survival] = ⍺ *[dose] + β *[dose]2. 
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Figure 5-17: Effect of 6 MV X-rays on the survival of DU145 cells treated with Bi-NPs at different 
concentration using (a) MTS assay, and (b) clonogenic assay. The errors are the standard error of the 
mean from three independent experiments (mean ± SEM, n=3). The difference between the control 
(without NPs) and experimental group (with NPs) are considered to be statistically significant at p values 
of less than 0.05 (* p < 0.05).  Survival data was fitted to the linear-quadric model using regression 
analysis: log [% survival] = ⍺ *[dose] + β *[dose]2. 
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5.4.1.6 The radiobiological analysis of dose enhancement 
The cell survival curves observed in Figures 5-10 to 5-17 in sections 5.4.1.4 and 5.4.1.5 shows 
that there are fewer cells surviving irradiation with Bi2S3-NPs and Bi-NPs compared to the 
control cells (where the cells were irradiated without the addition of NPs). These results indicate 
that the cell survival curve is influenced by the presence of NPs. As it is already been outlined in 
the introduction section 1.4.4, the shape of the cell survival curve can be quantitatively explained 
using a radiobiological model such as the linear quadratic model. In this model, there are two 
main components that can induce the cell inactivation by a free radical, one of which is 
proportional to the dose as a result of a single ionising hit, and the second is proportional to the 
square root of the dose resulting from two separate ionising events. The linear part is described 
by alpha (α) while the quadratic part by beta (β) (see section 1.4.4 for further information). The 
cell survival curves in sections 5.4.1.4 and 5.4.1.5 were fitted with linear quadratic model by 
plotting the data on a log (% survival) vs nominal dose (nominal dose refers to the standard dose 
that has been measured by the calibrated ionisation chamber). Tabulated α and β values as 
radiobiological parameters are shown in Table 5-3. It was observed that both NPs produced a 
larger increase to the linear parameter α, than they do to quadratic parameter β. For example, in 
the A549 cell clonogenic assays with 150 kVp radiation, the value of α for the untreated curve is 
0.077. This changed with the inclusion of Bi2S3-NPs (0.25 mM) to 0.117. For Bi-NPs at the same 
concentration, the α value increased to 0.347. The survival curves show a higher increase in α 
value with Bi-NPs compared to Bi2S3-NPs (Table 5-3). Also it is noticeable that α increases with 
the increasing concentration of NPs, but the β value does not appear to change as a result of the 
inclusion of NPs. 
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Table 5-3: Comparison of the Bi2S3- and Bi -NPs dose enhancement factors at 80% cell survival in A549 and DU145 cell lines exposed to 150 
kVp and 6 MV. N/A = Not Applicable. 
Radations Type of cells Bi2S3-NPs (mM) Bi-NPs (mM) 
MTS assay Clongeinc assay MTS assay Clonogenic assay  
0.25 0.5 1 0.25 0.5 1 0.25 0. 125 0.25 0.125 
150 kVp A549 N/A 1.24 1.41 1.11 1.45 N/A 2.29 1.69 2.50 1.81 
DU145 N/A  1.38 1.63 1.19 1.54 N/A 1.56 1.30 1.91 1.41 
6 MV A549 1.09 1.15 N/A 1.10 1.19 N/A 1. 26 N/A 1.39 N/A 
DU145 1.07 1.14 N/A 1.12 1.17 N/A 1.23 N/A 1.28 N/A 
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Table 5-4: The radiobiological analysis of alpha (α) and beta (β) parameters derived from the linear quadratic fits of the survival curves for A549 
and DU145 cells treated with different concentarions of Bi2S3- and Bi-NPs and irradiating by 150 kVp and 6 MV. N/A = Not Applicable. 
 
Radiations Type of cells NPs NPs 
concentration 
(mM) 
MTS assay Clonogenic assay 
α (Gy-1) β (Gy-2) α (Gy-1) β (Gy-2) 
150 kVp A549 Bi2S3 
Control 0.040 0.005 0.077 0.008 
0.25 N/A N/A 0.117 0.002 
0.5 0.11 0.006 0.203 0.012 
1 0.143 0.01 N/A N/A 
DU145 
Control 0.087 0.004 0.095 0.004 
0.25 N/A N/A 0.164 0.008 
0.5 0.199 0.015 0.252 0.024 
1 0.249 0.023 N/A N/A 
A549 Bi 
Control 0.012 0.010 0.077 0.008 
0.125 0.09 0.009 0.268 0.021 
0. 25 0.120 0.009 0.347 0.035 
DU145 
Control 0.087 0.004 0.095 0.004 
0.125 0.186 0.012 0.233 0.018 
0. 25 0.246 0.020 0.331 0.025 
6 MV A549 Bi2S3 
Control 0.084 0.002 0.060 0.008 
0.25 0.112 0.002 0.120 0.001 
0.50 0.127 0.003 0.121 0.002 
DU145 
Control 0.116 0.005 0.181 0.009 
0.25 0.126 0.006 0.245 0.019 
0.50 0.167 0.012 0.284 0.027 
A549 Bi 
Control 0.084 0.002 0.060 0.008 
0.25 0.179 0.013 0.160 0.006 
DU145 
Control 0.117 0.006 0.181 0.009 
0.25 0.212 0.02 0.281 0.025 
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5.4.2 Discussion  
The cytotoxicity tests conducted in this study show that the influence of Bi2S3- and Bi-NPs on 
the survival of A549 and DU145 cells is different. From analysis of Bi2S3-NPs data we can 
conclude that there is no significant toxicity effect on the studied cells up to 1 mM. When the 
cells are treated with higher NPs concentrations (1.6 mM), cell viability only fell to ~80% in 
A549 cell lines, which was similar to that seen in PC3 cell lines in section 5.3 [175], HeLa cells 
[31] and RAW264.7 mouse monocyte/macrophage cell lines [261]. At the same concentration in 
DU145 cells, the Bi2S3-NPs reduced the cell viability by ~30%. Therefore, these NPs have a 
higher cytotoxic effect in DU145 cells than A549 cells.  
In contrast, our study indicated that the 1 mM of Bi- NPs caused ~30% reduction in cell 
viability. In comparison with previous studies, Bi-NPs in 22 nm size have been synthesised using 
dodecanethiol ligand and further modified with oligosaccharide. In one such study, cytotoxicity 
analysis of 208 µg/ml Bi-NPs concluded that no significant cytotoxicity effects were observed in 
HeLa cells [144]. Another study conducted a comparative dose-response cytotoxicity between 
Bi-NH (amine modified NPs), Bi@SiO2 (silica modified NPs) and Bi–PEG (PEG modified NPs) 
on HeLa and MG-63 (Human osteosarcoma cell). The study showed the cell viability for the 
above cells when they treated with Bi-NPs was higher than 80% for the highest concentration of 
50 nM (very low concentration) for all NPs [262]. Lesser toxicity levels were found with our 
starch modified NPs when the cytotoxic profile is compared with previous results. Luo et. al also 
reported that the toxicity of bismuth NPs is higher than those reported for bismuth compounds at 
the same molar concentration [262]. This is in agreement with the studies performed using Bi-
NPs, Bi2S3 and BiOI-NPs as discussed in in chapter 4.  
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Results presented in sections 5.4.1.4 and 5.4.1.5 highlight that the radiation effects on the 
cells can be effectively enhanced by the inclusion of Bi2S3-NPs or Bi-NPs (Figures 5-10 to 5-
17). On comparing these survival curves, the level of radiation effects can be analysed and the 
dose enhancement that is caused by the inclusion of NPs can be explained. The ratio of the NPs-
treated irradiated cells that survived compared to that of irradiated cells alone enable us to 
establish the enhancement effects with the cell survival fraction considered to be 80%. This ratio 
was identified in section 5.3 as the DEF. The results indicate that the dose enhancement is most 
effective when the energy of the X-ray beams is in the kVp range, as depicted in Figures 5-10 
and 5-11 for Bi2S3-NPs, and Figures 5-14 and 5-15 for Bi-NPs. This enhancement is dependent 
on the concentration of the NPs. For a 150 kVp X-ray beam the maximum value of DEF 
obtained from 0.25 mM Bi-NPs is 2.29 (~129% radiosensitivity enhancement) for A549 cells 
and 1.56 (~56%) for DU145 cells. When these results are compared to the DEFs for Bi2S3-NPs, 
they were higher in A549 cells and similar in DU145 cells in than the values of DEF obtained at 
higher concentrations (1mM), which was 1.41 (~41) for A549 cells and 1.63 (~63 %) for DU145 
cells. These results are reduced when the NP concentration decreased: for Bi-NPs the DEF 
reduced to 1.69 (~69 %) in A549 cells and 1.30 (~30%) in DU145 cells, while for Bi2S3-NPs the 
value of the DEF reduced to 1.24 (~24 %) in A549 cells and 1.38 (~38%) in DU145 cells (see 
Table 5-3). 
A lower radiation dose enhancement was found when the energy of the beam is in the 
MV range. This is depicted in Figures 5-12 and 5-13 for Bi2S3-NPs, and Figures 5-16 and 5-17 
for Bi-NPs. Calculated DEFs of 1.26 (~26%) and 1.23 (~23%) were obtained for 0.25 mM of Bi-
NPs in A549 and DU145 cells, respectively, exposed to 6 MV X-ray beams. At the same 
concentration, the DEF values for Bi2S3-NPs were 1.09 (~9%) and 1.07 (~7%) in A549 and 
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DU145 cells, respectfully. Bi-NPs demonstrate a higher radiation dose enhancement when 
compared to Bi2S3-NPs. Similar results were obtained using clonogenic-based assays (see Table 
5-3). However, when compared to the MTS, the clonogenic assays generated higher DEF values, 
which could be attributed to the longer period of time involved in obtaining the results and hence 
be due to the affected cells dying in this period. These results show that the greater the number of 
NPs absorbed in the cells, the higher the probability of radiation interactions occurring in these 
cells. The observed difference in the dose enhancement between the kVp and MV energies 
supports the fact that dose enhancement is primarily caused by photoelectrons generated by 
photoelectric interaction (PEs). The probability for this interaction (PEs) is inversely 
proportional to the cube of the photon energy (E
3
). Hence it is expected that such interactions 
will be reduced at higher energies. The interaction of higher energy X-rays is dominated by 
Compton scattering (CS) which is involved with the outer shell electrons of the atom and results 
in a recoil electron and a lower energy photon, and this is influenced only by ρm and ρe. However, 
this explanation is based only on the physical effects; for a full discussion, other parameters must 
be taken into consideration such as biological and biochemical ones. These results are consistent 
with those reported in the literature for Au-NPs [240]. It should be noted here that for tissue 
exposed to photon energies > 100 kVp the dominant process of interaction is Compton 
scattering, while for high Z atoms such Bi at the kVp range of energies the dominant process of 
interaction is PE and at MV energies the Compton process dominates. 
Dose enhancement by inclusion of high Z elements in radiotherapy targets can be 
attributed to various reasons. The one most commonly addressed in the literature for similar 
metal based NPs such as gold is the physical effect (generation of copious free radicals) [250, 
263-266], since the free radicals yielded inside the NPs as a result of exposure to X-rays, deposit 
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most of their energy in the immediate vicinity of these NPs. These free radicals produce hot dose 
points that can trigger molecular cell death. However, this physical effect is dependent on the 
irradiation energy [159, 267-269]. This effect was always found to be more effective in the kVp 
energy range when compared to MV energies [270-272]. Yao et al. reported that metallic NPs 
can increase DNA damage by inducing its chemical radio-sensitivity [37]. Hence, the influence 
of NPs in dose enhancement (amplification) is believed to be caused by free radicals augmented 
by biochemical processes (Figure 5-18). Moreover, it is also expected that exposure of NPs to 
ionising radiation generates reactive oxygen species which if found close to the DNA or any 
important structure in the cell could lead to it’s damage and hence cell death. 
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Figure 5-18: Schematic representation of the realted interaction of X-rays with high-Z material NPs in 
cells (adapted from [273]). 
 
In order to compare the levels of dose enhancement inflicted by Bi-NPs to those by 
Bi2S3-NPs, the presence of the metallic high Z should be taken into account. In the case of Bi-
NPs compared to Bi2S3-NPs at the same concentration, there are more high Z (Bi) atoms in the 
former compared to the later. It is also important to consider the weight percentage of Bi2S3- and 
Bi-NPs compared to the organic coating. As previously mentioned (sections 3.2.2.5 and 3.3.2.5) 
the amount of elemental bismuth in Bi2S3 is 16 wt% elemental Bi, while in Bi-NPs it is 65 wt%. 
It should be taken into consideration that the concentration of the whole element and compound 
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with their coatings are with respect to their molarity. The actual amount of elemental Bi in these 
NPs should be considered when explaining the dose enhancement results. The higher amount of 
elemental Bi increases the probability of generating free radicals. Due to the increase in the 
number of released free radicals inside the cell, this could cause more efficient cell death. The 
free radicals that are directly generated can result from both photoelectric and Compton 
interactions and damage the DNA molecules inside the cell (biochemical effect) (see section 
5.3.1 for future explanation). The effects observed are in line with the in vitro studies 
documented earlier that used iodine compounds [21] and gold NPs [240, 243] as radiation 
sensitisers. However, since the Bi has a higher absorption coefficient, the dose enhancement is 
higher for Bi2S3 and Bi-NPs than both Au and iodine (at 100 keV: Bi: 5.74, Au: 5.16, I: 1.94 cm
2 
g
-1
). Additionally, the Z is higher for Bi (83) than for Au (79) and I (53). However, Bi is less 
dense than gold, which affects the interaction probabilities. This is compensated for by its higher 
Z and the higher density of free electrons that can be produced. Such electrons are crucial for 
enhancing the probability of Compton interaction which is the dominant interaction with higher 
energy beams. In section 5.3 we showed that Bi2S3-NPs generated a greater dose enhancement 
effect to that of Au-NPs in irradiated PC3 and B16 cells [175]. The dominant interaction for X-
rays when 150 kVp beams interact with NPs is the photoelectric effect. When the Bi-NPs and 
Bi2S3-NPs are internalised in the cells, the dose enhancement is observed, thereby indicating an 
increase in the photoelectric interactions.  
Based on the theoretical calculations of the DEF for Bi which was explained in chapter 1 
(see section 1.5.3.2), the total scattering cross section is expected to increase by a factor of 2.9 at 
5% Bi-NPs (5 mg/mL) in water. The DEF that was obtained experimentaly in this work by Bi-
NPs of 0.25 mM (52 µg/mL) was 2.50 in the case of kVp X-rays. This suggests that all 
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enhancements cannot be attributed to the increase in the number of interactions leading to the 
generation of secondary electrons (i.e. physical effect). Therefore, the radiosensitising effects of 
Bi and its compound NPs observed in the present study with high energy X-rays could also be 
involved similarly to the biochemical effects that make cells more sensitive to radiation. 
From the cell survival curves, the values of α and β were calculated on the basis of the 
linear quadratic relationship and are tabulated in Table 5-3. This relationship between cell 
viability and the delivered dose indicates an increase in the alpha value due to the inclusion of 
NPs but almost no observable change in the Beta value was observed. This may be related to the 
double streak strand which occurs when NPs are included in the cells. 
The importance of this study is that the inclusion of the high Z material Bi and its 
compound such as Bi2S3 in the cancer cells in combination with kVp or MV X-ray radiation can 
increase the radiosensitivity of the cells. Currently dose enhancments (radiosensitisation caused 
by Bi compound NPs reported in the literature are based only on Bi2O3-NPs. They are slightly 
easy to synthesise but they are not as effective as pure Bi NPs which have a higher Bi density. 
However, the later are challenging to synthesis. This study presents the novel application of high 
Z bismuth NPs (80% Bi) as radiosensitisers in comparison to compound Bi2S3-NPs for cancer 
therapy. 
The enhancement of radiation effects using Bi-based NPs has potential application in the 
field of radiotherapy. This is adequate for treatments that use X- rays of low or high energy but 
particularly useful for the lower energy beams. This means that it could find application in kVp-
based radiotherapy, or Brachytherapy. To some extent MV-based beams could also be used, 
particularly for the flattening filtered beams (which are becoming common) as they contain 
higher proportions of the low energy X-rays. Such dose reduction can have advantages for the 
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patients since it minimises the effect on healthy tissue during the treatment and so the patient can 
tolerate higher doses to the tumour. 
5.4.3 Conclusion  
These results clearly show that Bi and its compound Bi2S3-NPs can significantly radio-sensitise 
cells in culture displaying dose enhancement with kVp X-ray energies and to a lesser degree for 
MV energies. This study provides the first evidence of the efficacy of Bi nanoparticles as 
radiation dose enhancement agents. In particular, when delivered into cancerous cells, Bi-NPs 
are more efficient radiosensitisers compared to its compound due to the higher amount of 
elemental Bismuth present in Bi-NPs compared to Bi2S3-NPs. The results from this study suggest 
that Bi-NPs containing ~65 wt% elemental Bi have a higher radiological effect, to that of its 
compound Bi2S3-NPs. The radiosensitisation caused by the NPs can be attributed to three 
mechanisms which increase the efficiency of cell death in the low energy X-rays range. In this 
range (150 kVp) the most important factors influencing the higher sensitisation are the 
photoelectric effect enhancement (physical mechanism), radiocatalytic activity (chemical 
mechanism) as well as biological interactions. Such interaction is less with higher energy 
photons due to the reduction in the photoelectric effect and, in this case, the radiosensitisation 
most likely results from the Compton scattering effect and generation ROS. It was found that the 
linear parameter α value increases with the inclusion of NPs while the quadratic part of the curve 
or β value undergoes very small changes that do not show any predictable trend. The results 
suggest that Bismuth-based NPs can be considered as valuable dose enhancing agents when used 
in clinical applications.  
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Chapter 6 
 6 Final Remarks and Future Directions 
6.1 Final remarks 
This thesis comprises original work based on innovative techniques and methods of 
implementing nanotechnology in the field of medical imaging and radiotherapy. It investigates 
bismuth-based NPs to establish their suitability for use as novel tools for diagnostic agents and 
therapeutic agents for cancer. Beginning with an examination of the development and 
modification of NPs, the thesis discusses several characteristics of NPs which makes them 
outstanding candidates for enhancing existing processes and technologies in radiobiology. This 
includes the analysis of the effects of NPs on CT image contrast, by way of phantom studies, as 
well as on radiation dose enhancement, analysed using cell studies while simultaneously 
considering biocompatibility. This study investigates the influence of NPs on the biological 
effect of X-rays on the cancer cells PC3, B16, A549 and DU145. The major findings of the thesis 
in its two main objectives are: 
 For Diagnostics: 
 Over the range of clinically relevant energies (80 -150 kVp), X-ray attenuation is caused 
by the combination of PEs and CS. These two mechanisms are both energy and material-
dependent. For high Z material such as Bi compounds, X-ray attenuation is caused by the 
combination of the PEs and CS and exhibits the maximum effect within the higher 
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photon energy range. However, the interaction of X-rays with tissue and water, as well as 
the iodinated contrast agent, is dominated by CS. The attenuation of X-rays by iodine 
contrast agents resulting from the photoelectric effect is only pronounced within the low 
photon energy range (80 kVp).  
 Using the biocompatible Bi2S3-NPs as contrast agents for conventional CT can provide 
higher contrast efficacy than a clinical iodinate agent at the clinical tube potentials of 80 
to 140 kVp. At low tube potential, Bi-NPs can enhance the subject contrast to 
approximately one to two times that of iodine. At higher tube potential, Bi-NPs provide 
contrast enhancement approximately four times greater than iodine.  
 Using the biocompatible BiOI-NPs as a contrast agents for the in the conventional CT 
and DE-CT can provide higher contrast efficacy than a clinical iodinate agent at the 
clinical tube potentials of 80, 150 and 80/150 kVp. At a tube potential of 80 kVp, BiOI-
NPs can enhance the subject contrast to 3 times that of iodine. At the higher single tube 
potential of 150 kVp and Dual CT 80/150 kVp, a contrast enhancement of approximately 
four times can be obtained.  
 Using the biocompatible BiOI-NPs as a contrast agents for the MARS spectral scanner 
imaging can provide higher contrast efficacy than a clinical iodinate agent at the photon 
energy bins of 27-37, 37-47, 47-60, 60-91 and 91-118 keV. The MARS spectral CT 
system has the ability to simultaneously discriminate the two elements in BiOI-NPs 
materials.  
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 Theoretical mass attenuation predictions are in agreement with experimental results. The 
total mass attenuation coefficients for both I and Bi are a result of the contribution of both 
PEs and CS. The K-edge value represents a sudden attenuation increase in the attenuation 
profile of Bi and I at a particular energy. This increased attenuation occurs at 33.2 keV 
for I and 91 keV for Bi, due to binding energy of the K shell electron of the atoms 
interacting with the photons via PEs. Such enhancement occurs when the applied tube 
potential is about 60 kVp (~ 33.2 keV) for I, and 160 kVp (~90.5 keV) for Bi. As the 
potentials increases beyond these potentials, the attenuation gradually deceases. At 80 
kVp, iodine’s attenuative properties are maximised and are not further improved at higher 
tube potentials. Therefore, when the pattern of attenuation for Bi and I are compared, Bi 
has higher attenuation at all tube energies 80-160 kVp. At a high tube potential (>160 
kVp), bismuth’s K-edge optimum occurs at 90.5 keV, where it absorbs a high number of 
photons. Below this range (80 to 140 kVp) the strongest mass attenuation value for Bi 
occurs at 80 kVp due to the high number of X-ray photons contributing to the PE and CS 
and once more, less contribution occurs at higher potentials. The mass attenuation 
coefficient curve for BiOI followed the same trend as iodine close to its K-edg value at 
photon energy bins (27-37 keV), but suddenly increases close to photon energy bins 60-
91 keV, as result of the K-edge X-ray absorption of Bi. Thus, X-rays attenuation from the 
low tube potentials can be attenuated by I due to its K-edge value, but at higher tube 
potentials Bi can attenuate X-rays more as a resulting of the K-edge effect.  
 For Therapeutics:  
 Comparative dose enhancement level studies of Bi2S3 NP and Au NP agents were 
conducted using two cells in culture (PC3 and B16) as a medium for testing these 
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compounds’ ability to enhance the incident radiation doses or radio-sensitise the cells. 
Cells were irradiated with 1-7 Gy of radiation at different concentrations of both NPs. 
Results were quantified for kVp beam energies of external X-ray radiation. Radiation 
sensitisation of the dose enhancement levels in PC3 cells for Bi2S3 NPs were higher than 
those achieved by similar concentrations of Au-NPs. Similar dose enhancement levels 
between the two types of NPs was observed with B16 cells. However, this study suggests 
that Bi2S3 NPs containing ~16 wt% elemental Bi produced these effects compared to that 
of Au NPs which are comprised of 75 wt% elemental Au at the same concentration when 
taking into account their surface coatings. The levels of radiation dose enhancements 
produced by Bi2S3 are comparable or higher than those reported for Au-NPs.  
 The dose enhancement produced by Bi2S3- and Bi-NPs from experimental studies using 
A549 and DU145 irradiated with 1-5 Gy of radiation at different concentrations of both 
NPs was quantified for different beam energies of external X-ray radiation. The data was 
analysed in the form of cell survival curves, where DEFs were deduced. Dose 
enhancements were found to be maximal at the kVp range of energy, though significant 
dose enhancement was also observed for a MV beam. Dose enhancements are more 
prominent for low energy X-rays compared to high energy X-rays. NP concentration was 
found to affect the DEF values with higher DEF being observed at higher concentrations 
of NPs. The Bi-NPs generated a greater dose enhancement effect than Bi2S3-NPs in 
irradiated cells. This is likely due to the higher amount of elemental Bismuth present in 
Bi-NPs compared to Bi2S3-NPs. The results suggest that Bismuth-based NPs can be 
considered as valuable dose enhancing agents when used in clinical applications.  
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 The radiobiological effects of Bi2S3- and Bi-NPs on the cells were analysed and the data 
fitted to the linear quadratic model once the parameters alpha (α) and beta (β) were 
obtained. It was found that the linear parameter, or α value, increases with the inclusion 
of NPs while the quadratic part of the curve, or β value, undergoes very small changes 
that do not show any predictable trend. 
 The main conceptual approach for clinical applications of NPs in radiotherapy is that the 
presence of the metallic bismuth atom inside the target cells increases the interactions of 
incident X-rays with target cells. This is due to the photoelectric effect becoming 
dominant over the Compton scattering. Such interaction can be maximised around the 
energy of the K-edge value which leads to an increased production of secondary electron 
cascades. Larger number of released secondary electrons results in free radical production 
inside the cell, causing the early death of the cell. The free radicals that are directly 
generated can result from both photoelectric and Compton interactions, and damage the 
DNA molecules inside the cell. This explains the greater dose enhancement achieved at 
the kVp energy range and the differences between results for lower and higher energies. 
It is expected that this approach will improve local tumour control while minimising the 
irradiation of healthy tissue. It has been shown that the combination of Bi based NPs and 
radiation significantly increases the biological effect of the radiation. 
To conclude, results presented in this thesis support the hypothesised that the ability of bismuth 
and bismuth compounds NPs to act as a contrast agent to enhance CT imaging as well as 
radiosensitising improve the efficiency of dose delivery, hence with these promising findings 
such NPs can act as theranostic agents with dual effects which has implications for future cancer 
treatment and diagnosis.  
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6.2 Future directions 
This research has shown promising results and answered many questions but raised others. There 
is ample room for experimental and theoretical investigations to be conducted in future, 
particularly given the ongoing developments in the field of nanotechnology, especially in 
nanobiotechnology. The following investigations are currently in progress to complement the 
initial findings: 
 In the theoretical area: a Monte Carlo simulation of image contrast with Bi based NPs is 
suggested. This is useful since the transmitted photon fluency (area under the curve) for a 
poly-energetic X-ray beam is proportional to the signal at the detector. In the NIST mass 
attenuation data, the scatter effect is ignored. Also in practice, detector response is 
influenced by the energy of each bin in the X-ray spectrum both in terms of deposited 
dose and the probability of detection. Monte Carlo simulation can take all of this into 
account. 
 Towards translation of the fabrication of Bi-based radiosensitisers as a clinical 
theranostic, efforts should focus on the need to (i) overcome the biological obstacles 
faced by Bi-NPs in vivo; (ii) optimise physicochemical properties of NPs for better 
cellular internalization to enhance the diagnostic and radiotherapeutic performance; (iii) 
understand the chemical (e.g., ROS), physical and biological mechanism of Bi NP-based 
radio-sensitisation at clinically important radiation energies; (iv) optimise the main 
radiobiological factors, such as dose, size, shape and concentration; and (v) extensively 
investigate the in vivo toxicity of the targeted Bi-NPs. 
 In terms of the optimal concentration of NPs, different synthesis procedures for Bi based 
NPs of various shapes and sizes with a multitude of capping agents should be carried out. 
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Additionally, investigation into the effect of the surface coating in enhancing the CT 
image contrast and radio-sensitisation caused by Bi based NPs is recommended in order 
to find the optimal surface coatings for use in CT and radiotherapy applications.  
  Synthesis of non-toxic, targeted, Bi based NPs would be essential to improve the 
possibility of using these materials in medical imaging and radiobiology. 
 In practice, the most viable application for radiopaque NPs would employ targeted NPs in 
imaging as diagnostic agents and in treatment as therapeutic agents. There would be 
several related benefits to such a targeted material. First, the concentrations of NPs to be 
administered would be vastly reduced. That would remove the requirement to introduce 
the NPs at high concentration. It would also drastically lower administered dosage 
required per procedure, keeping pharmaceutical toxicity down. By binding to cell 
membranes, it is expected that both the circulation time and the retention time of these 
conjugated-type NPs would be high. This would have tremendous importance in the role 
of these agents as targeted theranostic agents. 
 Investigating energy dependence is recommended: Monoenergetic beams needs to be 
used to investigate the impact of X-ray energy on the dose enhancement by such 
particles. This should be carried out with further theoretical calculations to indicate an 
optimal energy higher than the K-edge value, as anticipated by theoretical studies using 
Bi atoms as radiation targets.  
 Our studies were focused on X-ray beams where optimal dose enhancements were 
observed. However, it will be of great value to the field of radiotherapy to extend such 
investigations into the use of different radiation beam types. Some such studies have 
already been conducted and some are currently in planning stages for our group where 
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Au-NPs are under investigation. These studies consider radiation sources such as electron 
beams and proton therapy, which is becoming an increasingly attractive treatment tool.   
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Appendixes 
A. Cell Lines Information 
A.1 PC3 Cell Lines 
Cell lines name: PC3 
Description: 
 Species: Human 
 Organ: Prostate 
 Disease: Grade IV, adenocarcinoma 
Depositor: ATCC (kindly provided by Dr. Taghrid Istivan at RMIT) 
Reference: ME Kaighn 
Biosafety level: 1 
Growth mode: Adherent 
Morphology: Epithelial-like 
Propagation: Complete RPMI medium: RPMI + 10% FBS + 1% Pen Strep (+5,000 Units/mL 
Pen; + ,000 μg/mL Strep) 
Subculturing: 
 Ratio: Split 1:3 to 1:6.  
 Seeding: at 3x104 cells/cm2. Remove spent medium, rinse with PBS (w/o Ca and Mg), 
add 3 mL of fresh 0.25 % Trypsin-EDTA (1X), incubate at 37 °C (usually 3-5 min) and 
observe cells under an inverted microscope until the cell layer detach. Add fresh medium, 
aspirate, and transfer into new flask. Incubate in incubator at 37 °C (and 5% (v/v) CO2). 
Preservation: Culture medium 90%; DMSO 10% (v/v) 
Passage number: 10. 
  
267 
 
A.2 B16-F0 Cell Lines 
Cell lines name: B16-F0 
Description: 
 Species: Mouse 
 Organ: Skin 
 Disease: Melanoma 
Depositor: ATCC (kindly provided by Dr. Terry Piva at RMIT) 
Reference: Fidler IJ 
Biosafety level: 1 
Growth mode: Adherent 
Morphology: Epithelial-like 
Propagation: Complete RPMI medium: RPMI + 10% FBS + 1% Pen Strep (+5,000 Units/mL 
Pen; + ,000 μg/mL Strep) 
Subculturing: 
 Ratio: Split 1:10 
 Seeding: at 4 x103 cells/cm2. Remove spent medium, rinse with PBS (w/o Ca and Mg), 
add 3 mL of fresh 0.25 % Trypsin-EDTA (1X), incubate at 37 °C (usually 3-5 min) and 
observe cells under an inverted microscope until the cell layer detach. Add fresh medium, 
aspirate, and transfer into new flask. Incubate in incubator at 37 °C (and 5% (v/v) CO2). 
Preservation: Culture medium 90%; DMSO 10% (v/v) 
Passage number: 8  
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A.3 A549 Cell Lines 
Cell lines name: A549 
Description:  
 Species: Human 
 Organ: Lung 
 Disease: Carcinoma 
Depositor: ATCC (kindly provided by Dr. Bryce Feltis at RMIT) 
Reference: M Lieber 
Biosafety level: 1 
Growth mode: Adherent 
Morphology: Epithelial-like 
Propagation: Complete DMEM medium: DMEM + 10% FBS + 1% Pen Strep (+5,000 Units/mL 
Pen; + ,000 μg/mL Strep) 
Subculturing: 
 Ratio: Split 1:3 to 1:8  
 Seeding: at 6 x103 to 6 x104 cells/cm2. Remove spent medium, rinse with PBS (w/o Ca 
and Mg), add 3 mL of fresh 0.25 % Trypsin-EDTA (1X), incubate at 37 °C (usually 3-5 
min) and observe cells under an inverted microscope until the cell layer detach. Add fresh 
medium, aspirate, and transfer into new flask. Incubate in incubator at 37 °C (and 5% 
(v/v) CO2). 
Preservation: Culture medium 90%; DMSO 10% (v/v) 
Passage number: 32  
  
269 
 
A.4. DU145 Cell Lines 
Cell lines name: DU145 
Description: 
 Species: Human 
 Organ: Prostate 
 Disease: Carcinoma 
Depositor: ATCC  
Reference: KR Stone 
Biosafety level: 1 
Growth mode: Adherent 
Morphology: Epithelial 
Propagation: Complete Alpha MEM medium: ⍺MEM + 10% FBS + 1% Pen Strep (+5,000 
Units/mL Pen; + ,000 μg/mL Strep) 
Subculturing: 
 Ratio: Split 1:4 to 1:6 
 Seeding: at 2-4 x103 cells/cm2. Remove spent medium, rinse with PBS add 3 mL of fresh 
0.25 % Trypsin-EDTA (1X), incubate at 37 °C (usually 3-5 min) and observe cells under 
an inverted microscope until the cell layer detach. Add fresh medium, aspirate, and 
transfer into new flask. Incubate in incubator at 37 °C (and 5% (v/v) CO2). 
Preservation: Complete culture medium 95%; DMSO 5% (v/v) 
Passage number: 4  
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A.5 BAOEC Cell Lines 
Cell lines name: BAOEC 
Description: 
 Species: cow 
 Organ: Turbinate 
Depositor: ATCC (kindly provided by Dr Taghrid Istivan at RMIT) 
Reference: AW McClurkin 
Biosafety level: 1 
Growth mode: Adherent 
Morphology: Epithelial-like 
Propagation: Complete DMEM medium: DMEM + 10% FBS + 1% Pen Strep (+5,000 Units/mL 
Pen; + ,000 μg/mL Strep) 
Subculturing: 
 Ratio: Split 1:3 to 1:8  
 Seeding: at 2.5-5 x103 cells/cm2. Remove spent medium, rinse with PBS (w/o Ca and 
Mg), add add 3 mL of fresh 0.25 % Trypsin-EDTA (1X), incubate at 37 °C (usually 3-5 
min) and observe cells under an inverted microscope until the cell layer detach. Add fresh 
medium, aspirate, and transfer into new flask. Incubate in incubator at 37 °C (and 5% 
(v/v) CO2). 
Preservation: Culture medium 90%; DMSO 10% (v/v) 
Passage number: 32 
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B. Subculture Adherent Cells – Protocol 
Materials 
 Sterile Materials 
o Healthy, 80-90% confluent cell culture in T 75 cm2 flask 
o Complete- medium (complete suitable medium supplemented with 10% FBS and 1% 
Pen Strep) 
o PBS (without Ca2+ and Mg2+) 
o 0.25 % Trypsin-EDTA (1X) 
o 1, 5, 10 and 25 mL pipettes 
o T 75 cm2 flasks 
 Other materials 
o Pippetor 
o Plastic transfer pipettes 
o Eppendorf tubes 
o Tube racks 
o Haemocytometer 
o Vortex 
o Handcounter 
o Microscope 
o Calculator 
o Gloves 
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o Ethanol 
o Wipes 
o Water bath set at 37 °C and incubator at 37 °C (and 5% (v/v) CO2) 
Procedure 
1. Warm up the appropriate growth medium, PBS, and trypsin-EDTA in water bath at 37 °C 
2. Follow the aseptic technique for cell culture in biosafety cabinet (BSC), all the following 
step should be in BSC. 
3. Wipe the work surface with 70% ethanol before and during work. 
4. Promptly clean all flasks, tubes, tubes rack, plastic transfer pipettes, pippetor, and gloves. 
5. Open and handle the lid of the flask of the cells in BSC (not on the bench). 
6. Aspirate the spent medium. 
7. Wash with PBS: shake it gently several times; discard the PBS 
8. Add 3 mL of trypsin; shake it several times. 
9. Placed in incubator at 37 °C for 3-5 min. 
10. Gently tapped the edge of flask; observe cells under an inverted microscope until the cell 
layer detach.  
11. Re-suspend with appropriate complete fresh medium; gently pipette it up and down to 
resuspend it well using centrifugation (centrifuge at 200 g for 3-5 min) and aliquot small 
sample to perform cell count (see next protocol Appendix C). 
12. Transfer the required number of cells into new flask (the flask should be labeled with 
initial, date, cell type, passage number, etc.). 
13. Incubate in the incubator at 37 °C (and 5% (v/v) CO2). 
 Note: It is important to follow the aseptic technique for cell culture to keep cells free 
from contamination  
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C. Cells Counting – Protocol 
C.1 Cells Counting – Protocol 
Materials 
o Vials containing a cell line 
o Haemocytometer 
o Trypan blue 
o Pipette and tips 
o Vortex mixer 
Procedure 
1. Vortex the vial containing a cell to resuspend the cells. 
2. Transfer a  0 μl sample to microfuge tube and then add a  0 μl of Trypan blue solution; mix 
thoroughly (pipette up and down). 
3. Remove  0 μl of cell suspension/Trypan blue sample with a pipette and place tips to the one 
of the edges of a coverslip on the haemocytometer (Figure B-1).  
4. Gently distribute the suspension into the space between coverslip and the haemocytometer 
(the counting chamber) until the counting chamber is filled.  
5. After allowing the cells to settle. Place the counting chamber on the microscope stage and the 
using low power focus on the counting grid, looking at the four corner grids (from the nine 
squares) where each square millimetre is divide into 16 squares (1-4) and the middle (5) 
which has a 25 squares, as shown in Figure B-1. 
6. Count the cells in all the 5 grids (1-5; Figure B-1). Average the 5 total cell count to the 
number of cells per grid. It should be noticed this value represents only the number of cells in 
of suspension applied to the haemocytometer and should be multiply the cell concentration 
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by total sample volume. The concentration of cells in the original sample: (Average count of 
cells per grid) X (dilution factor) X (10,000). 
 
Figure B- 1: Manual counting chamber of a haemocytometer [274].  
  
275 
 
D. Cryopreservation – Protocol 
1. Freezing Cells: 
Materials 
 Sterile materials 
o •Approximately 80-90% confluent cell culture in T 75 cm2 flask. 
o Complete cell culture media (suitable medium for each cells supplemented with 10% 
FBS and 1% Pen Strep) 
o Cell culture freezing medium (an appropriate medium for each cells supplemented 
with10% FBS and 10% DMSO) place in ice. 
o PBS (without Ca2+ and Mg2+) 
o 0.25 % Trypsin-EDTA (1X) 
o Pipettes (sizes: 1, 5, 10 and 25 mL) 
o Centrifuge tubes 10 mL 
o Labeled Cryogenic vials (2 mL)  
 Other materials 
o Pippetor 
o Plastic transfer pipettes 
o Centrifuge tubes  
o Tube racks 
o Haemocytometer 
o Microscope 
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o Gloves 
o Ethanol 
o Wipes 
o Water bath set at 37 °C and incubator at 37 °C (and 5% (v/v) CO2) 
Procedure 
1. Prepare in advance the freezing media (An appropriate cells culture medium+ 10% FBS+10 
% DMSO). 
2. Detach cells; aspirate the old media; wash the cell with 10 ml of PBS (twice) and add to it 2 
mL of the trypsin-EDTA (1X); put in incubator at 37 °C for 2–5 min; use microscope to 
check whether the cells detached or not. 
3. Spin cells down in in conical tube (centrifuge at 200 g for 5 min) to pellet them and 
resuspend them with fresh complete medium (an appropriate cells culture medium+ 10% 
FBS+1 % Pen Strep). 
4. Before resuspending, prepare vials, label including cell line name and date of freezing. 
5. Take a small aliquot of cells and resuspend it in cold freezing medium to obtain the final cell 
concentration 2-4x106 cells/mL. 
6. Pipette 1 mL into each prepared Cryogenic vials and place immediately in ice. 
7. Place all vials in -80 °C freezer for 24 h. 
8. Transfer all the Cryogenic vials to a gas phase liquid nitrogen for long term storage.  
 Note: 
  Cells can survive in -80 for 1 year. 
 Do not freeze more than 10 vials at once, to avoid extended period in DMSO at high 
temperature. 
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2. Thawing Cells 
Materials 
 Sterile materials 
o Complete cell culture media (an appropriate complete supplemented with 10% FBS and 
1% Pen Strep) 
o T 75 cm2 or T 25 cm2 flasks 
o 50 mL conical tubes 
 Other materials 
o Pippetor 
o Eppendorf tubes 
o Tube racks, 
o Haemocytometer 
o Vortex 
o handcounter 
o Microscope 
o Calculator 
o Gloves 
o Ethanol 
o Wipes  
o Water bath set at 37 °C and incubator at 37 °C (and 5% (v/v) CO2) 
Procedure 
1. Warm up the complete culture media at 37 °C water bath. 
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2. Place frozen Cryogenic vial into dry ice. 
3. Put 10 ml warm media into 15 ml conical tube. 
4. Thaw vial by holding in 37 °C water bath and gently shake until almost od the content is 
liquid (this should be as quick as possible). 
5. Promptly clean vial with a tissue soaked in 70% ethanol and place it in the hood, in a special 
rack. 
6. Transfer the thawed cells into tube with media using a plastic transfer pipette (drop wise 
while gently swirling the flask in a circular motion to slowly equilibrate the cells to the 
medium).  
7.  Spin cells at low spin to maximise the cells recovery. 
8. Aspirate media and gently resuspend by tapping on tube.  
9. Resuspend in complete media and place it in dish.  
10.  Incubate cells in incubator at 37 °C (and 5% (v/v) CO2) and leave for couple hours or until 
attached (or leave overnight). 
9. Once the cells have attached and had a chance to expel the DMSO, remove the media and 
add fresh media. 
 Note  
 It is very important not to thaw cells until ready to place into fresh media. 
  Flask size depends on cell number T 25 cm2 for low cell number or cells requiring close 
contact or T 75 cm
2
 for higher cell number or extremely fast growing cells. 
  For T 25 cm2 flask, use 5-8 mL total volume of media. 
  For T 75 cm2 flask, use 10-20 mL total volume of media.  
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E. Permission to reproduce published 
materials in Chapter 4 
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F. Permission to reproduce published 
materials in Chapter 5 
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